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Despite being the “gold standard” for toxicity testing, rat in vivo studies are 
estimated to be only 37-50% accurate at predicting xenobiotic toxicity in humans.  If 
validated, in vitro systems could be incorporated into toxicity testing, allowing 
direct comparisons to be made between humans and rats and facilitating a 
reduction of in vivo testing. In this project, a normal rat urothelial (NRU) cell culture 
system was developed and optimised for comparison against an established normal 
human urothelial (NHU) cell culture system. NRU cells had a reduced lifespan in 
culture compared to NHU cells, leading to an investigation of the pathways 
regulating cellular proliferation. The PI3K/Akt pathway was found to be active in 
proliferating NRU cells, whereas the EGFR/MAPK and β-catenin pathways were 
confirmed to regulate NHU cell proliferation. Inhibition of the PI3K/Akt pathway 
enabled NRU cells to be subcultured to passage 2, most probably by enabling 
EGFR/MAPK and β-catenin pathway activation, although this requires 
experimental confirmation. To further increase cell lifespan, the proto-oncogene 
BMI1 was overexpressed in NRU and NHU cells, with the effects on lifespan and 
differentiation compared against both human telomerase reverse transcriptase 
(hTERT) overexpressing and control (empty vector) cells. NRU cell lifespan was not 
increased by BMI1 or hTERT overexpression. BMI1 overexpression increased NHU 
cell lifespan in culture, comparable with hTERT overexpression, but further work is 
required to determine the extent of the effects on lifespan and phenotype beyond 
passage 12. Finally, the metabolic competence of urothelial cells was explored, with 
a focus on the cytochrome P450 2B (CYP2B) family of metabolic enzymes. 
Xenobiotic induction of CYP2B expression by rat urothelium was demonstrated in 
vivo but not in NRU and NHU cells. Xenobiotic-induced CYP2B protein expression 
was achieved in a rat ex vivo organ culture model. Together these results identify a 
previously unknown metabolic capability of urothelial cells that can be modelled ex 
vivo, and demonstrate fundamental differences in rat and human urothelial cell 
physiology that support the validation of human tissue-specific in vitro models for 
assessment of xenobiotic toxicity.  
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1.1 The in vitro paradigm  
 
The in vitro paradigm describes a system that allows for the extrapolation of 
clinically relevant data from in vivo animal models to humans using cell culture 
systems. In vitro models have the potential to act a conduit between species, 
ensuring that results seen in animals in vivo accurately predict the effects in man 







Figure 1.1 – The in vitro paradigm is a potential system for improving the extrapolation of 
data from rats in vivo to humans in vivo. Schematic of the in vitro paradigm illustrating 
how rat and human in vitro models can be combined with rats in vivo to predict results in 
humans in vivo.    
 
Through the use of in vitro models, interspecies variations in physiology can be 
detected and accounted for when extrapolating results to humans. The 
establishment of robust methods to propagate and differentiate human cells in 
culture has significantly increased the potential of human cell culture models and, in 
addition to bridging the gap between in vivo animal models and humans, in vitro 
models may also have the ability to replace animals in a number of circumstances 
(Andersen and Krewski, 2009; McKim, 2010; Perel et al., 2007).  In vitro models have 
the additional advantage of having lower ethical and financial costs when compared 
to experiments in vivo (reviewed by Andersen and Krewski, 2009). The full potential 
of in vitro systems, however, has yet to be realised and it is only with further 
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The development of comparable in vitro cell culture systems in different species has 
allowed for side-by-side experimentation and assessment. By developing 
comparable rat and human in vitro cell culture systems, the relevance of results 
generated by rat in vivo studies to humans can be determined. Any differences in 
cellular physiology between rats and humans are revealed by such comparisons, 
allowing for more informed extrapolations of results to be made between the species 
(reviewed by Krewski et al., 2011).   
 
1.2 Predicting human toxicity 
Toxicology studies aim to identify whether a chemical entity will have toxic effects 
on humans after administration or exposure (Wexler, 2009). By understanding the 
risk posed to humans by novel chemical entities, they can be removed from 
development or appropriate levels of control put in place to avoid toxic exposure. 
Current toxicity studies rely heavily on in vivo assays in multiple species to 
understand a chemical’s toxicity, with the findings being extrapolated from 
mammalian in vivo models to humans (reviewed by Blaauboer and Andersen, 2007)  
 
Approximately 80% of animals used in toxicology studies are rodents with rats 
being the most commonly used species (reviewed by Guarino, 2009). Regulatory 
agencies normally require compounds to be subsequently tested in an additional 
non-rodent species in order to satisfy chemical/pharmaceutical safety licensing 
criteria. In 2008 a review of toxicity studies found that xenogeneic in vivo models 
were on average 37-50% reliable at predicting the effects of novel chemical entities 
on humans (reviewed by Perel et al., 2007). It attributed the number of novel 
chemical entities failing during clinical trials (post mammalian in vivo testing) to the 
low predictive accuracy in translating results between animals in vivo and humans.   
 
Although animals such as rodents have for many years been the “gold standard” 
model for toxicological research, it has become apparent that the genetic, molecular 
and physiological differences that exist between animals and humans can inhibit 
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results from accurately being extrapolated between species (Rosenkranz and 
Cunningham, 2005). In response to xenobiotic or physical insults, different species 
are capable of responding in different ways. To quote the title of one review on the 
effect of species variations in toxicology, “A mouse is not a rat is not a man” 
(reviewed by Cunningham, 2002).  There is an ever-increasing body of literature 
that demonstrates that species differences can significantly inhibit accurate 
extrapolation between rodents and humans.  
 
There are a number of reported cases in which normal rat physiology has lead to 
inaccurate predictions of human toxicity. One example that demonstrates this is in 
relation to kidney and bladder cancer. Rat hepatocytes synthesize alpha-2U 
globulin, a protein that binds to a number of xenobiotic compounds in blood before 
being filtered by the kidneys. Bound alpha-2U globulin accumulates in rat kidneys, 
leading to nephropathy and tumours. One of the compounds that alpha-2U globulin 
is known to bind to in rats is the artificial sweetener saccharin. The conjugate 
formed is filtered by the kidneys and stored in the bladder where it forms silicate 
crystals. These crystals mechanically damage the lining of the bladder and can lead 
to pathologies including cancer. Results produced in rats in vivo showing saccharin 
was carcinogenic were responsible for the compound being banned by a number of 
countries in the 1970s and 1980s (Priebe and Kauffman, 1980).  As humans do not 
synthesize alpha-2U globulin this mechanism of carcinogenesis is not relevant to 
humans and in 1999, a review by the International Agency for Research on Cancer 
conclusively showed that saccharin could not be considered a human carcinogen 
(IARC, 1999; Takayama et al., 1998; Whysner and Williams, 1996).  
 
Alternatively, examples exist in which pharmaceutical compounds believed to be 
safe based on animal in vivo data were toxic when given to human patients at 
concentrations significantly lower than the No Observable Adverse Effect Level 
(NOAEL). In 2006, an experimental immunoregulatory agent (the monoclonal 
antibody TGN1412), which had passed pre-clinical testing in both rodents and non-
human primates, caused multi-organ failure when given to healthy clinical trial 
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volunteers at a dose 500 times lower than the NOAEL. The symptoms observed in 
the trial volunteers are thought to be as a result of CD4+ effector memory T-cell 
activation by TGN1412. Variations in CD4+ effector memory T-cells between the test 
species and humans (in particular the lack of CD28 expression), is thought to be 
responsible for the failure to predict this compounds toxicity in humans 
(Suntharalingam et al., 2006; Stebbings et al., 2007; Eastwood et al., 2010).  
 
These examples, while rare, are by no means unprecedented and highlight the 
necessity for alternative, more relevant, model systems to be developed to replace or 
validate results generated by in vivo studies. Additionally, models that can be used 
to understand the mechanisms of toxicity enable species variations in physiology to 
be accounted for when extrapolating between rats and humans.  From an industry 
perspective, methods that can accurately detect toxicity at an earlier stage of the 
chemical development pipeline are beneficial as they increase efficiency and reduce 
costs.   
 
 
Figure 1.2 – The pharmaceutical compound development pipeline. Details of the use of in 
vitro models in target discovery, validation and optimisation (Blue) and in vivo models in 
preclinical and clinical toxicology testing (red). The approximate time periods, costs and 
number of compounds at each stage of development as of 2000 in the US are indicated 
(adapted from DiMasi et al., 2003). 
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1.3 In vitro toxicology studies 
 
Currently in vitro models are used to a limited extent in early toxicity studies to 
identify whether xenobiotics affect a small number of specific targets, such as the 
human Ether-a-go-go Related Gene (hERG) channel. These targets are studied due 
to the consequences of inhibiting their normal function, for example blockade of the 
hERG channels causes long Q-T (LQT) syndrome or torsade de pointes, which can 
lead to acute heart failure and death (Witchel and Hancox, 2000; Netzer et al., 2001).  
 
The use of in vitro models in toxicology has been strongly advocated as a means to 
improve the predictive accuracy of toxicity studies (Andersen, 2003; Andersen and 
Krewski, 2009; Andersen and Krewski, 2010; Krewski et al., 2011). The need to 
supplement and/or replace animal in vivo testing with more human-relevant models 
has driven advancements in human in vitro systems, as well as tissue engineering 
research, but as of yet their use has not been widely adopted (reviewed by 
Pampaloni et al., 2007; McKim, 2010; Parasuraman, 2011; Thomas et al., 2012; 
Soldatow et al., 2013). In vitro systems offer the advantage of providing moderately 
high-throughput screening systems at a significantly reduced cost when compared 
to in vivo studies. They also offer the ability to understanding cellular mechanisms 
of toxicity (Burden et al., 2015; Krewski et al., 2011). The current disadvantages with 
in vitro systems, however, include a lack of consistency in generating cell lines, a 
difficulty in producing cell lines with a high capacity for expansion and developing 
cell lines that retain their normal characteristics in vitro (Hartung and Daston, 2009).  
These factors have led to a lack of confidence in the predictive accuracy and 
reproducibility of results obtained from in vitro models. In order to validate existing 
human in vitro models and establish credible in vitro systems to support and replace 
in vivo models in toxicity studies, comparative rodent and human in vitro systems 
need to be developed and assessed.  By having the ability to conduct side-by-side 
comparisons of xenobiotic toxicity in rats and humans in vitro, interspecies 
differences in responses to xenobiotics can be determined, increasing the predictive 
accuracy of toxicity studies (van Ravenzwaay and Leibold, 2004; Roesems et al., 
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1997; Louisse et al., 2010; reviewed by Andersen and Krewski, 2009; reviewed by 
Hartung and Daston, 2009).  
In this study, bladder-derived epithelial (urothelial) cell lines will be developed, 
optimised and analysed as potential models for use in toxicity testing. In vitro 
systems enable the analysis of organ-specific toxicity, and having validated models 
of the organs systems at risk of insult from toxic xenobiotics would be of value. As 
described in Chapter 3, the urothelium can be exposed to high levels of xenobiotics 
secreted in urine and, as such, the use of in vitro models of the urothelium in toxicity 
testing would allow for the risks of xenobiotic-induced urothelial toxicity to be 
established.  
  




To conduct a comparison of normal rat and human urothelial cell culture systems as 
a means of validating a normal urothelial in vitro system for use in toxicity studies. 
Species variations in normal urothelial cell physiology will be explored, attempts 
made to immortalise normal urothelial cells and novel metabolic capabilities of 
urothelial cells investigated both in vivo and in vitro.  
 
1.4.1 Objectives 
1. Develop a normal rat urothelial cell culture system that has congruence to an 
already established normal human urothelial cell culture system  
2. Investigate the signal transduction pathways regulating NRU cell 
proliferation 
3. Immortalise NRU and NHU cells through the overexpression of BMI1 and 
hTERT 
4. Investigate the induction of Cytochrome P450 2B expression in normal rat 
urothelial cells in vivo and in vitro 
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All experimental work within this thesis was conducted within the Jack Birch Unit 
for Molecular Carcinogenesis or the central Technology Facility in the Department 
of Biology at the University of York, with the exception of tissue harvesting and in 
vivo studies which were conducted at several locations listed in Appendix 1.1. 
 
2.2 Commercial Suppliers 
Details of all commercial suppliers and manufacturers can be found in Appendix 
1.2. The supplier or manufacturer is indicated in the text.   
 
2.3 General laboratory equipment 
All metal dissection instruments, Pasteur glass pipettes (SLS) and pipette tips 
(Starlab) were autoclaved in a Harvard/LTE Series 100 autoclave at 121oC (1 bar) for 
20 minutes and air dried at 80 oC. Sterile, single use plasticware was purchased 
from Sterlin (SLS) with the exception of RNase/DNase-free pipette tips which were 
from StarStedt, RNase-free tubes (Ambion) and serological pipettes (StarStedt).  
 
2.4 Stock Solutions 
Unless otherwise indicated stock solutions were prepared with ultra-pure water 
from a Purelab Ultra Genetic (Elga) ultraviolet purification unit. Heat-stable 
solutions were autoclaved at 121 oC (1 bar) for 20 minutes and cooled to ambient 
temperature before use. Solutions that were unable to be autoclaved were filter-
sterilised using an Acrodisc low-protein binding Tuffryn® HT syringe filter (pore 
size 0.2 µm; Sigma Aldrich) if intended for cell culture use.  
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2.5 Cell and Tissue Culture 
 
2.5.1 General 
Aseptic technique was employed when isolating and culturing cells. Routine cell 
culture procedures were conducted within a recycling laminar flow class II safety 
cabinet (Medical Air Technology) and work involving retroviruses was conducted 
in an externally ducted (Envair) cabinet. All cabinets were disinfected using 70 % 
ethanol (Sigma) before each use and were cleaned once per week using Mikrozid® 
AF disinfectant (SLS). All waste medium from cells was aspirated into Virkon® (10  
% w/v) traps and left for at least 30 minutes before disposal. Medium from cells 
exposed to retrovirus was left for 24 hours in Virkon® (10 % w/v) prior to disposal. 
All reagents were obtained from Sigma Aldrich, unless otherwise indicated, and 
were of tissue culture grade. Cells were incubated in Heracell 240 incubator 
(Thermo Scientific) at 37 oC in a humidified atmosphere of 5 % CO2 (urothelial cells) 
or 10 % CO2 (PT67 cells) in air. Cells were counted as single cell suspensions using 
an improved Neubauer haemocytometer (VWR) and a phase contrast microscope 
(EVOSTM;). All centrifugation was carried out in a bench top centrifuge (Sigma 
Aldrich) at 400 g for 5 minutes, unless otherwise stated.  
 
2.5.2 Primary Normal Urothelial Cell Culture 
2.5.2.1 Rat Tissue Specimens 
Surplus rat bladders were donated by the Food and Environment Research Agency 
(FERA), Sand Hutton, York, and research groups at the University of Manchester, 
the University of Leeds and the University of York. A small number of rats were 
also purchased for the specific purpose of harvesting bladder tissue. Ethical 
approval was obtained from the Department of Biology Ethics committee at the 
University of York to use both surplus tissue and to purchase animals as a source of 
bladder tissue.  
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Rats were killed using an approved schedule one procedure. Whole rat bladders 
were aseptically dissected from the animals at time of death (appendix 1.7) and 
placed into 25 mL polystyrene Universal tubes containing 10 mL of sterile transport 
medium (Southgate et al., 1994) (Hanks balanced salt solution (HBSS) (Gibco) 
containing 20 kallikrein-inhibiting units/mL of Aprotonin (Trasylol; Bayer), 10 mM 
HEPES pH 7.6 (Gibco) for a maximum of 4 hours. Samples were kept, where 
possible, at 4 oC until processing. Rat bladders from the same source were given an 
arbitrary record number (R-number) and the origin, age, strain and sex of the 
animals were recorded as well as details on whether tissue was fixed in 10 % (v/v) 
formalin for histology. Details of the R-numbers used can be found in the 
experimental approach section of each chapter.  
 
2.5.2.2 Human tissue Specimens 
Human bladder, ureter and renal pelvis specimens were obtained by surgeons at 
York District Hospital, St. James’s University Hospital in Leeds, Leeds General 
Infirmary in Leeds and Pinderfields Hospital, Mid Yorkshire Hospitals NHS Trust 
in Wakefield. Tissue biopsies were taken with fully informed consent from patients 
with no history of urothelial neoplasia and with the permission of an NHS Research 
Ethics Committee. Biopsies were collected in sterile 25 mL polystyrene Universal 
tubes containing 15 mL of sterile transport medium. Samples were stored at 4 oC 
until processed. Upon processing each sample was given a sequential record 
number (Y-number) and details of the patient’s age, gender and operation were 
recorded.  Details of the Y number used can be found in the experimental approach 
section of each chapter.                                                                                                                                                                       
 
2.5.2.3 Isolation of Primary Urothelial cells 
The protocol for isolating urothelium from human tissue samples was performed as 
described in Southgate et al. (1994; 2002). Normal human tissue specimens were 
placed in a Petri-dish (Thermo Fisher) and dissected to remove excess fat and 
expose the urothelium using scissors and forceps. Tissue was incubated at 37 oC for 
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4 hours in 5 mL of EDTA stripper medium (Appendix 1.4.2) before urothelial sheets 
were physically removed using forceps. These sheets were collected via 
centrifugation and resuspended in Collagenase IV (400 U) solution (Appendix 
1.4.2). The solution was incubated for 20 minutes at 37 oC before the cells were 
collected again via centrifugation and resuspended in Keratinocyte Serum Free 
Medium complete with 5 ng/mL epidermal growth factor (rhEGF; Life 
Technologies), 50 µg/mL bovine pituitary extract (BPE; Life Technologies) and 30 
ng/mL cholera toxin (Sigma Aldrich) (KSFMc). Cells were counted and then seeded 
into N2 plasma treated tissue culture flasks, petri dishes or plates (Starstedt). The 
normal rat urothelial cell isolation protocol was based upon the above method for 
NHU cell isolation, but optimised as described in Chapter 3. 
 
2.5.2.4 Subculture of Rat and Human urothelial cell lines 
NRU cells were passaged when cell colonies appeared to reach a maximum size and 
density. NHU cells were subcultured when approximately 90 % confluent. Cells 
were incubated in 0.1 % (w/v) Ethylenediaminetetra-acetic acid disodium salt 
(EDTA) solution (Appendix 1.4.2) for 5 minutes at 37 oC to chelate calcium and 
initiate cell dissociation. Cells were then incubated in 0.5 mL of Hank’s balanced 
salt solution (HBSS; Life Technologies) containing 0.25 % (w/v) trypsin and 0.02 % 
(w/v) EDTA for 1-2 minutes at 37 oC . Cells dissociation was enhanced by physically 
tapping the flask/dish/plate several times. Upon dissociation cells were 
resuspended in 5 of KSFMc containing 2 mg of Soya bean trypsin inhibitor (Sigma 
Aldrich) and collected by centrifugation. NRU cells seeding densities and 
subculture are optimised in Chapter 3. NHU cells were reseeded at a ratio of 1:3 and 
used for experiments between passage 0-7 (P0-P7). 
 
2.5.2.5 Differentiation of normal human urothelial cells 
NHU cells were cultured until 80 % confluent in KSFMc. At 80-90 % confluent the 
medium was supplemented with 5 % of batch tested adult bovine serum (ABS; 
Harlan Sera-lab). Cells were cultured in KSFMc +5 % ABS until confluent at which 
                                                                                                                   Chapter 2 
37 
 
point the extracellular calcium concentration was increased to 2 mM using CaCl2. 
Once the calcium ion concentration was increased, cells were used for experiments 
after 5 days. For experimental controls, the same Y-number NHU cells were 
cultured in KSFMc and harvested at the same time point.  
 
2.5.2.6 Pharmacological Agonists & Antagonists 
The agonists and antagonists used in this study are listed in Table 2.1 along with 
their working concentrations. Compounds were reconstituted under aseptic 
conditions in sterile Elga H2O or tissue culture grade dimethyl sulfoxide (DMSO; 
Sigma) according to manufactures instructions and frozen (-20 oC) in single use 
aliquots. All compounds were titrated before use to determine effective 
concentrations and stock concentrations were calculated to ensure that DMSO 
concentrations did not exceed 0.1 % total volume.  
 
Table 2.2.1 - Agonists/Antagonists 
Compound Target Supplier **Published 
IC50   
Vehicle (0.1 
%) 
PD153035 (PD) EGFR Calbiochem 25 pM DMSO 
UO126  MEK1/2 
inhibitor 
Calbiochem 72/58 nM DMSO 
SB415286 (SB) GSK3β Sigma Aldrich 2.9 µM DMSO 
IGF1 IGFR Sigma Aldrich n/a PBS 










2.5.3.1 Cell biomass assay 
The alamarBlue® assay was used to assess urothelial cell growth over 10 daytime 
courses. Urothelial cells were cultured in either 96 or 12 well plates. AlamarBlue® 
reagent (Serotec) was diluted 1:10 in culture medium and added to cells (200 µL per 
well on a 96 well plate, 1.5 mL per well on a 12 well plate) for 4 hours in a 
humidified incubator at 37 oC (5 % CO2). 96 well plates could be immediately 
analysed on a MultiSkan Ascent 96/384 Plate Reader (Thermo Scientific) at 
wavelengths of 570 and 630 nm. Medium from 12 well plates was carefully removed 
and pipetted into a 96 well plate before being analysed. A no cell control was 
always included.  
The percentage reduction in alamarBlue® was calculated using the following 
equation provided by the manufacturers:  
(34798 x NRU cells @ 570 nm) – (80586 x NRU cells @ 630 nm)      x100 
(155677 x no cells @ 630 nm) – (5494 x no cells @ 570 nm) 
 
34798  - molar extinction coefficient of oxidized alamarBlue (Blue) at 600nm 
80586  - molar extinction coefficient (E) of oxidized alamarBlue (Blue) at 570nm 
155677  - molar extinction coefficient of reduced alamarBlue (Red) at 570nm 
5494  - molar extinction coefficient of reduced alamarBlue (Red) at 600nm 
 
After analysing the reduction, diluted alamarBlue® reagent was removed from cells 
and replaced with fresh KSFMc medium and the cell cultures maintained.  
 
2.5.3.2 Colony formation assay 
NRU cells were isolated using either the EDTA/collagenase IV or Dispase II 
isolation protocols and seeded at a range of densities onto N2 plasma treated tissue 
culture plastic 6 well plates (StarStedt) or 6 well plates (StarStedt) coated with 5 
µg/cm2 Collagen I (from rat tail; Sigma Aldrich) in sterile PBS for 2 hours 
immediately prior to seeding. Cell medium was changed after 24 hours and then 
every 2-3 days. After 5 days of culture, urothelial cells were fixed using methanol: 
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acetone (1:1; v/v) for 30 seconds at ambient temperature before being stained with 
0.1 % crystal violet (sigma Aldrich) in 75 % ethanol (v/v) for 5 minutes. Plates were 
rinsed for 5 minutes under running tap water and air-dried inverted at ambient 
temperature. Colonies were imaged using an Odyssey infrared imaging system 
(LiCor) and analysed using ImageJ software.  
 
2.5.4 Population doubling curves 
Population doubling (PD) values were calculated for NHU cells when passaged 
according to the following formula:       
               PD=    log(Chn/Cpn) 
                      
 
Ch is the number of cells harvested after passage, Cp is the number of cells seeded and n 
is the passage number.  
 
2.5.5 NHU cell differentiation 
2.5.5.1 Differentiation 
A method of inducing NHU cell differentiation and the subsequent formation of a 
“biomimetic urothelium” has previously been established (Cross et al. 2005). Briefly, 
80 % confluent NHU cells were cultured for 5 days in KSFMc medium 
supplemented with 5 % adult bovine serum (ABS) (v/v). Cells were passaged, left 
for 24 hours and the extracellular calcium ion concentration increased to 2 mM 
through the addition of CaCl2 (Sigma Aldrich) in PBS. Cells were maintained for up 
to 10 days after the increase in calcium concentration.  
 
2.5.5.2 Transepithelial electrical resistance (TEER)  
To generate a “biomimetic urothelium” that generated a TEER, NHU cells were 
seeded onto SnapwellTM membranes after 5 days culture in KSFMc + 5 % ABS at a 
density of 5 x 105 cells per SnapwellTM in a volume of 500 µL. 4 mL of medium was 
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placed in the outer chamber and at 24 hours all medium replaced with KSFMc (2 
mM Ca2+) + 5 % ABS (v/v). Medium was changed every 2-3 days. 
 
TEER was measured, as an indicator of barrier function and differentiation 
capability, using an EVOM TM Epithelial Voltohmmeter (World Precision 
Instruments) after sterilisation in Cidex Plus reagent (World Precision Instruments) 
and having been rinsed twice in sterile KSFMc medium + 5 % ABS (v/v).  
 
2.5.6 Retropack TM PT67 Packaging Cell Line 
The PT67 packaging cell line is a NIH3T3 fibroblast derived cell line purchased 
from Clontech. This cell line has been genetically engineered to produce retroviral 
genes gag, pol and env, enabling it to produce a replication-defective retrovirus 
with a broad (amphotropic) mammalian host range once transfected with a 
retroviral vector such as pLXSN.  PT67 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Life Technologies) supplemented with 10 % (v/v) fetal 
bovine serum (FBS; Harlan Sera-Lab) and were passaged using the same protocol as 
for urothelial cells (2.6.2.4). Before being transfected with a retroviral vector, PT67 
cells underwent Hypoxanthine Aminopterin Thymidine (HAT; Life Technologies) 
medium selection as recommended by the supplier. PT67 cells were cultured for 5 
days in DMEM/10 % FBS with 100nm aminopterin followed by 5 days in DMEM/10 
% FBS-HAT medium (30nm hypoxanthine, 1 M aminopterin, 20 mM thymidine). 
Finally cells were cultured for 5 days in DMEM/10 % FBS-HT (30 mM 
hypoxanthine, 20 mM thymidine) and immediately cryo-preserved.  
 
2.5.7 Cryo-preservation and thawing 
Cells were harvested using EDTA/trypsin in versene as during passaging. Cells 
were centrifuged and resuspended in cell medium (KSFMc for urothelial cells, 
DMEM/10 %FBS for PT67 cells) containing 10 % (v/v) FBS and 10 % dimethyl 
sulfoxide (DMSO). Approximately 1x106 cells were aliquoted into polypropylene 
                                                                                                                   Chapter 2 
41 
 
cryovials (Greiner) and placed into a  “Mr Frosty” (Nalgene; Thermo Scientific) 
containing 250 mL of isopropanol (SLS) that had been kept at 4 oC for >2 hours. The 
“Mr Frosty” was placed into a -80 oC freezer for 12-16 hours before the cryovials 
were transferred into Statebourne storage dewers containing liquid nitrogen (-196 
oC).  
 
To thaw cells, Cryovials were removed from liquid nitrogen and rapidly warmed to 
37 oC. 5 mL of appropriate medium was added and cells centrifuged before being 
resuspended in medium and seeded as required.  
 
2.5.8 Testing cell lines for Mycoplasma 
All cell lines were tested for Mycoplasma by looking for the presence of extra-
nuclear staining with the DNA intercalator Hoechst 33258 (Sigma Aldrich). Cells 
were seeded at a density of 1x104 cells per well onto autoclaved 12 well glass slides 
(Hendley-Essex) in sterile Hereaus boxes (Sartorius). Cells were allowed to attach 
for 4 hours before the chambers of the Hereaus box were flooded with 5 mL of the 
appropriate medium. Cells were cultured until 50-60 % confluent before being fixed 
for 30 seconds in methanol: acetone (1:1; Sigma Aldrich), air-dried and stored at -20 
oC. To stain cells with Hoechst 33258, slides were defrosted to room temperature 
and incubated for 5 minutes in 0.1 µg/mL Hoechst 33258 in PBS in the dark. Cells 
were rinsed twice in PBS, air-dried and mounted in antifade. Slides were examined 
using an Olympus Bx60 microscope using the appropriate epifluorescence filter set.   
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2.6 Molecular Biology 
 
2.6.1 General 
Microbiology work was conducted according to the University of York guidelines 
for Good Microbiological Practise. Aseptic technique was used at all times and all 
benches were cleaned before and after use with 2 % (w/v) Virkon® and 70 % ethanol 
(Sigma). All waste solutions were treated in 2 % (w/v) Virkon® for 24 hours before 
disposal. Glass and plasticware used was submerged in 2 % Virkon® for 24 hours 
before being either autoclaved and disposed of or washed for reuse.  
 
2.6.2 Glass and Plasticware 
5 and 10 mL liquid cultures were incubated in 25 mL polystyrene Universal tubes. 
500 mL glass Buchner flasks were used for overnight incubation of liquid cultures. 
Luria-Broth Agar was poured into 9 cm UV-irradiated Petri dishes (Thermo Fisher) 
and allowed to set at room temperature. Single use inoculating loops (Thermo 
Fisher) and a 100 % ethanol (Sigma Aldrich) sterilised glass L-shaped spreader was 
used for plating bacteria.  
 
2.6.3 Analysis of Gene Expression 
2.6.3.1 General 
RNase Zap® was used to treat all surfaces and pipettes before working with RNA. 
All glass and plasticware was incubated overnight at ambient temperature in 0.1 % 
diethyl pyrocarbonate (DEPC; Sigma Aldrich) to inactivate any RNase’s present. 
DEPC was inactivated by autoclaving in a Harvard/LTE Series 100 autoclave at 
1210C (1 bar) for 20 minutes and air dried at 80 oC. Only DNase and RNase free 
pipette tips (Axygen; Thermo Fisher) and nuclease-free microcentrifuge tubes 
(Ambion; Thermo Fischer) were used. All water was incubated in DEPC overnight 
at room temperature and autoclaved prior to use.  
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2.6.3.2 RNA extraction 
RNA was extracted from cultured cells and tissue samples using TRIzolTM reagent 
(Life Technologies). For cultured cells, medium was removed and the cells rinsed 
twice in 8 mL’s of PBS. 1 mL of TRIzolTM was added and the flask left for 5 minutes 
on a rotary shaker. A cell scraper (StarStedt) was used to remove all of the cells from 
the tissue culture plastic and they were collected in the TRIzolTM reagent into 1.5 mL 
microcentrifuge tubes. At this point samples were able to be stored at -80 oC and 
defrosted on ice when required. Samples were left at ambient temperature for 5 
minutes before 0.2 mL of chloroform (BDH) was added and the tubes vortexed for 
15 seconds. Samples were incubated for 5 minutes at ambient temperature and 
centrifuged (12,000 g) for 15 minutes at 4 oC in a Hettich Mikro-200R. The upper 
aqueous (clear) phase was carefully removed into a fresh 1.5 mL 
microcentrifuge tube, 0.5 mL of isopropanol added and the sample mixed by 
inverting 5 times. The samples were incubated at ambient temperature for 10 
minutes before being centrifuge (12,000 g) for 20 minutes at 4 oC. The 
supernatant was removed and the RNA pellet resuspended in 0.5 mL of 75 % 
(v/v) ethanol. The pellet was recovered by centrifuging (7,500 g) for 5 minutes at 
4 oC, resuspended a second time in 75 % (v/v) ethanol before being collected for 
a final time by centrifuging (7,500 g) for 5 minutes at 4 oC. The pellet was air-
dried and resuspended in 30 µL of DEPC-treated H2O.  
 
 2.6.3.3 DNase treatment 
RNA samples were treated using a DNase I, RNase-free kit (Thermo Scientific) 
according to the manufacturer’s instructions. Briefly, to a 30 µL RNA sample, 3.7 µL 
of 10 x reaction buffer with MgCl2 and 3.7 µL of DNase I, RNase-free were added 
and incubated for 30 minutes at 37 oC. 3.7 µL of 50 nM ethylenediaminetetraacetic 
acid (EDTA) were added, the solution mixed by pipetting and heated to 65 oC for 10 
minutes.  
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2.6.3.4 RNA quantification 
The quantification and quality of isolated RNA was assessed after DNase treatment 
using a NanodropTM UV/visible spectrophotometer (Shamadzu).  
 
2.6.3.5 Removing RNA contamination 
If RNA was found to be contaminated (e.g. with ethanol or salt), as indicated by low 
spectrophotometer 260:230 nm ratio values, it was cleaned by alcohol and salt 
precipitation. 3 M sodium acetate (1:9) and 100 % ethanol (2.5 x volume) were 
added, the sample vortexed and then left at -80 oC overnight (16 hours). Samples 
were centrifuged (12,000 g) for 30 minutes at 4 oC in a Hettich Mikro-200R, the 
pellets resuspended in 500 µL of 70 % (v/v) ethanol and collected again by 
centrifugation (7,500 g) for 5 minutes at 4 oC. Pellets were air-dried and 
resuspended in 30 µL of DEPC-treated H2O.  
 
2.6.3.6 cDNA Synthesis 
cDNA was generated from 1 µg of total RNA using 50 ng of random hexamer 
primers and the SuperscriptTM first-strand cDNA synthesis kit (Invitrogen). RNA 
and random hexamer primers were added together and the total volume made up 
to 12 µl with DEPC-treated water. The sample was heated to 65 oC for 10 minutes 
before being left on ice for 2 minutes. 7 µL of a “master mix” containing 2 µL of 
reverse transcriptase buffer, 2 µL of 25 mM MgCl2, 2 µL of 0.1 mM dithiothreitol 
(DTT) and 1 µL of 10 µM dinucleotide triphosphate (dNTP) mix was added to each 
sample and incubated at ambient temperature for 2 minutes. 1 unit of SuperscriptTM 
II reverse transcriptase enzyme was added and samples incubated for 10 minutes at 
25 oC and 50 minutes at 42 oC. The reaction was inactivated by heating to 70 oC for 
15 minutes. cDNA was stored at -20 oC. For each RNA sample a negative control 
reaction was conducted in which SuperscriptTM II reverse transcriptase enzyme was 
not included (RT negative).   
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2.6.3.7 PCR Primer design and optimisation 
The messenger RNA (mRNA) coding sequences for the gene of interest were 
accessed from the Ensembl database. If multiple protein-coding transcript variants 
exist for the gene of interest, or if the primers were being designed to amplify 
multiple genes with high sequence homologies, sequences were aligned using 
Kalign (EMBL library).  Primers were designed using Primer-Blast (NCBI) to be 17-
23 base pairs (bp) in length and have a melting temperature (Tm) of between 55 and 
65 oC. GC content was restricted to 40-60 %. Where possible primers were designed 
to amplify a region within a single exon. Primers were ordered from Eurofins and 
upon arrival reconstituted to a concentration of 100 mM in DEPC-treated H2O 
before being stored at -20 oC. Primer stocks were diluted 1:10 (10 mM) prior to use. 
Primer sequences can be found in appendix 1.6.  
 
The optimal Tm and primer binding efficiency were established by gradient RT-
PCR (appendix 2.2). RT-PCR reactions were set up as described in section 2.6.3.8. 
with either genomic DNA (non-exon spanning primers) or control cDNA (exon-
spanning primers) used in place of sample cDNA. 8 identical samples were 
subjected to the standard RT-PCR conditions but at a range of temperatures 
between 55 and 65 oC. The efficiency of the PCR reactions at the range of 
temperatures was assessed by agarose gel electrophoresis (section 2.6.5.2 and 
2.6.5.3). The Tm in which the strongest band at the correct molecular weight was 
produced and in which no additional bands occurred was chosen for RT-PCR.  
 
2.6.3.8 RT-PCR  
Standard RT-PCR was conducted using GoTaq® G2 Flexi DNA Polymerase 
(Promega) according to the manufactures instructions. Briefly, a master mix was 
created containing 4 µl of 5X Green GoTaq® Flexi Buffer, 2 µl of 25 mM MgCl2, 2 µl 
of 10 mM forward primer, 2 µL of 10 mM reverse primer, 0.4 µl of dNTP mix (25 
mM of aDTP, dCTP, dGTP, dTTP; Promega), 8.5 µl of DEPC-treated H2O and 0.1 µl 
of GoTaq® G2 Flexi DNA Polymerase (Promega). 19 µL of master mix was added to 
1 µl of sample cDNA in a thin-walled 8-well strip PCR tube (Axygen; Thermo 
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Fisher). The RT-PCR reaction was conducted in a Bio-Rad T100TM thermocycler. 
Samples were heated to 95 oC for 3 minutes initially to activate the enzyme before 
completing 30 cycles of 95 oC for 30 seconds, the annealing temperature (Tm) for 1 
minute and 72 oC for 1 minute. After 30 cycles samples a final elongation step of 72 
oC for 5 minutes was conducted before samples were cooled to and kept at 4 oC. 
Assessment of RT-PCR products was by gel electrophoresis (see sections 2.7.4.2 and 
2.7.4.3). 
  
2.6.3.9 Next generation sequencing 
Next generation sequencing data was accessed from the JBU next generation 
sequencing archive. This data was generated from samples of freshly isolated (P0), 
proliferating (Pro) and differentiated (ABS/Ca2+) NHU cells from three individual 
donors. Samples were analysed on a Illumina Hiseq2000 and results normalised 
before being uploaded onto the database.  
 
2.6.4 Plasmids 
Details of the two plasmids used within this project are listed in Error! Reference 
ource not found..2 and diagrams can be found in Error! Reference source not 
found.2.1 and 2.1. 
 
Table 2.2 Plasmids 
Vector name Supplier Size (Kb) Promoter Use 
pGEM T easy 
Vector 
Promega 3.015 T7 & SP6 Cloning PCR products 
pLXSN  Clontech 5.874 SV40 Gene overexpression 
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Figure 2.1 - Schematic representation of pGEM®T easy vector adapted from the Promega 
pGEM®T and pGEM®T easy vector technical manual showing the T7 and SP6 promoter 
regions.  




Figure 2.2 -  schematic representation of pLXSN vector used for gene overexpression 
adapted from the Clontech pLXSN technical manual. The four restriction enzyme 
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2.6.5 Molecular cloning and retroviral plasmid generation 
2.6.5.1 Restriction enzyme digest 
Restriction digest enzymes were chosen based upon sites that existed in pLXSN 
retroviral plasmid. BamH1 and Hpa1 sites were incorporated onto the end of 
primers designed to amplify the target gene cDNA. Once ligated into pGEM®T easy 
vector, restriction digest was carried out. 2-3 µg of plasmid DNA were digested 
with 5 units of a single restriction enzyme (New England Biolabs) in the appropriate 
buffer at a temperature of 37 oC for 3 hours. The DNA was recovered using a PCR 
purification kit (Quiagen) and the process repeated using a second restriction 
enzyme. The order in which the two enzymes (BamH1 and Hpa1) were used varied 
with no difference noted in the efficiency.  
 
2.6.5.2 Agarose gel preparation 
A plastic gel mould was cleaned with distilled H2O, the ends sealed with autoclave 
tape and plastic gel combs inserted into the designated positions. High purity 
agarose (Life Technologies) was mixed with TBE buffer (Appendix 1.4.4) and 
microwaved for 2-5 minutes until all of the agarose had dissolved. The amount of 
agarose used was dependent on the size of the product expected (Error! Reference 
ource not found.). SYBR®Safe DNA gel stain (Invitrogen) was added according to 
the manufactures instructions (1:1000), the solution mixed by swirling and poured 
into the mould. The gel was then left to set at room temperature for 20-30 minutes. 
The combs and autoclave tape were removed and the gel mould carefully placed 
into a Horizon® 58 electrophoresis gel tank (Gibco®; Life Technologies). The tank 
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Table 2.3 Agarose gel preparations (w/v) 
Percentage agarose gel Agarose (mg) per 200 mL 
TBE 
PCR product length (bp) 
1.5 % 3 mg >1500 
2 % 4 mg 500 - 1500 
2.5 % 5 mg <500 
4 % 8 mg *Separating 2 bands within 
50 bp of each other 
 
* When separating two bands, temperature and electrophoresis times were optimised for 
each individual product 
 
 
2.6.5.3 Agarose gel electrophoresis 
DNA samples from restriction digests and mini/maxi preps were diluted in 6x 
loading buffer (Blue: orange loading dye; Promega) and 18 µL were loaded into 
wells of an agarose gel. 6 µL of Hyperladder IV (DNA < 1000 bp; Bioline) or 4 µL of 
GeneRuler (DNA<10,000; Thermo Fisher) were added to a separate well and a 
voltage of 100 V passed across the gel for 30-60 minutes. In the case of separating 
two bands of similar lengths (<50 bp), a 4 % gel would be made and run on ice at 40 
V overnight. Gels were visualised using a Gene Genius bio-imaging system and 
Genesnap 7.07 software (Syngene).  
 
2.6.5.4 Ligation 
The amount of vector and insert DNA used in a reaction were calculated using the 
following formula: 
   Mass (ng) of Vector    x    Length (kb) of insert 
            Length (kb) of Vector 
 
50 ng of cut vector was ligated as standard. The solution also contained the insert 
DNA, 2 µL of 10x ligation buffer (50 mM Tris-HCL [pH 7.8], 10 mM MgCl2, 20 mM 
dithiothreitol, 10 mM ATP, 50 mg/mL of bovine serum albumin; Promega), 1 µL 
(200 units) of T4 DNA ligase (Promega). dH2O was added to make a final volume of 
X 3   = Mass (ng) of insert 
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Sequencing was conducted by the Technology Facility (Genomics) in the 
department of biology, University of York. 300 ng of plasmid template and specific 
primers (Appendix 1.6) were sent for analysis on an Applied Biosystems 3130XL 
genetic analyser. Results were analysed using Chromas (v2.4.3; Technelysium Pty 
Ltd). Alignment was conducted using Kalign (EMBL library).   
 
 
2.6.6 Amplification of plasmid DNA 
2.6.6.1 Transformation of competent E-coli 
A 50 µL aliquot of XL1-Blue Subcloning-Grade Competent cells (Agilent) were 
transformed using 5 µL of ligated plasmid DNA. The plasmid and cells were gently 
mixed together by pipetting and incubated on ice for 30 minutes. The cells were 
then heats shocked at 42 oC for 45 seconds before being returned to nice for 2 
minutes. 250 µL of S.O.C medium (Life Technologies) was added to the cells and 
the culture incubated on an orbital shaker at 225 rpm for 1 hour at 37 oC. Various 
volumes (50-200 µL) of the cell suspension was spread onto a LB Agar (Appendix 
2.4.4) plate containing 100 µg/mL ampicillin and incubated overnight, inverted, at 
37 oC. 5 mL of LB containing 100 µg/mL ampicillin was then inoculated with a 
single colony, picked using a sterile pipet tip, and incubated for 4 hours at 37 oC on 
an orbital shaker (225 rpm). This culture was then used to inoculate 50 mL LB broth 
which was incubated overnight at 37 oC on an orbital shaker (225 rpm).   
 
2.6.6.2 Plasmid purification 
Plasmid purification was conducted using Midi Endotoxin-free plasmid extraction 
KitsTM (Quaigen) according to the instructions. Overnight 50 µL cultures of 
transformed bacteria were collected by centrifugation (4000 g for 15 minutes) and 
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the pellet resuspended in 4 mL of P1 buffer. 4 mL of P2 buffer was added and the 
solution inverted several times before being incubated at ambient temperature for 5 
minutes. 4 mL of N3 buffer (chilled to 4 oC) was added and the solution inverted 
several times until mixed thoroughly.  
 
2.6.6.3 Bacterial Glycerol stocks 
750 µL of overnight LB cell suspensions were aliquoted into a 1.5 mL cryovial® with 
250 µL of sterile 80 % (v/v) glycerol. The solution was mixed and then stored at -80 
oC. To recover bacteria a glycerol stock was removed from -80 oC and a sterile 
inoculation loop used to streak colonies on a LB agar plate (Appendix 2.4.4) (100 
µg/mL ampicillin) which was then incubated, inverted, overnight at 37 oC.  
 
2.7 Protein Analysis 
2.7.1 Antibodies 
The primary antibodies in this work are listed in Table 2.4 with details of the 
concentrations that they were used at. Working antibody concentrations were 
optimised for each technique using known positive controls and positive and 
negative controls were included in each experiment conducted (Appendix 2.1). 
Antibody diluents were specific for each technique. Primary antibodies were 
aliquoted and stored according to the manufactures instructions. Fluorochrome-
conjugated or biotin-conjugated secondary antibodies are listed in Table 2.5 with 
details of working concentrations. Antibodies were titrated prior to use and stored, 
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Table 2.4 Primary Antibodies 
Antigen Clone Host Supplier Use Molecular 
weight of 
antigen 
Cytokeratin 7 LP1K Mouse CRUK IHC 1:1000  
IF   1:1000 
56 kDa 
Cytokeratin 5  Sheep The Binding Site IHC 1:250 
IF 1:100 
 
Ki67 MM1 Mouse  Novocastra IHC   1:100   




8.00E+07 Mouse Millipore IHC    1:300   
IF   1:500   




D9E Rabbit Cell Signalling IF   1:100   





D13.14.4E Rabbit Cell Signalling IF   1:100   
WB   1:1000 
42/44 kDa 
Claudin 4  3E2C1 Mouse Zymed IF   1:250 22 kDa 
ZO-1 ZO1 Rabbit Zymed IF   1:800 68 kDa 
Uroplakin 3a AU1 Mouse Progen IHC 1:200 
IF 1:25 
 
CYP2B1/2 2S3 Rabbit Kind gift from 
Dr R Edwards 
IHC 1:2000   
WB   1:1000 
42 kDa 
CYP2B6 1.6.94 Rabbit Kind gift from 
Dr R Edwards 
WB 1:1000 42 kDa 
 
Table 2.5 - Secondary antibodies 
Antigen Conjugate Host Supplier Application 
Mouse IgG Alexa 488 Goat Molecular Probes Immunofluorescence 
Mouse IgG Alexa 594 Goat Molecular Probes  Immunofluorescence 
Rabbit IgG Alexa 488 Goat Molecular Probes Immunofluorescence 
Rabbit IgG Alexa 594 Goat Molecular Probes Immunofluorescence 
Goat IgG Alexa 488 Donkey Molecular Probes Immunofluorescence 
Goat IgG Alexa 594 Donkey Molecular Probes Immunofluorescence 
Mouse IgG Alexa 680 Goat Life Technologies Western Blotting 
Rabbit IgG Alexa 800 Goat Life Technologies Western Blotting 
Mouse IgG Biotin Rabbit Dako Immunohistochemistry 
Rabbit IgG Biotin Goat Dako Immunohistochemistry 
Goat IgG Biotin  Rabbit Dako Immunohistochemistry 
 
 




2.7.1 Immunofluorescence labelling 
Specific antibody labelling of NHU cells was used to quantify protein expression 
within cells and assess distribution throughout cells. A target-protein specific 
primary antibody is used to label the target within cells before a fluorophore-
conjugated secondary antibody was used to bind specifically to the primary 
antibody. The fluorophore was then excited by an appropriate wavelength of light 
and visualised and quantified. 
 
2.7.1.1 Slide preparation 
Teflon® coated 12-well multisport slide (CA Hendley) were cleaned with 70 % (v/v) 
ethanol and sterilised by autoclaving, after which aseptic technique was observed. 
Slides were placed into Hereaus boxes using forceps and 50 µL of cells suspension 
at a density of 5x104 cells/mL seeded directly onto each well. Slides were incubated 
for 4 hours at 37 oC to allow cell adhesion before slides were flooded with 5 mL of 
cell culture medium.  At the time points indicated in the results, cell culture 
medium was removed and cells fixed. 
 
2.7.1.2 Fixation 
Cells were fixed with either methanol: acetone (50:50) or with 10 % (v/v) formalin 
(appendix 1.4.3) depending on the target protein and/or primary antibody being 
used. For methanol: acetone fixation, cells were incubated for 30 seconds at ambient 
temperature in 5 mL methanol: acetone before being air-dried and stored at -20 oC. 
For formalin fixation, cells were incubated for 30 minutes in 10 % (v/v) formalin in 
PBS and then rinsed twice for 5 minutes in PBS. Cells were permeabilised with 0.5 
% (v/v) Triton-X in PBS for 1 hour before being rinsed for 5 minutes in PBS. Cells 
were stored in PBS at 4 oC for no more than 48 hours. Before labelling slides were 
removed from PBS but the cells were not allowed to dry.  
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2.7.1.3 Immunofluorescence labelling of cells 
A liquid blocker super pap pen (Daido Sangyo) was used to draw around wells 
before labelling. 50 µL of primary antibodies, diluted in TBS (appendix 2.4.4) with 
0.1 % (v/v) BSA (Pierce) and 0.1 % NaN3 (w/v; Sigma Aldrich), was added to each 
well of the slide and incubated at 4 oC overnight (approximately 16 hours). A 
negative TBS only well was always included. After incubation, slides were rinsed 3 
times for 5 minutes in TBS at ambient temperature on an orbital shaker. 50 µL of the 
appropriate Alexa 488 or Alexa 594 secondary antibody diluted in TBS was then 
placed on each well and the slides incubated at ambient temperature for one hour in 
the dark. Slides were rinsed a further 3 times for 5 minutes in TBS on an orbital 
shaker before being stained with Hoechst 33258 (0.1 µg/mL in TBS). Slides were 
rinsed a final time for 5 minutes in TBS on an orbital shaker before being air-dried, 
mounted in DABCO/glycerol antifade (Appendix 1.4.3) and a coverslip secured 
using nail varnish.  
 
2.7.1.4 Imaging immunofluorescence labelled cells 
Cells were imaged using either the x20, x40 and x60 oil immersion objectives on a 
Olympus BX60 microscope under epifluorescent illumination or using the 
fluorescence imaging function of a Axio Scan.Z1 slide scanner (Zeiss). The Olympus 
BX60 microscope was equipped with excitation and emission filters for 
bisnenzimide, FITC and Texas Red and an Olympus DP50 digital camera for 
imaging. Images were assessed in Image-Pro® Plus software (MediaCybernetics). 




2.7.2 Immunolabelling of tissue sections 
2.7.2.1 Tissue fixation, embedding and sectioning 
Rat and human tissue was fixed in 10 % (v/v) formalin for 24 hours (less than 1 cm2) 
or 48 hours (1-2 cm2) dependant on size. If tissue was larger than 2 cm2 in size it was 
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dissected into an appropriate number of pieces, which were embedded separately. 
Formalin was removed and replaced with 70 % (v/v) ethanol for at least 24 hours 
before embedding. For long-term storage before embedding, 70 % (v/v) ethanol was 
replaced like for like at 24 hours and samples stored at ambient temperature. Tissue 
was placed into labelled cassettes and then either a short dehydration protocol used 
for small (less than 1 cm2) bladder tissue or a longer dehydration protocol used for 
larger (1-2 cm2) bladder samples and denser tissue types including liver and kidney. 
The short protocol involved 3 x 10 minute washes in 100 % ethanol followed by 2 x 
10 minute washes in 100 % propan-2ol (Thermo Fisher) and 4 x 10 minute washes in 
100 % xylene (Fisher Scientific). Cassettes were then immersed in molten paraffin 
wax (Thermo Scientific) at 60oC which was changed every 15 minutes for an hour. 
The longer dehydration protocol involved a 2 hour incubation in 90 % (v/v) ethanol 
followed by a 2 hour incubation in 100 % ethanol and a 2 hour incubation in xylene. 
Samples were then left overnight (approximately 16 hours) in paraffin wax at 65 oC 
which was followed by 3 x 30 minute incubations in fresh paraffin wax. After both 
dehydration protocols, tissue sections were orientated appropriately and embedded 
in fresh paraffin wax which was chilled on a cold plate set at -12 oC at left for at least 
12 hours before sectioning. To generate sections, blocks were chilled on the cold 
plate set at -12 oC for at least half an hour before 5 µm sections were cut on a 
microtone (Leica RM 2135). Individual sections were floated in a water bath set at 40 
oC and collected onto Superfrost® Plus glass slides (Thermo Fisher). Slides were air 
dried and baked at 50 oC on a hot plate for 30 minutes. Immediately prior to use 
slides were dewaxed and rehydrated by 4 x 1 minute incubations in xylene, 3 x 1 
minute incubations in 100 % ethanol and 1 x 1 minute incubation in 70 % (v/v) 
ethanol before being left in distilled water for one minute. 
 
2.7.2.2 Endogenous peroxidase inactivation and antigen retrieval 
Endogenous peroxidases are present in a number of cells (e.g. red blood cells) and 
could interfere with the labelling process. To inhibit endogenous peroxidase activity 
slides were incubated at ambient temperature in 3 % (v/v) H2O2 (Thermo Fisher) for 
10 minutes and rinsed in distilled water for 10 minutes.  
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To prevent formalin cross-linking from masking antigens one of four antigen 
retrieval protocols was used after peroxidase inhibition. These protocols were: 
i. Citric acid 
Slides were immersed and weighted down in 10 mM citric acid (pH 6.0; Thermo 
Fisher) and microwaved at 900 W for 13 minutes. Following microwaving slides 
were chilled on ice and rinsed in distilled water.  
 
ii. Trypsin 
Slides were incubated at 37 oC in 100 mL 0.1 % (w/v) trypsin from porcine pancreas 
(Sigma Aldrich) in 0.1 % (v/v) CaCl2 solution at pH 7.8 for 10 minutes and then 
rinsed in distilled water.  
 
iii. Trypsin and citric acid 
Slides were incubated for 1 minute at 37 oC in 100 mL 0.1 % (w/v) trypsin from 
porcine pancreas in 0.1 % (v/v) CaCl2 solution at pH 7.8 before being transferred 
into 10 mM citric acid (pH 6.0) and microwaved at 900 W for 13 minutes. Slides 
were subsequently chilled on ice and rinsed in distilled water.  
iv. EDTA 
Slides were immersed and weighted down in 1 mM EDTA solution (pH 8.0) and 
microwaved at 900 Watts for 13 minutes before being chilled on ice and rinsed in 
distilled water. 
Each antibody was tested with each of the antigen retrieval protocols at a range of 
concentrations and with a concentration and protocol chosen that produced clear 
labelling with minimal background.  
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2.7.2.3 Immunoperoxidase labelling 
Slides were immersed in TBS (Appendix 1.4.3) and placed into Shandon Sequenzas 
(Thermo Fisher) on cover plates. Each slide was blocked for 10 minutes with 100 µl 
Avidin (Vector Laboratories), washed twice with TBS, and blocked for 10 minutes 
with 100 µL Biotin (Vector Laboratories). Slides were washed twice in TBS, 
incubated for 5 minutes in 100 µL of 10 % (v/v) serum (Dako) from the secondary 
antibody host animal followed by overnight (approximately 16 hour) incubation in 
an appropriate concentration (Table 2.4) of the primary antibody at 4 oC. The 
primary antibody was removed by washing slides twice in TBS. Slides were then 
incubated at ambient temperature for half an hour in an appropriate concentration 
(Table 2.5) of an appropriate biotinylated secondary antibody. The secondary 
antibody was removed by washing twice in TBS and 100 µL of streptavidin-
Horseradish peroxidase (HRP) (Vector Laboratories), prepared 30 minutes prior to 
use according to the manufactures instructions, was added to each slide and 
incubated at ambient temperature for 30 minutes. Slides were washed twice in TBS 
and 200 µL  SigmaFAST diaminobenzidine (DAB) (Sigma Aldrich), prepared in 
dH2O according to the manufactures instructions, added to each slide for 10 
minutes. Slides were rinsed in dH2O, counterstained for 30 seconds in Mayers 
Haematoxylin (appendix 2.34.3) and dehydrated through 1 x 1 minute 75 % (v/v) 
ethanol incubation, 3 x 1 minute 100 % ethanol incubations and 2 x 1 minute 100 % 
Xylene incubations. Slides were left air dry and mounted under a coverslip in DPX 
mounting fluid (CellPath).  
 
2.7.2.4 Immunoperoxidase labelling using the catalysed signal amplification 
kit 
An catalysed signal amplification (CSA) kit was purchased from Dako and used 
according to the manufacturer’s instructions. Briefly, after antigen retrieval (Section 
2.7.2.2), slides were placed into sequenzas and blocked with avidin and biotin as 
described in section 2.7.2.3 but with the exception of TBS being replaced with TBST 
(Appendix 1.4.3). Slides were blocked with serum free protein block reagent (Dako) 
for 5 minutes and incubated in the primary antibody, diluted appropriately in 
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antibody dilution buffer (Dako), for 15 minutes. Three 5 minute TBST washes were 
used to remove the primary antibody and 100 µL of secondary antibody 
(biotinylated link antibody (Dako) for mouse primary antibodies and biotinylated 
anti-rabbit antibody (Table 2.5) for rabbit primary antibodies) applied to each slide 
for 15 minutes. Slides were then washed 3 times in TBST and Streptavidin-biotin 
complex (Dako), pre-prepared 30 minutes prior to use, added for 15 minutes. Slides 
were washed three times in TBST and 100 µL of amplification reagent (Dako) added 
to each slide for 15 minutes before being removed by three TBST washes. 100 µl of 
Streptavidin-HRP (Dako) was added to each slide for 15 minutes and removed with 
three TBST washes and 100 µL of DBA reagent (Dako) added to each slide for 10 
minutes. Slides were then removed from sequenzas, washed in dH2O before being 
counterstained in Mayers Haematoxylin, dehydrated and mounted as described in 
section 2.7.2.3.  
 
2.7.3 Image capture and analysis 
TissueGnostics software was used to quantify immunolabelling of specific proteins 
in images of tissue sections or cultured cells. Samples were only comparable if 
labelled at the same time and if TissueGnostics settings were unaltered after initial 
optimisation.    
 
2.7.3.1 Image acquisition 
 
Images of whole tissue sections/cultured cell layers were taken using an Axio 
Scan.Z1 slide scanner and Zen 2012 (blue edition) software. Images were stored as 
.czi files and reopened using TissueGnostics HistoQuest (immunoperoxidase) or 
TissueQuest (immunofluorescence) software.  
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2.7.3.2 Cell identification and immunolabelling assessment 
An initial region of interest (ROI) was selected for software optimisation consisting 
of less than 200 cells. By altering the nuclear size, remove small objects, remove 
weakly labelled objects and the automatic background parameters, individual cell 
nuclei were identified. Immunolabelling intensity was then quantified using the 
identified cell mask parameter. Dependent on whether the labelled protein was 
nuclear or cytoplasmic, an outside, inside and outside or inside cell mask was 
selected. These masks projected from the identified cell nuclei and the scale settings 
were adjusted until cells boundaries were clearly identified.  All labelling within the 
masks was quantified to produce arbitrary intensity values. Once complete, a larger 
ROI was selected and the labelling intensity quantified using the optimised settings.   
Individual cells in immunoperoxidase labelled images were selected based on 
haematoxylin staining of cell nuclei by the HistoQuest software. Individual cells in 
immunofluorescence labelled images were identified based on the Hoechst 33258 
labelling of their nuclei by the TissueQuest software. 
 
2.7.3.3 Analysis 
DAB/fluorescence intensity values (arbitrary units) were either exported directly 
into Microsoft excel and statistical analysis conducted or used within 
TissueGnostics software to generate positive/negative cell labelling ratios. To 
achieve this, a positive/negative cut-off threshold was established based on visual 
assessment of labelling and the percentage of cells falling into each group 
determined.  
 
2.7.4 Western Blotting 
2.7.4.1 Cell Lysis 
Cultured cells or cells harvested from tissue were washed twice in cold (4 oC) PBS 
and lysed in 50 µL of 2 % (w/v) SDS lysis buffer (appendix 1.4.5) containing 
protease inhibitor cocktail (1:500; Sigma Aldrich) and 13 mM dithioreitol (DTT) 
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(Sigma Aldrich). To facilitate adherent cell removal into lysis buffer, cells were 
gently scraped using a cell scraper. Lysed cell solution was collected in a 1.5 mL 
microcentrifuge tube on ice and sonicated (25 W) for a 10 seconds before being 
rested for 10 seconds on ice and sonicated for a further 10 seconds. Post-sonication, 
lysates were rested on ice for 30 minutes before being centrifuged for 30 minutes at 
14,000 rpm. The supernatant was collected into a fresh microcentrifuge tube with 
care being taken not to collect any of the pellet which was discarded. 
 
2.7.4.2 Protein concentration assay 
 Coomassie Plus reagent (Thermo Fisher) was used to quantify protein 
concentrations. Bovine serum albumin (BSA) (Thermo Fisher) standards of 25, 125, 
250, 500, 750 and 1000 µg/mL were generated from a 2 mg/mL stock solution. 10 µL 
of each standard was pipetted in duplicate onto a 96 well plate (Corning) along with 
cell lysates which were first diluted 2:25 in dH2O. 200 µL of Coomassie Plus reagent 
at ambient temperature was added to each sample and the absorbance read at 
wavelengths of 480 and 630 nm on a Multiskan Ascent microplate reader (Thermo 
Electron Corporation). The protein concentration was calculated from the BSA 
standard curve taking into account the dilution factor (1:12.5).  
 
2.7.4.3 Protein sample preparation 
Samples containing 20 µg of protein were generated. Samples also contained LDS 
sample buffer (Invitrogen) in a ratio of 1:4 (v/v) and Reducing agent (Invitrogen) in 
a ratio of 1:10 (v/v). Samples were made up to a total volume of 35 µL with dH2O 
and heated to 70 oC for 10 minutes before loading.  
2.7.4.4 SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
A precast Novex 10 well 4-12% Bis-Tris gel (Invitrogen) was removed form its 
package and rinsed in dH2O. The comb was removed and the gel placed into the 
running apparatus according to the manufacturers instructions. Approximately 200 
mL of running buffer (appendix 1.4.5) was placed into the central well of the 
apparatus (enough to cover the top of the gel) and 200 µL of antioxidant 
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(Invitrogen) added. The chamber was checked for leaks before 600 mL of running 
buffer was then poured into the outer well. Samples were loaded into individual 
wells. 5 µL of precision plus protein™ All Blue prestained protein standard (Bio-
Rad) was added to a separate well, the apparatus lid attached and ice packed 
around the outside.  Electrophoresis was carried out at 200 V for 50 minutes.   
 
2.7.4.5 Protein transfer and imaging 
PVDF membrane (Millipore) was cut to the approximate size of the gel, dipped into 
100 % methanol and rinsed in dH2O for 2 minutes. Filter paper was also cut to the 
approximate size of the gel (2 per gel) and together with blotting pads soaked in 
transfer buffer (appendix 1.4.5). The gel sandwich was assembled and placed into a 
transfer apparatus (Novex) according to the manufacturers instructions with care 
being taken to avoid air bubbles from becoming trapped within the system. The 
central chamber was filled with transfer buffer and the outer chamber filled with 
dH2O. The apparatus lid was attached, the apparatus surrounded by ice and a 
voltage of 30 V passed through the system for 2 hour.  Upon completion the 
membrane was removed from the gel sandwich and placed into TBS buffer 
(appendix 1.4.5). Protein transfer to the membrane was visualised by staining with 
42mM Ponceau red in 3 % (v/v) trichloroacetic acid, and washed off in dH20. The 
membrane was blocked in 10 mL of Odyssey blocking buffer diluted 1:1 (v/v) with 
TBS on an orbital shaker for 1 hour. The blocking solution was removed and the 
primary antibody added, diluted in Odyssey blocking buffer / TBST (1:1 v/v) 
(appendix 1.4.5). The sample was incubated overnight at 4 oC. The membrane was 
rinsed 4 times for 5 minutes in TBST before the secondary antibody, diluted in 
Odyssey blocking buffer / TBST (1:1 v/v), was added. The membrane was placed in 
the dark on an orbital shaker for 1 hour before being rinsed for 5 minutes in TBST 
and 3 times for 5 minutes in TBS. Epifluorescence imaging at 700 and/or 800 nm 
using the Odyssey v1.1 software (Li-Cor) was conducted to visualise 
immunolabelling.  
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2.7.4.6 Membrane stripping 
Membranes were stripped using the Western Blot recycling kit (Autogen Bioclear) 
according to the manufactures instructions. The membrane was incubated for 30 
minutes in stripping buffer diluted 1:10 (v/v) in dH2O.  The membrane was 
rescanned to ensure that stripping had been successful before being rinsed for 5 
minutes in TBS. The membrane was then blocked and probed again as described in 
section 2.7.3.5.   
 
2.8 Statistical analysis 
Data was represented graphically using Excel® (Microsoft). Where possible, data 
was presented as the mean of all replicates with error bars representing ± 1 standard 
deviation (SD). Statistical analysis was conducted using instat 3.1 software 
(Graphpad) when at least three data points were obtained, in which case, the data 
were confirmed to be drawn from Gaussian distribution. 2-way analysis of variance 
(ANOVA) tests were used to compare three or more sample means, along with the 
appropriate post-test. Tukey range test (Tukey test) were used to test which 
treatments were significantly different from each other. A 2-tailed, paired student T-
test was used to compare two sample means generated from the same cell lines.  
Levels of significance are cited in the test and assumed to be significant where 
p<0.05.  
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3.1 Chapter Introduction 
3.1.1 The Bladder 
The urinary bladder is the organ responsible for the storage of urine produced   by 
the kidneys, prior to voiding. As such, the bladder has to be highly compliant in 
order to expand and maintain low pressure as the volume of urine increases and to 
contract when urine is voided (reviewed by Andersson and Arner, 2004). As an 
important route of excretion for numerous endogenous and exogenous compounds 
(discussed by Anzenbacher and Zanger, 2012), urine represents a hostile 
environment and the bladder must be able to  maintain a tight barrier in order to 
prevent toxin, ion, solute and water flux into the body. The concentrating effect of 
filtration by the kidneys can result in the lining of the bladder being exposed to 
higher concentrations of potentially toxic compounds than other organs in the body. 
The duration of exposure can also exceed that of other organs. Exposure to 
increased concentrations of toxic compounds for longer durations than other organs 
increases the risk of damage, and can result in toxicity that is specific to the bladder 
(Kawanishi et al., 2002; Akagi et al., 2003).  
 
 
3.1.2 The Urothelium  
The urothelium is a highly specialised, transitional epithelium that lines much of 
the urinary tract including the renal pelvis, the ureters and the urinary bladder. It 
has a stratified structure comprising the three specialised cell zones of the 
superficial “umbrella” cells, intermediate cells and basal cells. Although superficial 
cells are regarded as being terminally differentiated (Varley et al., 2004), urothelial 
cell phenotype has been shown to be plastic, with the cellular localisation or niche 
determining the differentiation status of urothelial cells (Wezel et al., 2014).   
 
Human urothelial cells normally exist in a quiescent state, undergoing mitosis an 
estimated 1-2 times per year (Marceau N, 1990).  In response to injury or damage, 
however, the urothelium has been shown to have a high capacity for regeneration 
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(Baskin et al., 1997; Cohen, 1989; Rebel et al., 1994), which has led to the hypothesis 
that a urothelial stem cell population exists to regulate this response (Gaisa et al., 
2011; discussed by Ho et al., 2012).  
In rodent urothelium, cells within the basal cell layer have been shown to be label-
retaining in vivo, highly proliferative in response to injury and capable of 
communication with the underlying stroma through sonic Hedgehog/Wnt 
signalling (Shin et al., 2011; Zhang et al., 2012). This strongly suggests the presence 
of a stem or progenitor cell population within the basal cell layer (Nguyen et al., 
2007; Kurzrock et al., 2008) and that these cells are in close communication with the 
underlying stromal cells across the basement membrane. 
 
In human urothelium, fewer studies looking for stem cells have been published. By 
tracking urothelial cells containing non-pathogenic age-related mutations of 
mitochondrial DNA, Gaisa et al. found that clonal units of cells with the same 
lineage exist within the urothelium (Gaisa et al., 2011). These units were shown to 
span all cell layers of the urothelium and all contained a small number of basal cells 
in contact with the basement membrane.  Gaisa et al. proposed that these basal cells 
could be urothelial stem cells, although they acknowledged that is difficult to 
confirm without a definitive stem cell marker.  A separate study cultured isolated 
human urothelial cells in the presence of epithelial growth factor (EGF) and basic 
fibroblast growth factor (bFGF). By doing so they were able to isolate self-renewing 
CD34+, DC45- urothelial cells that grew into spheroids, which were proposed to be 
a functional urothelial progenitor/stem cell (Fierabracci et al., 2007). 
Alternatively, human urothelial cells have been shown in vitro to be capable of self-
regulating proliferation and wound response. Urothelial cells from all cell layers of 
the urothelium are capable of undergoing mitosis (Hicks, 1975) and regulating 
proliferation and migration in response to wounding through an EGFR mediated 
autocrine signalling loop (Varley et al., 2005). Furthermore, it has been 
demonstrated that all normal human urothelial cells have the same capacity for 
proliferation in vitro, independent of their origin in vivo (Wezel et al., 2014). These 
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findings suggest a global urothelial response to injury, thus supporting the concept 
of cellular localisation or niche determining the differentiation phenotype of 
urothelial cells.  
 
The urothelium is generally regarded as the tightest epithelial barrier in the human 
body (reviewed by Anderson and Van Itallie, 2009), allowing it to function as an 
effective barrier to urine. This is achieved by the expression of asymmetric unit 
membrane (AUM) plaques on the apical surface of superficial cells, and the 
presence of tight junctions between urothelial cells. AUM plaques cover between 
70-90% of the apical membrane of superficial cells and are divided by hinge areas 
formed of flexible plasma membrane segments. They are composed of several 
uroplakins (UPKs), the expression of which has been well characterised (reviewed 
by Lee, 2011). AUM plaques are found on the apical surface of superficial cells and 
are reliable markers of differentiation in urothelial cells of all mammalian species, 
including humans and rats. AUM plaques limit the contact of superficial cells with 
urine, increasing the durability of cells and their resistance to damage by harmful 
constituents of urine (Walz et al., 1995; reviewed by Lewis, 2000). Urothelial cell 
tight junctions are formed from multiple proteins including occludins and claudins, 
and are regulated during cell differentiation by PPARγ activation (Varley et al., 
2006). Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the 
nuclear hormone receptor superfamily. When ligand-bound, PPARγ 
heterodimerises with retinoid X receptor (RXR), forming a transcription factor that 
binds to specific peroxisome proliferator response elements (PPREs) in the 
promoter regions of target genes. PPARγ is known to be upstream of several 
transcription factors, including IRF1, FOXA1, ELF3, KFL5 and GATA3 (Varley et al., 
2009; Bock et al., 2014). In urothelial cells, PPARγ activation is known to promote 
the activation of differentiation-associated genes including uroplakin (UP) 1a, UP2, 
UP3b, cytokeratin (CK) 13 and CK20 as well as claudins 3, 4 and 5 (Varley et al., 
2004; Varley et al., 2006; Varley and Southgate, 2008).   




Figure 3.1 – PPARγ activation of urothelial differentiation-associated gene expression. 
Cartoon depicting activation of PPARγ binding through the binding of a PPARγ ligand, 
initiating heterodimerization with RXR. The PPARγ-RXR transcription factor then binds to 
peroxisome proliferator response elements (PPRE), resulting in secondary transcription 
factor expression. These transcription factors subsequently activate differentiation-
associated genes.  
 
In particular, the expression of claudin 3, in conjunction with a ZO-1 switch from 
the ZO-1α- isoform to the ZO-1α+ isoform, have been shown to be essential for 
barrier function in vitro (Smith et al., 2015). Tight junctions function to prevent 
paracellular movement of ions and solutes across the urothelium. A 
glycosaminoglycan (GAG) layer is also present on superficial urothelial cells and 
may contribute to urothelial barrier function and defence (reviewed by Parsons, 
1993).  
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The urothelium has been reported to have sensory ability, disruption of which may 
be involved in pathological conditions such as interstitial cystitis (discussed by 
Apodaca, 2004; Birder et al., 2010). Thus, urothelial cells are able to detect chemical, 
mechanical and thermal stimuli through the expression of receptors including 
purinergic, nicotinic and muscarinic receptors and ion channels including TRP 
channels and epithelial sodium channels (ENaC) (Beckel and Birder, 2012; Birder et 
al., 1998; Chopra et al., 2008a; Kullmann et al., 2008). Urothelial cells are reported to 
be capable of responding to stimuli by releasing chemical signalling molecules such 
as ATP, nitric oxide (NO) and acetylcholine (ACh), allowing for communication 
within the urothelium and with underlying stromal cells in the lamina propria 
(reviewed by Birder, 2010). As the urothelium is aneural, chemical communication 
across the basement membrane allows for urothelial-neuronal interactions and 
signalling.  A useful example of these sensory interactions is in normal and 
pathological conditions involving bladder voiding. Sensory urgency, a dysfunction 
condition in which the sufferer continually feels the desire to empty their bladder, is 
associated with a significant increase in TRPV1 receptors in the urothelium (Daly et 
al., 2007). Similarly, TRPV4, TRPA1 and TRPM8 antagonists have been shown to 
have some therapeutic merit in treating lower urinary tract symptoms (Franken et 
al., 2014). Other prominent TRP channels in the urothelium including TRPV4 are 
thought to be involved in the sensory regulation of normal bladder voiding 
(Gevaert et al., 2007; Olsen et al., 2011; Ogawa et al., 2015). In mouse models, TRP1 
and TRPV4 knockout animals showed altered voiding characteristics when 
compared to wild type littermates (Yoshiyama et al., 2015).  Although a strong case 
for the sensory role of urothelium has been presented by some, there are 
contradictions in the experimental approaches used to support the claims, including 
the specificity of reagents and the nature of the tissue preparations used (reviewed 
by Yu & Hill 2011). In cultures of human urothelial cells in vitro, a lack of 
responsiveness to specific TRPV1 and TRPV4 agonists and antagonists has been 
reported in conjunction with the urothelial expression of functional P2Y4 receptors 
(Shabir et al., 2013).  
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3.1.3 Urothelial cell culture models 
Normal Human Urothelial (NHU) cells 
NHU cells can be isolated from surgical biopsies and grown in culture where they 
switch from a quiescent to a regenerative and migratory phenotype (Hutton et al., 
1993; Rebel et al., 1994; Southgate et al., 1994). Cultured in keratinocyte serum free 
medium under conditions of low calcium and exogenous epithelial growth factor 
(EGF), Cholera toxin (CT) and bovine pituitary extract (BPE) supplementation 
(KSFMc medium), isolated NHU cells can be subcultured over several passages 
(Southgate et al., 1994; Southgate et al., 2002). The proliferative phenotype of NHU 
cells can be maintained for up to at least 6 passages without changes occurring in 
cell morphology and NHU cells can be induced to adopt a differentiated phenotype 
through the addition of adult bovine serum (ABS) and increasing the extracellular 
calcium concentration to an approximately physiological (2mM) concentration 
(Cross et al., 2005). When induced to differentiate by this method, NHU cell 
proliferation is inhibited and the cells express differentiation-associated proteins 
such as uroplakins and claudins. ABS/Ca2+ differentiated NHU cells also create a 
stratified structure in vitro that resembles the urothelium in situ and acts as a 
functional barrier, demonstrated by the generation of a transepithelial electrical 
resistance (TEER) (Rubenwolf and Southgate, 2011; Baker et al., 2014).  
 
Normal Rat Urothelial (NRU) cells 
Isolation and culture of normal rat urothelial (NRU) cells have been described in the 
literature by several research groups (detailed in Table 3.1). NRU cells have been 
reported to grow in “cobblestone-like” colonies which produce a three-dimensional 
tiered structure in culture and which do not expand to cover all of the available 
surface area (Zhang et al., 2001).  This phenotype is likely to be the result of 
isolation protocols and/or culture conditions. In particular the use of serum, which 
is known to induce a differentiated phenotype in NHU cells, would likely result in 
alterations in NRU cell phenotype and growth characteristics. The culture of NRU 
cells in KSFMc (low calcium) medium, in which NHU cells adopt a proliferative 
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phenotype and expand until becoming contact inhibited, has not been reported. 
Two publications have reported serially sub-culturing NRU cells beyond passage 2 
(Zhang et al., 2001; Kurzrock et al., 2005) but this has not been replicated, as all 
other publications only culture primary NRU cells. 
 
The lack of a standardised NRU cell culture model has resulted in numerous 
differences between published NRU cell cultures. The strains, ages, weights, 
gender, isolation protocols and culture conditions that have been published differ 
greatly (described in Table 3.1). Published NRU cell isolation protocols are different 
to each other and to the established NHU cell isolation protocol. Varying protocols 
for isolation and culture could affect NRU cell yield and cell phenotype in culture 
and result in NRU cell cultures that are contaminated with stromal cells. This would 
result in NRU cell cultures with different capacities for growth, which is possibly 
represented by the time that NRU cells were cultured for before being harvested or 
fixed for analysis. When combined with the differences of strain, age/weight and 
sex, the various protocols generate NRU cell cultures, which are difficult to compare 
either with each other or with the NHU cell culture system.  
 
One significant difference between reported culture conditions for NRU cells is the 
use of serum supplemented cell culture medium, with the most common being fetal 
bovine serum (FBS). FBS is a common cell culture medium supplement that is 
required for the growth, proliferation and adhesion of multiple cell lines but is not 
required for NHU cell proliferation in vitro and has an inhibitory effect on NHU cell 
growth (Southgate et al., 1994; Cross et al., 2005).  FBS contains a cocktail of growth 
factors, antibodies and various other proteins that can have multiple stimulatory 
effects on cells in vitro. (Honn et al., 1975). Despite being used for over 50 years, FBS 
has never been fully characterised and the most recent studies have shown that it 
contains in excess of 1,800 protein and 4000 metabolites that can vary significantly 
between batches (reviewed by Jochems et al., 2002; Gstraunthaler et al., 2013). The 
exact mechanisms by which FBS stimulates cellular growth are unknown, due to the 
large number of growth factors it contains, making its use in researching normal 
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cellular functions and physiology contra-indicated (Gstraunthaler, 2003; discussed 
by van der Valk et al., 2010). Similarly the use of irradiated fibroblast feeder layers 
can also distort normal cellular mechanisms by releasing or stimulating the 
production of a cohort of factors (Eiselleova et al., 2008; Wang et al., 2012).  
The lack of consistency in rats sourced, isolation protocols and NRU cell culture 
conditions poses a problem when attempting to compare NRU cell culture system 
against both each other and against the normal human urothelial (NHU) cell 
system. As such, there is a necessity to develop a standardised NRU cell culture 
system. For the purposes of fulfilling the aims of this project, the standardised 
system is required to be as similar as possible to the established NHU cell culture 
system to allow accurate comparisons to be made of the two systems.  
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Rozell et al. 1997 
 
Sprague-Dawley 3-6 weeks Male Collagenase IV / Trypsin (4 
hours at 4 oC) 
Collagenase IV / Trypsin (7 
mins at 37 oC on a shaker) 
24-28 hours 
Zhang et al. 2001 
 
Wistar  540-600 g Male 1 % Collagenase IV (1 hour at 
37 oC) 
None 13 days 
Kurzrock et al. 2005 Sprague-Dawley 200-500 g - 0.05 % Trypsin (1 hour at 37 
oC in 95 % CO2) 
None Passage 10 
Chopra et al. 2008 
 
Sprague-Dawley -  - Dispase (overnight at 4 oC) Trypsin / EDTA (15 mins at 
36 oC) 
Confluence 
Chopra et al. 2008 
 
Wistar  9 months Male 0.1 % EDTA (4 hours at 37 oC) Collagenase IV (30 mins at 
37 oC) 
Passage 1-3 
Kullman et al. 2008 Sprague-Dawley 200-250 g Female Dispase (overnight at 4 oC) Trypsin / EDTA (15 mins at 
36 oC) 
48-72 hours 
Olsen et al. 2010 
 
Sprague-Dawley -  Female 0.05 % Trypsin (1 hour at 37 
oC in 95 % CO2) 
None 7 days 
Beckel et al. 2012 
 
Sprague-Dawley 250-300 g Female Dispase (overnight at 4 oC) Trypsin / EDTA (15 mins at 
36 oC) 
1-2 days 
Juszczack et al. 
2012 
Wistar  200-250 g Female Dispase (overnight at 4 oC) Trypsin / EDTA (15 mins at 
36 oC) 
48 hours 
O’Mullane et al. 
2013 
Sprague-Dawley 8-12 weeks Female Dispase (3-4 hours at 37 oC) Trypsin / EDTA (15 mins at 
37 oC) 
48-72 hours 




3.2 Chapter Aim 
To develop and optimise a standardised normal rat urothelial (NRU) cell culture 
system in which cells can be cleanly isolated and cultured in complete keratinocyte 
serum free medium (KSFMc) for comparison against an existing normal human 
urothelial (NHU) cell culture system. 
 
3.2.1 Objectives 
1. Test the effectiveness of a NHU cell isolation protocol at isolating NRU cells 
and, if ineffective, develop and optimise an alternative protocol for NRU cell 
isolation 
2. Optimise various cell culture conditions including the presence of serum, 
the surface substrate and seeding density in order to maximise the lifespan 















3.3 Experimental approach 
3.3.1 Cell isolation protocol 
An established NHU cell isolation protocol was initially used and subsequently 
adapted for NRU cell isolation based on protocols in the literature. The established 
NHU cell isolation protocol is described below.  
 
NHU cell isolation protocol  (Illustrated in Figure 3.2) 
 
1. Human bladder/ureter tissue is cut with scissors to expose the urothelium 
and incubated for 4 hours in an EDTA “stripper” solution at 37oC. The 
urothelium is then gently removed from the underlying tissue using forceps. 
2. Isolated sheets of urothelial cells are incubated for 20 minutes in a 
collagenase type IV solution at 37oC before being collected by centrifugation 
and resuspended in KSFMc medium. 
3. Urothelial cell number is established by counting cells on a haemocytometer. 
4. Urothelial cells are seeded onto N2 plasma treated tissue culture plastic and 











Figure 3.2 - The isolation of normal human urothelial (NHU) cells. An annotated cartoon detailing the various stems of the NHU cell isolation protocol 
including the initial EDTA “stripping” phase, urothelial cell sheet removal and finally the collagenase IV disaggregation of NHU cells prior to cell seeding. 
 
Bladder/ureter tissue is 
cut to expose the 
urothelium 
Tissue is incubated in 
EDTA “stripper” solution 
at 37oC for 4 hours 
The urothelium was 
removed with forceps 
Urothelial sheets are 
incubated in collagenase 
IV solution for 20 minutes 
at 37oC, collected by 
centrifugation and seeded 
onto N2 plasma treated 
tissue culture plastic in 
KSFMc medium 
Stripped urinary tissue 
can be fixed (10% 
formalin) for 24 hours, 
embedded in paraffin 
wax and labelled with a 
urothelial cell marker to 
determine whether all 
urothelial cells were 
isolated.    




3.3.2 Adapting the NRU cell isolation protocol 
The NHU cell isolation protocol was adapted based on NRU cell isolation protocols 
in the literature. The various aspects of the protocols were optimised to generate the 
greatest possible yield of NRU cells (see Table 3.1). Following testing, the optimised 
protocol replaced the 4 hour EDTA “stripper” solution incubation with a 3 hour 
dispase II incubation and the 20 minute collagenase IV incubation with a 10 minute 
0.25% trypsin in versene incubation step. Briefly: 
1. Rat bladders were cut with scissors to expose the urothelium and incubated 
for 3 hours in a 0.5% (w/v) dispase II solution at 37oC. The urothelium was 
then gently removed from the underlying tissue using forceps. 
2. Isolated urothelial sheets were incubated for 10 minutes in a 0.25% trypsin in 
versene solution at 37oC before being collected by centrifugation and 
resuspended in KSFMc medium. 
3. Urothelial cell number was established by counting cells on a 
haemocytometer and seeded at 1 x 104 cells /cm2. 
 
3.3.3 Optimising NRU cell culture conditions 
Having tested the isolation protocol, other aspects of the NRU cell culture system 
were optimised for maximum NRU cell growth. The presence of bovine serum, the 
cell seeding density and the tissue culture surface substrate were all optimised for 
NRU cell culture. To achieve this, NHU cell culture conditions were tested against 
those reported in the literature to determine which promoted the greatest level of 






3.3.4 Summary of experimental approach 
 
Figure 3.3 – The NRU cell isolation protocol. A cartoon illustrating the various processes 
involved in urothelial cell isolation and culture. The stages (numbered in red) correspond to 
those in Table 3.2.  
 
Table 3.2 – The main stages of NRU cell isolation and culture with potential variables  
Number Stage Variables 
1.  Primary enzyme 
incubation 
 EDTA 
 0.5% Dispase II 
2.  Secondary enzyme 
incubation 
 Collagenase IV 
 0.25% Trypsin in versene 
3.   




4.  Serum  + 5% fetal bovine serum (FBS) 
 - 5% fetal bovine serum 
5.  Tissue culture 
surface substrate 
 N2 plasma treated 

















3.3.5 Cell lines 
Table 3.3 – NRU cell lines 
 
NRU cell lines were generated from donated rat bladder tissue from three strains of rat: 
Wistar (NRU-W), Sprague Dawley (NRU-SD) and Homozygous Scottish (NRU-HS). 
 
Table 3.4 - NHU cell lines 
Code Tissue of origin Sex Age Age of cells during 
experiments 
Y984 Bladder M 70 Passage 1-5 
Y1052 Renal pelvis unknown unknown Passage 1-5 
Y1183 Ureter M 75 Passage 1-5 
 
 
Code No. of 
animals 
Sex Source Strain Age/Weight 
R006a, 
b & c 
30 M/F FERA Homozygous Scottish 5 weeks 
R007 5 M University of York Sprague Dawley 9 months 
R008 20 M University of Leeds Wistar 6-9 months 
R009 30 M/F FERA Homozygous Scottish  3-6 weeks 
R010 5 M/F University of York Wistar 4 weeks 
R012 6 M/F University of York Wistar 6 weeks 
R013 13 M/F FERA Homozygous Scottish  3 weeks 
R015 25 M/F FERA Homozygous Scottish  2-3 weeks 
R016 20 M/F FERA Homozygous Scottish  3 weeks 
R017 30 M/F FERA Homozygous Scottish  3.5 weeks 
R020 12 M/F FERA Homozygous Scottish  250g 
R022 20 M/F FERA Homozygous Scottish  3 weeks 
R023 4 M/F FERA Homozygous Scottish  250g 
R024 10 M/F FERA Homozygous Scottish  5 weeks 
R025 15 M/F FERA Homozygous Scottish  3 weeks 
R027 9 M/F FERA Homozygous Scottish  250g 





3.4.1 Initial comparisons of rat and human urothelium in situ 
The epithelial cell marker cytokeratin 7 (CK7) and the proliferation marker Ki67 
were immunolabelled in rat and human bladder sections (Figure 3.4). Native rat 
urothelium was found to be, on average, 3-4 cells in depth unlike human 
urothelium, which exceeded 6 cells. Ki67 labelling was present in all but superficial 
cells in rat urothelium whereas Ki67 positive cells were not seen in human 
urothelium.  
 
3.4.2 NRU cell culture using protocols established for NHU cells.  
NRU cells were isolated using the published protocol for NHU cell isolation, seeded 
at an approximate concentration of 1 x 104 cells/cm2 onto N2-plasma treated tissue 
culture plastic and cultured in KSFMc medium.  
 
After isolation, NRU-HS cells were difficult to distinguish from cell debris, making 
seeding inaccurate (Figure 3.5). Growth curves generated over 9 days indicated that 
NRU-HS cells achieved approximately one cell doubling between 1 and 5 days, 



















Figure 3.4 – Differences in the tissue thickness and number of proliferative cells in the 
native urothelium of humans and rats. Immunolabelling of the urothelial cell marker 
cytokeratin 7 (CK7) (top & middle) and the cell proliferation marker Ki67 (bottom) in rat 
(left) and human (right) bladders. Superficial, intermediate and basal cell zones are labelled. 

















Figure 3.5 – NRU cells were not cleanly isolated by the NHU cell isolation protocol. Phase 
contrast images of NRU-HS cells after isolation using the NHU cell (EDTA/Collagenase) 
isolation protocol (Section 3.3.1), prior to being seeded. Scale bar = 250 µm.  
 
Figure 3.6 – NRU cells isolated with the NHU cell isolation protocol had limited growth 
in culture. Growth curve were generated (Section 2.5.3.1) for NRU-HS cell growth over 9 
days cultured in KSFMc after isolation using the NHU cell isolation protocol (Section 3). 














































Due to the inability of NRU cells to be cleanly isolated or cultured using the NHU 
cell isolation protocol, the methods were adapted based on published protocols for 
NRU cells. Efforts were made to keep the adapted protocol as similar as possible to 
the NHU cell isolation protocol.  
3.4.3 Optimisation of the NRU cell isolation protocol 
A Dispase II / Trypsin in versene protocol (NRU cell isolation protocol) was 
compared against the established EDTA/Collagenase IV protocol for NHU cell 
isolation (NHU cell isolation protocol) (Southgate et al., 2002).  To confirm effective 
isolation of the urothelium, immunohistochemical labelling of the urothelial cell 
marker CK7 was conducted on rat bladder tissue after stripping with both protocols 
(Figure 3.7). With the exception of a small number of labelled cells (which were 
specially identified and imaged) the majority of tissue was negative for urothelial 
cells after both protocols. To illustrate the high level of urothelial cell isolation, 
native rat bladder sections were also labelled as a positive control (Figure 3.7, A&B). 
Visual assessment of the tissues suggested that more CK7 labelled cells were 
present after the EDTA stripping protocol compared to dispase II.     
 
Prior to seeding, NRU cells were counted using a haemocytometer and phase 
contrast images captured. Cell and tissue debris obscured the images after 
EDTA/collagenase isolation, making it impossible to accurately count individual 
NRU cells (Figure 3.9). By contrast, NRU cells could be clearly seen and counted on 
the haemocytometer after isolation using the Dispase II / Trypsin in versene 
protocol.  
To determine the effectiveness of the two protocols in isolating NRU cells, cells 
isolated using each protocol were cultured for 5 days and colony formation assays 
performed. The Dispase II / Trypsin in versene isolation protocol achieved the 
greatest number of NRU-HS cell colonies after 5 days in culture when compared to 























Figure 3.7 – EDTA/Collagenase and Dispase/trypsin isolation protocols enabled near-
complete isolation of urothelial cells. Urothelial cell marker cytokeratin 7 (CK7) 
immunolabelling in native rat bladders (A&B) and in rat bladders after urothelial cell 
isolation using the EDTA protocol (Section 3.3.1; C, E & G) and Dispase/trypsin protocol 
(Section 3.3.2; D, F & H). Labelled cells were specifically identified and imaged. Scale bar = 















Figure 3.8 – Complete removal of the urothelium was achieved by stripping human 
bladder tissue using the EDTA/Collagenase protocol. Labelling of the urothelial cell 
marker cytokeratin 7 (CK7) in native human ureter (left) and human bladder tissue after 










Figure 3.9 – Clean isolation of NRU cells was achieved using the dispase/trypsin but not 
the EDTA/collagenase protocols. Phase contrast images showing primary NRU-HS cells in 
suspension after isolation with the EDTA/collagenase (Section 3.3.1; left) and 
Dispase/trypsin (Section 3.3.2; right) protocols on a haemocytometer. Scale bar = 250µm. 








Figure 3.10 – Primary NRU cells formed more colonies after dispase/trypsin isolation 
compared to EDTA/collagenase isolation. Colony formation assay (Section 2.5.3.2) of NRU-
HS (adult) cells isolated using both the EDTA/collagenase (Section 3.3.1) and dispase/trypsin 
(Section 3.3.2) protocols as indicated and cultured on N2 plasma treated tissue culture 
plastic. Cells from 2.5 bladders were pooled per well and cultured for 5 days in KSFMc 


























3.4.4 The effect of fetal bovine serum on primary NRU cell 
cultures  
NRU-W, NRU-SD and NRU-HS cells were cultured on nitrogen plasma treated 
tissue culture plastic. NHU cells were also cultured for comparison with NRU cells.  
Cells were monitored in culture over 7 days by phase contrast microscopy and 
differences in cell growth rate and morphology observed (Figure 3.11 to Figure 
3.14). All NRU cells grew in “cobblestone-like” colonies. NRU-W cell colonies 
cultured in the absence of serum grew over 5 days whereas the cells grown in the 
presence of serum did not grow. NRU-HS cell growth only occurred when cells 
were cultured with 5% FBS whereas NRU-SD cells grew in both the presence and 
absence of FBS and had no visible effect on phenotype or colony formation. All 
NRU cell colonies appeared to reach a maximum density and size after 
approximately 7 days of culture after which colony diameter stopped increasing 
and appeared to have a three dimensional as opposed to monolayer structure. As a 
result of this, NRU cell cultures never became fully confluent. This was in contrast 
to the complete monolayers seen in NHU cell cultures after 5 to 7 days (Figure 3.14). 
NHU cell growth occurred in the absence of FBS but was inhibited by FBS. The 
presence of 5% FBS also resulted in an altered NHU cell morphology with cells 






















Figure 3.11 – NRU-HS cells grew in presence but not in the absence of serum. 
Representative phase contrast images of NRU-HS cell growth in culture over 7 days in 
KSFMc medium ± 5%Fetal Bovine Serum (FBS) (n=3 NRU cell lines, R009, R013, R015). Scale 





















































Figure 3.12 – One NRU-SD cell line grew equally in both serum-free and serum-
supplemented medium. Representative phase contrast images of NRU-SD cell growth in 
culture over 7 days in KSFMc medium ± 5%Fetal Bovine Serum (FBS) (n=1 NRU cell line, 





















































Figure 3.13 – NRU-W cells grew in the absence but not in the presence of serum. 
Representative phase contrast images of NRU-W cell growth in culture over 7 days in 
KSFMc medium ± 5%Fetal Bovine Serum (FBS) n=3 NRU cell lines, R008, R010, R012). Scale 
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Figure 3.14 – NHU cells grew normally in serum-free medium but had reduced growth 
and an altered morphology in serum-supplemented medium. Representative phase 
contrast images of NHU cell growth in culture over 7 days in KSFMc medium ± 5%FBS (n=3 
NHU cell lines, Y984, Y1052, Y1183). Scale bar = 50µm.  
 
 
































To further explore the proliferative capability of NRU cells, cell biomass assays 
were conducted on NRU-W, NRU-HS and NHU cells using the AlamarBlue cell 
biomass assay (Figure 3.15 & Figure 3.16). Growth curves were generated over 10 
days. NRU-W cell growth increased in KSFMc medium but was inhibited by the 
presence of 5% FBS resulting in cell biomass being significantly reduced by day 6 of 
culture (Figure 3.17). NRU-HS cells alternatively had the greatest level of growth in 
the presence of 5% FBS and cell biomass was significantly increased after 6 days by 
the presence of serum compared to cells cultured in KSFMc alone (Figure 3.18). As a 
positive method control, growth curves were also generated for three NHU cell 
lines (detailed in Table 3.4) cultured in KSFMc medium. NHU cells grew rapidly 













Figure 3.15 – NRU-W cells grew in the absence of serum whereas NRU-HS cells required 
serum to grow. Growth curves were generated (Section 2.5.3.1) for NRU-W (R008, R010, 
R012) & NRU-HS (R009, R013, R015) cell cultured over 7 days in KSFMc ± 5% FBS. Data 
points represent mean percentage reduction in alamarBlue®  ±SD (n=3). 
 
Figure 3.16 – NHU cells show standard expansion and plateau phases of growth when 
cultured in KSFMc medium. Growth curves were generated (Section 2.5.3.1) for three 
subcultured (P2) NHU cell lines cultured over 7 days in KSFMc medium. Data points 
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Figure 3.17 – NRU-W cells had significantly greater growth in serum-free medium 
compared to serum-supplemented medium. Graphs show percentage of alamarBlue® 
reduction (Section 2.5.3.1) by NRU-W cell cultures on days 6 (left) and 10 (right) of 
maintenance in KSFMc medium. Data points represent mean ±SD (n=3). Student T-Test 







Figure 3.18 – NRU-HS cells had significantly increased growth in serum-supplemented 
medium compared to serum-free medium. Graphs show the percentage of alamarBlue® 
reduction (Section 2.5.3.1) by NRU-HS cell cultures on days 6 (left) and 10 (right) of 
maintenance in KSFMc medium. Data points represent mean ±SD (n=3).  Student T-Test 




























































































































































3.4.5 NRU cell seeding density 
An appropriate NRU cell seeding density was established using colony formation 
assays, allowing for the minimal amount of NRU cells to be used per experiment. 
As can be seen (Figure 3.18), seeding NRU cells at 1 x 104 cell/cm2 significantly 
increased the number of colonies formed compared to cells that had been seeded at 
1 x 103 cells/cm2 after 5 days of culture. There was no significant increase in NRU 
cell colony formation between cultures seeded with 1 x 104 cells/cm2 and 1 x 105 
cells/cm2 after 5 days of culture. Based on these results, a seeding density of 1 x 104 
cells/cm2 was adopted as the standard NRU cell seeding density for all future 
experiments.   
 
Figure 3.19 – 1x104 cells/cm2 was the optimal seeding density for NRU-HS cells. NRU-HS 
cells were seeded at 1x103, 1x104 and 1x105 cells per cm2, cultured in KSFMc +5% FBS for 5 
days before a colony formation assay (Section 2.5.3.2) was performed. Data points represent 































3.4.6 Optimising surface substrate for NRU cell growth 
The colony forming ability of NRU-HS cells was assessed on collagen I coated and 
N2 plasma treated tissue culture plastic. Supporting earlier observations, NRU-HS 
cells cultured in the presence of 5% FBS had significantly greater colony numbers 
than cells cultured in KSFMc alone. Cells cultured on nitrogen plasma treated tissue 
culture plastic formed significantly more colonies than those cultured on collagen I 
coated tissue culture plastic after 5 days of culture.  
 
                     
  
Figure 3.20 – NRU-HS cells grew best in the presence of serum and on N2-plasma treated 
tissue culture plastic. Colony formation assays (Section 2.5.3.2) were conducted to examine 
NRU-HS (P0) cell growth on collagen I and N2 plasma-treated tissue culture plastic in 
KSFMc ± 5%FBS. Cells were cultured for 5 days on 6 well plates. Data points represent the 
mean number of colonies ±SD (n=3, R016, R017, R020). Student T Tests (Paired, 2-tailed) 






































3.4.7 Subculture of NRU cells  
NRU-HS cells isolated using both the EDTA/collagenase and dispase II/trypsin 
protocols were cultured up to day 8 in KSFMc, before sub-culture, involving harvest 
using EDTA/trypsin in versene and reseeding onto fresh substrates. As shown in 
Figure 3.21, EDTA/collagenase isolated NRU-HS cell cultures did not recover after 
passage and the majority of cells had died by day 13. NRU-HS cells isolated using 
the dispase II/trypsin protocol did grow after subculture. This result was seen in 
several NRU-HS cell lines.  
 
To quantify this result, growth curves were generated (Figure 3.22 and Figure 3.23). 
When compared to cells isolated using the EDTA/collagenase protocol, dispase 
II/trypsin isolated NRU-HS cells had a greater proliferative capacity in primary 
culture between 3 and 7 days and, when subcultured, continued to proliferate over 
5 days. Subcultured NRU-HS cells after dispase II/trypsin isolation did not achieve 
the same biomass as primary NRU-HS cells but did achieve approximately a 4 fold 
increase in population size over 5 days. Attempts to subculture dispase II/trypsin 














Figure 3.21 - NRU-HS cells were successfully subcultured after dispase/trypsin isolation but not after EDTA/collagenase isolation. NRU- HS cells growth 
after EDTA/Collagenase and Dispase/trypsin isolation. On day 8 cells were passaged (Section 2.5.2.4) and split 1:3 before being reseeded at a density of 1x104 
cells/cm2. Growth curves were generated for these cells (see  
 
Figure 3.22 & Figure 3.23; n=3, R025, R027, R028). 













Figure 3.22 – EDTA/collagenase isolated cells did not grow after being passaged. Growth 
curves were generated (Section 2.5.3.1) for three NRU-HS cell lines isolated using the 
EDTA/collagenase protocol (Section 3.3.1) in primary culture (day 1-7) and after subcultured 
(day 9-13). Data points represent mean percentage reduction in alamarBlue®  ±SD (n=3, R025, 
































































Figure 3.23 – Dispase/trypsin isolated cells were capable of growth after being passaged. 
Growth curves were generated (Section 2.5.3.1) for three NRU-HS cell lines isolated using 
the dispase/trypsin protocol (Section 3.3.2) in primary culture (day 1-7) and after 
subcultured (Day 9-13). Data points represent mean percentage reduction in alamarBlue®  
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3.5 Conclusions and Discussion 
NRU cells are capable of being isolated using multiple isolation protocols but the 
method of isolation appears to have an effect of the growth capabilities of the cells. 
The ability to subculture NRU cells also appears to be affected by the method of 
isolation. NRU cells isolated using the dispase II / trypsin protocol were capable of 
being subcultured once whereas NRU cells isolated using the EDTA/collagenase IV 
protocol could not survive a passage. As a result of this finding, the dispase II / 
trypsin protocol was adopted as standard for all further experiments (Chapters 4, 5 
and 6).  
Although NRU cells were cultured to passage 1, attempts to subculture cells further 
were unsuccessful. NHU cells are capable of undergoing several passages before 
becoming senescent, possibly indicating a difference between the 
growth/proliferative abilities normal human and rat urothelial cells. As such the 
pathways regulating NRU and NHU cell proliferation were further investigated 
(Chapter 4) to both understand any differences in regulation between rats and 
humans and to explore whether NRU cell lifespan in culture could be increased 
through modulation of these pathways.  
A strain difference was found to exist between the NRU-W and NRU-HS cells in 
regard to the requirement of FBS in the culture medium. Such a difference could 
impact on the results toxicity tests conducted using different strains. Despite this 
strain difference being an interesting finding, it was decided to continue exploring 
interspecies variations between human and rat urothelial cells. As such, subsequent 
experiments would only utilise cells from the commonly used Wistar rat strain and 
not cells from the rare inbred Homozygous Scottish rat strain. 
Several aspects of NRU cell culture were optimised including seeding density, 
surface substrate and the presence/absence of FBS in culture medium. These 
optimised conditions will be adopted as standard for all future NRU cell cultures.  
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3.6 Key findings 
 A dispase II / trypsin NRU cell isolation protocol enabled the clean isolation 
of NRU cells from bladder tissue and produced NRU cultures that could be 
subcultured up to P1. NRU cell isolation using an EDTA / collagenase 
protocol optimised for NHU cell isolation produced cultures that were 
difficult to count and which failed to grow after subculture 
 Bovine serum being a prerequisite for NRU-HS cell growth but has 
inhibitory on NRU-W cell proliferation.  
 Seeding NRU cells at a concentration of 1x104 cells/cm2 onto nitrogen plasma 
treated tissue culture plastic after isolation with dispase II / trypsin allowed 
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4.1 Chapter Introduction 
 
In vivo, human urothelial cells are considered mitotically quiescent, proliferating 1-2 
times per year on average. When cultured in keratinocyte serum free medium under 
conditions of low extracellular calcium (0.09 mM) and supplemented with bovine 
pituitary extract, epidermal growth factor (EGF) and cholera toxin, NHU cells adopt 
a proliferative “basal-like” phenotype.  Proliferation in NHU cells, due to the 
absence of the instructive signalling present in vivo, is regulated via an autocrine 
signalling loop in which the epithelial growth factor receptor (EGFR) / Mitogen-
activated protein Kinase (MAPK) pathway drives the cell proliferation (Varley et al., 
2004; Varley et al., 2005). In addition to exogenous EGF present in KSFMc medium, 
proliferating NHU cells are known to be capable of secreting EGF, as well as the 
EGFR ligands epiregulin, TGF-alpha, and amphiregulin (Varley et al., 2005). As 
illustrated in Figure 4.1, activation of the EGFR/MAPK pathway also activates the 
Wnt/ β-catenin pathway under conditions of low (0.09 mM) extracellular calcium 
ion concentrations, by inhibiting GSK3β–mediated destruction of β-catenin, 
allowing β-catenin to translocate to the cell nucleus and regulate gene expression, 
facilitating proliferation (Georgopoulos et al., 2014).   
 
NHU cells proliferation can also, in conditions of near physiological extracellular 
calcium ion concentrations, be regulated by the phosphoinositide 3-kinase (PI3K)/ 
protein kinase B (Akt) pathway. Under conditions of near physiological 
extracellular calcium (2 mM Ca2+), the EGFR/MAPK pathway is inactive and β-
catenin is sequestered to the cell membrane where it is incorporated, with E-
cadherin, into adherens junctions. Phenotypically cells assemble into a 3-
dimensional, structure but continue to proliferate via PI3K/Akt pathway regulation 
(Georgopoulos et al., 2010; Georgopoulos et al., 2014). The exact method by which 
the switch between the EGFR/MAPK and PI3K/Akt pathway is achieved is still 
under investigation. 
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 In culture, NRU cell lifespan was found to be greatly reduced compared to NHU 
cells. NRU cells also grew in colonies, which failed to expand across all of the 
available surface area (Chapter 3). In an attempt to increase NRU cell lifespan in 
culture, and better understand interspecies differences between NRU and NHU 
cells, the pathways regulating NRU cell proliferation were investigated. 
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4.2 Chapter Aim 
 
To compare the intracellular signalling pathways regulating NHU and NRU cell 
proliferation and to explore candidate methods of increasing NRU cell 
proliferation/longevity in culture through modulating the activity of these pathways 
either pharmacologically or by varying the extracellular environment.  
 
4.2.1 – Objectives 
 
1. Identify and interrogate the signal transduction pathways regulating NHU 
and NRU cell proliferation  
 Identify which pathways are active in NHU and NRU cells  
 Use pharmacological or recombinant factors to activate/inhibit 
candidate pathways and assess the effects on proliferation and 
survival of NRU cells in culture.  
 
2. Explore the effect of modifying extracellular calcium ion concentration on 
NRU cell proliferation and phenotype  
 Determine the effect of altered exogenous calcium ion concentrations 
on NRU cell proliferation 
 Determine whether lowering extracellular calcium promotes a more 
proliferative NRU cell phenotype and investigate the mechanisms 
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4.3 Experimental Approach 
 
4.3.1 - Proliferation pathways 
 
Pharmacological agonists and inhibitors of the EGFR/MAPK, β-catenin and 
PI3K/Akt signal transduction pathways were used to modulate activity (Table 4.1). 
The effects on cell proliferation were assessed via growth curves and the expression 
of pathway or proliferation markers.  
 
4.3.2 Extracellular calcium 
 
Extracellular calcium ion concentrations are known to evoke urothelial cells to form 
tight junctions and switch their proliferative regulation from the EGFR/MAPK 
pathway to the PI3K/Akt pathway (Georgopoulos et al., 2010; Georgopoulos et al., 
2014). To investigate the effect of extracellular calcium on NRU cell proliferation the 
calcium concentration of KSFMc was reduced as follows: 






Growth curves were generated to assess NRU cell proliferation and the activation of 
the pathways assessed by quantifying protein marker expression. The ability of cells 
to form cell-cell junctions was investigated by looking at the localisation and 
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Table 4.1 Pharmaceutical agonists/antagonists 







1µM 25pM DMSO 











10µM 2.9µM DMSO 
IGF1 IGFR 
activator 
PI3K/Akt  1µM n/a PBS 
LY294002 
(LY) 
PI3K inhibitor PI3K/Akt  5µM 1.4uM DMSO 
 
* Concentrations previously optimised for NHU cells 
** Vehicle concentration did not exceeded 0.01% final volume 
 
All pharmacological agents were administered in KSFMc medium containing bovine 
pituitary extract (BPE), EGF and cholera toxin.  




Figure 4.1 - Summary of the EGF/MAPK, Wnt/β-catenin and PI3K/Akt pathways. Release of β-catenin (left) from the GSK3β destruction complex enables β-
catenin to translocate to either the cell nucleus where it regulates gene expression to promote cell proliferation and survival or, under conditions of high 
calcium, be incorporated into adherens junctions at the cell membrane. Activation of EGFR (centre) by EGF activates the MAPK pathway to regulate gene 
expression to promote cell proliferation, survival and migration while inhibiting apoptosis. Activation of the PI3K/Akt pathway (right), for instance by IGFR 
activation can activate the mTOR pathway through TCS complex inhibition, inhibits apoptosis through inhibition of Bad and while regulating gene 
expression to promote cell growth and inhibit apoptosis. 
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4.3.3 - Cell lines 
All NHU and NRU cell lines used in this chapter are listed in Tables 4.2 & 4.3. All 
NRU cells were used in primary (passage 0) culture unless otherwise indicated.  
 
Table 4.2 NHU Cells 
Code Tissue of origin Sex Age Age of cells during 
experiments 
Y1430 Ureter F 71 Passage 2-3 
Y1437 Ureter F 65 Passage 3-4 
Y1461 Ureter M 39 Passage 2-3 
 
 
Table 4.3 NRU Cells 
Code No. of 
animals 
Sex Source Strain Age 
/Weight 
RO37 6 M/F University of York Wistar 9 month 
RO38 10 M/F Covance Inc. Wistar 1 year 
R039 4 F University of York Wistar adult 
R040 12 M University of York Wistar 250-300g 
R041 12 M University of York Wistar 250-300g 
R042 10 M/F Covance Inc. Wistar 300-350g 
R046 10 M University of York Wistar 300-350g 
R047 12 F University of York Wistar 250g 
R048 40 F University of Manchester Hooded Lister 250-280g 
R049 2 F University of York Wistar 200g 
R050 10 M/F University of Manchester Hooded Lister 200-300g 
R051 20 M/F University of Manchester Hooded Lister 200-300g 
R052 25 M/F University of Manchester Hooded Lister 200-300g 
R055 30 M/F University of Manchester Wistar 200-300g 
R056 5 F University of York Wistar 200-300g 
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4.4. Results – NHU cells 
 
4.4.1 – Growth Kinetics 
Growth curves (Figure 4.2 & Figure 4.3) were generated for NHU cells cultured in 
KSFMc medium alone and with the pharmacological agents listed in Table 4.1.  
Results showed that when cultured in low calcium (0.09mM) KSFMc medium 
(control), NHU cell proliferation increased between 1 and 5 days n culture before 
plateauing between 5 and 9 days as cultures became confluent.  
 
Activation of the β-catenin pathway, through inhibition of GSK3β (SB415286), and 
the PI3K/Akt pathway (IGF1) had no significant effect on the growth kinetics of 
NHU cells over 7 days of culture. Between days 7 and 9, NHU cells cultured with 
IGF1 showed a reduction of biomass compared to controls but this decrease was not 
significant (p > 0.05).   
 
Inhibition of EGFR (PD153035) or downstream ERK (UO126) appeared to resulted 
in an initial increase in proliferation between 1 and 3 days of culture but a 








Figure 4.2  – NHU cell growth was inhibited by EGFR/MAPK inhibition but GSK3β 
inhibition and PI3K/Akt activation had no effect on growth. A cell biomass assay (Section 
2.5.3.1) was conducted on NHU cells cultured in KSFMc medium ± the agonists/inhibitors 
indicated. Cell culture medium was changed on the days indicated. Data points represent 





Figure 4.3 - NHU cell growth was significantly inhibited by EGFR inhibition on Days 5, 7 
and 9. Statistical analysis was conducted on Growth curves presented in Figure 4.2 
comparing treatment versus control (n=3; Y1430 & Y1437). An ANOVA test was conducted 
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4.4.2 – Proliferation pathways 
NHU cells were fixed (methanol: acetone) on day 5 of culture and 
immunofluorescence labelling used to investigate the expression of the proliferation 
marker Ki67 and marker of activation of the EGFR/MAPK pathway (phospho-ERK), 
β-catenin pathway (active β-catenin) and PI3K/Akt pathway (phospho-Akt). Initial 
labelling was conducted on proliferating NHU cells (Figure 4.4) and NHU cells 
differentiated using the published adult bovine serum (ABS)/ calcium protocol 
(Figure 4.5).  
 
Proliferating NHU cells expressed the proliferation marker Ki67. The nuclear 
localisation of phospho-ERK and β-catenin in NHU cells suggested that 
proliferation in these cells was being regulated by the EGFR/MAPK and β-catenin 
pathways. The lack of phospho-Akt expression in proliferating NHU cells indicated 
that the PI3K/Akt pathway was not actively involved in regulating proliferation.  
 
When induced to differentiate (Figure 4.5), NHU cells maintained Ki67 expression 
but active β-catenin can be seen to be sequestered to the cell membranes as well as 
being present in the nuclei. Phospho-ERK immunolabelling was almost completely 
absent in differentiated NHU cells but phospho-Akt immunolabelling was 
increased. 
 





Figure 4.4 – In undifferentiated NHU cells, Activeβ-catenin and phospho-ERK expression 
is nuclear and phospho-Akt is not expressed. Representative immunofluorescence labelling 
of Ki67, Activeβ-catenin, phospho-ERK and phospho-Akt in NHU cells cultured in KSFMc 








































Figure 4.5 – In differentiated (ABS/Ca2+), Activeβ-catenin is both nucleus and membrane 
localise and a switch in phospho-ERK and Phospho-Akt expression has occurred 
compared to undifferentiated NHU cells (Figure 4.6). Representative immunofluorescence 
labelling of Ki67, Activeβ-catenin, phospho-ERK and phospho-Akt in differentiated NHU 
cells cultured in KSFMc (2mM Ca2+) medium supplemented with 5% ABS. Scale bar = 50µm 
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4.4.3 – Pharmacological interrogation of proliferation pathways 
The effect of pharmacological interrogation of the EGFR/MAPK, β-catenin and 
PI3K/Akt pathways was investigated on the expression of Ki67, active nuclear β-
catenin, phospho-Akt and phospho-ERK in proliferating NHU cells and the results 
quantified (Figure 4.6). When compared to controls, inhibition of EGFR (PD153035) 
significantly reduced Ki67 and the three proliferation pathway markers labelled for 
which agrees with the growth curve data (Figure 4.2). Inhibition of ERK in NHU 
cells (UO126) over 5 days significantly reduced the expression of phospho-Akt and 
phospho-ERK when compared against controls but did not have an effect on Ki67 
or β-catenin expression.  
 
Activation of the β-catenin pathway through GSK3β inhibition (SB415286) led to a 
significant increase in β-catenin and phospho-ERK expression in proliferating NHU 
cells and caused a significant reduction in nuclear phospho-Akt expression. 
Activation of the PI3K/Akt pathway (IGF1) caused a significant increase in 
phospho-Akt expression but caused a reduction in Ki67 expression. β-catenin and 
phospho-ERK were not significantly altered by treatment with IGF1.  
 




Figure 4.6 – EGFR/MAPK inhibition significantly reduced expression of proliferation 
marker Ki67 and proliferation pathway markers Active β-catenin, phospho-ERK and 
phospho-Akt compared to control cells. Inhibition of GSK3β and activation of the 
PI3K/Akt pathway (IGF1) did not affect proliferation marker Ki67 expression. 
Quantification of fluorescence intensity of Ki67, Nuclear active β catenin, phospho-Akt and 
phospho-ERK labelling in NHU cells cultured for 5 days in KSFMc medium (control) with 
the agonists/inhibitors indicated. (n=3 cell lines; Y1430, Y1437, Y1461). Error bars = SD. An 
ANOVA test was conducted with a Tukeys post hoc test (*=p<0.05, **=p<0.01, ***=p<0.1 
compared to control) 
4.4.4 – Conclusions 
Together these results show the specificity of these four pharmacological agents for 
their targets (Table 10) and show that blocking the active EGFR/MAPK pathway or 
activating the opposing PI3K/Akt pathway in NHU cells results in a decrease in cell 
proliferation as indicated by the expression of Ki67. They also demonstrate how 
increased β-catenin activation, which can be regulated by the MAPK pathway 
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4.5 Results – NRU cells 
 
4.5.1 – Growth Kinetics  
(Figure 4.7 & Figure 4.8) 
EGFR/MAPK inhibition 
Inhibition of EGFR or the downstream MAPK pathway molecule ERK by PD153035 
and UO126 respectfully had a minimal effect on cell growth over 5 days. Between 
days 5 and 9, inhibition of both targets resulted in a significant reduction in cell 
biomass when compared to control cells (KSFMc medium + 0.1% DMSO).  
GSK3β inhibition 
β-catenin activation through GSK3β inhibition did not result in significant 
differences in NRU cell biomass over 9 days in culture but cell proliferation did 
appear to be slightly reduced when compared to controls.  
PI3K/Akt activation 
Over 9 days in culture, PI3K/Akt activation (IGF1) in NRU cells had no significant 
effect on cell growth (p > 0.05).  
  





Figure 4.7 – EGFR/MAPK inhibition reduced NRU cells growth over 9 days of culture. 
Cell biomass assay (Section 2.5.3.1) for NRU cells cultured in KSFMc medium ± the 
agonists/antagonists indicated. Cell culture medium was changed on the days indicated. 




Figure 4.8 – Quantification of NRU cell growth curves presented in Figure 4.7. Results 
represent combined means ±SD (n=3; R037, R038, R039). An ANOVA test was conducted 
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4.5.2 –Ki67 expression  
After 5 days of culture NRU cells were fixed and labelled for the proliferation 
marker Ki67 (Figure 4.9). Ki67 is expressed by all proliferating cells but is absent 
when cells become senescent or quiescent.  
 
Ki67 labelling was positive in three separate primary NRU cell lines and the 
intensity   of labelling quantified (Figure 4.13) In comparison to control NRU cells, 
EGFR inhibition caused both a visible reduction in Ki67 expression and a significant 
decrease in labelling intensity in all three cell lines. ERK inhibition did not have an 
effect on Ki67 expression in NRU cells.  Activation of β-catenin, through GSK3β 
inhibition, had no significant effect on Ki67 expression or intensity but activation of 
the PI3K/Akt pathway resulted in a significant increase in Ki67 labelling intensities 
compared to control NRU cells (p < 0.01).  
 
4.5.3 – Phospho-ERK, β-catenin and phospho-Akt expression 
Phospho-ERK expression was used as a measure of EGFR/MAPK activity in NRU 
cells (Figure 4.10). In control NRU cells and EGFR, ERK and GSK3β inhibited cells 
Phospho-ERK immunoreactivity was minimal to none. PI3K/Akt activation resulted 
in a small increase in nuclear phospho-ERK immunoreactivity. These results were 
too small to quantify but appear to show a lack of EGFR/MAPK activation in 
proliferating NRU cells.  
 
Labelling of active β-catenin (Figure 4.11) revealed nuclear localisation in control 
and EGFR/ERK inhibited cells. GSK3β inhibition also resulted in perinuclear 
localisation of active β catenin but did not produce and increase in nuclear 
expression when compared against control cells.  PI3K/Akt activation resulted in 
sequestering of β-catenin at the cell membrane, possibly indicating adherens 
junction formation, and a significant reduction in nuclear β-catenin labelling 
intensity in two out of three cell lines (Figure 4.13).  




Phospho-Akt was labelled as a marker of PI3K/Akt pathway activation 
(Figure 4.12). Images are difficult to compare due to expression being both nuclear 
and cytoplasmic however when nuclear labelling intensity was quantified 
(Figure 4.13), all treatments significantly increased phospho-Akt expression 
compared against control cells. After PI3K/Akt activation (IGF1), phospho-Akt 
appears to be specifically localised to the nuclear membrane where as in control, 
EGFR/MAPK and GSK3β inhibited cells phospho-Akt is present throughout both 
cell nuclei and cytoplasm.  
  
























Figure 4.9 – Ki67 expression appears increased in NRU cells after 5 days of PI3K/Akt 
expression. Representative images of Ki67 labelling in NRU cells cultured for 5 days in 
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  Phospho-ERK  
 




















Figure 4.10 – Phospho-ERK was not expressed in control, EGFR/MAPK inhibited, β-
catenin pathway activated or PI3K/Akt pathway activated NRU cells. Representative 
images of Phospho-ERK labelling in NRU cells cultured for 5 days in KSFMc with the 
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Active β catenin  
 
Figure 4.11 - Active β-catenin labelling was clearly nuclear in control and MAPK 
inhibited cells, nuclear/perinuclear in GSK3β-inhibited cells and clearly membrane-
localised in PI3K/Akt pathway activated NRU cells.  Cells were cultured for 5 days in 





































Figure 4.12 – Phospho-Akt expression was present in control and in proliferation pathway 
activated/inhibited NRU cells. Representative images of phospho-Akt (S47333) labelling in 
NRU cells cultured for 5 days in KSFMc with the agonists/antagonists indicated (n=3;  R040, 






















Figure 4.13 – Ki67 and phospho-Akt expression were significantly increased by IGF1 
stimulation but Ki67 was reduced by EGFR/MAPK inhibition. Mean fluorescence intensity 
of Ki67, Active β-catenin and phospho-Akt labelling (arbitrary values) for three separate 
NRU cell lines. Results represent combined means from three separate cell lines ±SD. 
Quantification was conducted using TissueGnostics TisueQuest software (Section 2.7.3). 
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4.5.4 – Removal of exogenous EGF  
Growth assays (Figure 4.14) revealed that the presence of exogenous EGF in the 
KSFMc medium had no significant effect on the growth of two separate NRU cell 
lines over 9 days in culture. Cells cultured with and without exogenous EGF 
showed the same traits in growth, plateauing (reaching confluence) at the same 
time. The high level of consistency in these data suggests that exogenous EGF is not 
required for NRU cell growth in vitro. The experiment was only conducted in two 
cell lines, each consisting of cells from several (4-5 individual) animals. 
 
R050      R051 
 
Figure 4.14 – Removal of EGF had no effect on NRU cells growth in two cell lines (R050 & 
R051). NRU cell biomass assays (Section 2.5.3.1) for two NRU cell lines (R050 and R051) 
cultured in KSFMc medium and KSFMc medium without exogenous EGF. Cell culture 
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4.5.5 – PI3K/Akt pathway inhibition 
The PI3K/Akt pathway was inhibited by itself and in combination with activation of 
the β-catenin pathway through GSK3β inhibition. PI3K inhibition with and without 
activation of the β-catenin pathway enabled NRU cells to survive in culture up to 
passage 2 (Figure 4.15) as opposed to becoming senescent after a single passage 
(Results chapter 1 – NRU cell optimisation chapter). PI3K inhibition alone did not 
affect the expression of the proliferation marker Ki67 in NRU cells but in 
combination with β-catenin activation, Ki67 expression was visibly increased 
(Figure 4.16).  
 
Active β-catenin was not affected by PI3K inhibition in NRU cells but was increased 
by GSK3β inhibition. Localisation of active β catenin after combined PI3K and 
GSK3β inhibition was predominantly nuclear in NRU cells. Use of the PI3K 
inhibitor LY294002 completely inhibited NRU expression of phospho-Akt.  
 
Inhibition of PI3K with and β –catenin activation did not have an effect on the 
expression of the tight junction proteins claudin 4 and ZO-1 in NRU cells (Figure 
4.17 & Figure 4.18). Quantification of expression showed no significant difference in 
claudin 4 or ZO-1 between control and treated NRU cells.  In control samples the 
distinct membrane localisation of claudin 4 and ZO-1 is clearly visible however in 
PI3K inhibited cells this localisation is difficult to see. This could indicate that PI3K-










Figure 4.15 – NRU cells grew being passaged twice when the PI3K/Akt pathway was inhibited whereas NRU cells cultured in KSFMc alone died after 
passage. 2 Phase contrast images showing NRU cells after passage 2 having been cultured in KSFMc alone or in the presence of the PI3K/Akt inhibitor 
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Figure 4.16 – Phospho-Akt was inhibited in NRU cells by the PI3K/Akt inhibitor 
LY294002. Representative Immunofluorescence labelling of Ki67, active β catenin and 
phospho-Akt (red) in NRU and NHU cells cultured in KSFMc with DMSO (0.01%), 
LY294002 or LY294002 + SB415286. Nuclei were labelled with Hoechst 33248 (blue). (n=2; 




























Figure 4.17– Differentiation-associated markers ZO-1 and Claudin 4 were expressed in 
control and PI3K/Akt inhibited NRU cells.  Representative immunofluorescence labelling 
of Claudin 4 and ZO-1 in NRU cells after 5 days of treatment with LY294002 and LY294002 + 
SB415286. Nuclei were labelled with Hoechst 33258 (blue). (n=2; R048 & R055). Scale bar = 
50µm. 
 
Figure 4.18 – No difference was seen in the expression of differentiation-associated 
markers ZO-1 and Claudin 4 in control and PI3K/Akt inhibited NRU cells. Mean 
fluorescence intensity of Claudin 4 and ZO-1 labelling (arbitrary values) for two separate 
NRU cell lines after treatment with LY294002 with and without SB415286. Results represent 
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4.5.6 – Physiological (2mM) extracellular calcium 
When compared to results conducted in low calcium (0.09mM; Figure 4.21 & Figure 
4.22), NRU cell biomass was reduced compared to controls on days 3, 7 and 9. The 
agonists/inhibitors used all had negative effects on cell biomass in 2mM Ca2+ 
however only EGFR and ERK inhibition (PD153035 and UO126) caused a significant 
reduction when compared to the controls. NRU cells cultured in 2mM Ca2+ had a 
reduction in biomass after 5 days in culture, varying from NRU cells cultured in 
0.09mM Ca2+ which plateaued after day 7.  
 
The tight junction proteins ZO-1 and claudin 4 and the differentiation-associated 
markers uroplakin 3a (late) and aquaporin 4 (early) were labelled for in control 
NRU cells cultured in low (0.09mM) and physiological (2mM) calcium (Figure 4.23 
& Figure 4.24). ZO-1 and claudin 4 expression was not altered by extracellular 
calcium concentration. UP3a expression was slightly increased in 2mM calcium 
compared to 0.09mM but the early differentiation-associated marker aquaporin 3 









Figure 4.19 – NRU cells cultured in high extracellular calcium (2 mM) showed the same 
growth kinetics as those seen in low (0.09 mM Ca2+) up to 5 days in culture. NRU cell 
biomass assay (Section 2.5.3.1) for cells cultured in KSFMc medium (2mM Ca2+) ± the 
agonists/antagonists indicated. Cell culture medium was changed on the days indicated. 




Figure 4.20 – EGFR/MAPK inhibitors significantly reduced NRU cell growth over 9 days 
of culture whereas all cells cultured in KSFMc (2 mM Ca+) had reduced growth at day 9 
compared to cells cultured in KSFMc medium (0.09 mM Ca2+). Results represent combined 
means ±SD (n=3; R046, R047, R049). (*=p<0.05, **=p<0.01 using a 2-way ANOVA with a 
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Figure 4.21 – ZO-1 and Claudin 4 were both expressed in NRU cells cultured in KSFMc 
medium with 0.09 mM and 2 mM extracellular calcium ion concentrations. Representative 
immunofluorescence labelling of ZO-1, and claudin 4 in NRU (P0) cells. Cells were cultured 
for 5 days in low and physiological (2mM) calcium concentrations before being fixed and 
labelled. Cell nuclei were labelled with Hoechst 33258 (n=3; R046, R047, R049). Scale bar = 
50µm. 
 
        
Figure 4.22 – Uuroplaskin 3a (UP3a) was not expressed by NRU cells but aquaporin 3 
(AQP3) was expressed by NRU cells cultured in 0.09 and 2 mM calcium ion 
concentrations. No visible difference was visible in AQP3 expression between cells 
cultued in differncet calcium ion concentrations. Representative immunofluorescence 
labelling of the differentiation-associated markers uroplakin 3a (UP3a), and aquaporin 3 
(AQP3) in NRU (P0) cells. Cells were cultured for 5 days in low and physiological (2mM) 
calcium concentrations before being fixed and labelled. Cell nuclei were labelled with 
Hoechst 33258 (n=3; R046, R047, R049). Scale bar = 50µm. 
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4.5.7 – Reduced extracellular calcium 
Phase contrast imaging revealed that cells cultured in 0.06mM Ca2+ did not cluster 
into densely packed colonies, as was the case in 0.09mM (Figure 4.23). Cells 
cultured in the two lowest calcium ion concentrations also grew in less densely 
populated colonies however fewer cells were present. 
 
A cell biomass assay (Figure 4.24 and Figure 4.25) was conducted to assess the effect 
of reduced calcium on NRU cell proliferation. A reduction in Ca2+ from 0.09mM to 
0.06mM had no significant effect on NRU cell proliferation over 9 days in culture. 
Further reducing extracellular calcium to 0.03 and 0.015mM caused a decrease in 
cell biomass after 5 days of culture and a significant reduction by day 7. Cell 
biomass in all concentrations decreased between 7 and 9 days of culture, possibly as 
a result of cells becoming over-confluent.  
 
 
Figure 4.23 – NRU cell density was visibly reduced at 0.015 mM calcium ion 
concentrations compared to cells cultured on 0.09 mM Ca2+. Phase contrast images of NRU 
cells cultured in KSFMc medium conatining 0.09. 0.06, 0.03 and .0.015mM calcium as 
indivated on day 5 of culture. Scale bar  = 50µm. 




Figure 4.24 - Extracellular calcium ion concentratiosn of 0.015 and 0.03 mM reduced NRU 
cell growth in culture. NRU cell growth assay (Section 2.5.3.1)  in KSFMc medium 
containing 0.09, 0.06, 0.03 and 0.015mM calcium as indicated. Growth curvces were 
measured using the alamarBlue assay. Data points represent combined means = ±SD, (n=3; 




Figure 4.25  – Extracellular calcium ion concentrations of 0.015 and 0.03 mM significantly 
reduced NRU cell growth after 5 and 7 days of culture, respectfully. Growth curves 
(Section 2.5.3.1) of NRU cells cultured  KSFMc containing 0.015, 0.03, 0.06 and 0.09mM Ca2+ 
ions. Results represent combined means ±SD, (n=3; R052, R055, R056). (*=p<0.05, **=p<0.01, 
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Figure 4.26  – Phospho-Akt expression appeared to decrease when the extracellular calcium concentration was decreased however the Ki67 expression was 
unaffected at calcium concentrations of 0.06 and 0.03 mM.  Representative immunofluorescence images of Ki67 and phospho-Akt labelling in NRU cells 
cultured in 0.09, 0.06, 0.03 and 0.015mM Ca2+  KSFMc for 5 days (n=2; R055, R056). Scale bar = 50µm.  
 





Immunofluorescence labelling of the proliferation marker Ki67 revealed no 
difference in the expression between control (0.09mM) cells and cells cultured in 
0.06 or 0.03mM Ca2+ (Figure 4.28).   A reduction in extracellular calcium to 0.015mM 
caused a visibly significant reduction in Ki67 expression. Nuclear phospho-Akt 
expression, which is present in NRU cells culture in all 4 Ca2+ concentration, was 
also reduced by the reduction in extracellular calcium.  
 
 




4.6 Results summary 










Figure 4.27– Summary of the effects on activating/inhibiting the EGFR/MAPK,  
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4.7 Conclusions and Discussion 
 
Through the inhibition of the PI3K/Akt pathway, NRU cells were successfully 
subcultured up to passage 2. Although it is unknown how PI3K inhibition led to the 
increase in NRU cell viability, one possibility is that PI3K inhibition enabled 
activation of the EGFR/MAPK pathway, which is known to regulate proliferating 
NHU cell proliferation in vitro (Varley 2005). This would suggest that NRU cells can 
adopt a proliferative phenotype equivalent to that of NHU cells, but they require 
exogenous stimulation to achieve this switch instead of adopting regenerative 
phenotype through an autocrine EGFR/MAPK signalling loop.   
 
Extracellular calcium concentrations can result in the generation of cell-cell junctions 
and result in variations in the proliferation pathways driving urothelial cell 
proliferation. Lowering extracellular calcium did not prevent the expression of tight 
junction proteins, suggesting that NRU cells remained in a more differentiated state 
than NHU cells. This could indicate an inability of NRU cells to fully differentiate in 
the same way as NHU cells or that an aspect of the cell culture system was 
preventing them from adopting a fully proliferative phenotype. Again this could 
indicate a basic cellular difference between normal rat and human urothelial cell 
physiology.  
 
Despite being able to extend their lifespan in culture, NRU cells could only be 
subcultured to passage 2 before becoming senescent. In an attempt to improve the 
NRU cell culture system so that it could be used in toxicity testing, and in order to 
facilitate further comparisons of the NRU and NHU cell culture systems, NRU and 
NHU cells were immortalised using two separate methods (Chapter 5).  
 
 




4.8 Key findings 
 
 In culture NHU and NRU cells regulate proliferation via different 
proliferation pathways 
 Inhibition of the PI3K/Akt pathway allowed NRU cells to be subcultured up 
to passage 2. 
 Removal of exogenous EGF did not affect NRU cell proliferation but EGFR 
inhibition caused a reduction in NRU cell proliferation, suggesting an 
autocrine signalling loop 
 When cultured in low calcium (0.09mM) KSFMc medium, proliferating NRU 
cells express cell-cell junction and differentiation-associated proteins. 
 Decreased extracellular calcium (0.06mM) prevented densely populated  
NRU cell colonies from forming but did not affect cell proliferation, growth 
in culture or NRU cell’s ability to be subcultured.  
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5.1 Chapter Introduction 
 
5.1.1 Immortalised cell lines 
Normal cells undergo a pre-determined and finite number of divisions, beyond 
which proliferation ceases and cells reach a state of replicative senescence (reviewed 
by Sherr, 2000). Replicative senescence is the result of telomere erosion that occurs 
with every cell division. The majority of normal cells do not express telomerase, the 
enzyme that is able to restore telomeres, and as such have a finite number of cell 
divisions before reaching senescence, known as the Hayflick limit. In vitro, cells are 
also capable of becoming senescent without the loss of telomeres. Culture stress-
induced senescence can occur when the cell culture conditions are not favorable for 
cell growth. Tissue culture plastic substrate, cell culture medium and cell seeding 
density are among a number of conditions that can induce cells to become 
senescent. Urothelial cells in general show a reduction in their proliferative rate in 
vitro before passage 10, resulting in the need to regularly isolate cells from fresh 
tissue samples and limiting both the number of cells that can be generated from one 
sample (Puthenveettil et al., 1999). Having to freshly isolate cells also results in 
multiple isolation protocols and culture systems being developed (described in 
Chapter 3).   
 
To increase lifespan, normal cells can be immortalised to generate cell lines with 
extended proliferative capacities. Immortalised cell lines are a useful tool as they can 
be serially expanded and widely distributed between research groups and industrial 
companies.  They also have the ability to be used in experiments over several 
months, where finite cell lines would have become senescent, but immortalisation 
can have the disadvantage of significantly altering the characteristics of cell lines. 
The techniques required to immortalise cells can reduce cells similarity to their 
counterparts in vivo, reducing their usefulness as predictive models (Stampfer et al., 
1997; Castell et al., 2006). If, however, cells can be immortalised without 
compromising their original characteristics then these cells would provide a 
valuable tool for use in studies including toxicology testing.  





5.1.2 In vitro immortalisation  
Multiple methods exist for establishing immortalised cell lines. The simplest method 
is to isolate and culture cancer cells from existing tumours. The commonly used 
HeLa cell line, the first human cell to be cultured, was originally isolated from 
cervical cancer cells in 1951 (reviewed by Gilgenkrantz, 2014).  
 
In order to immortalise a normal (non-cancerous) cell line, cells can be transfected 
with either cell-cycle regulatory genes isolated from viruses or through the 
overexpression of particular human proteins associated with immortalisation. The 
immortal human embryonic kidney cell line HEK 293 was generated by transfecting 
human embryonic kidney cells from an aborted fetus with the adenovirus E1 gene 
(Graham et al., 1977).  This caused an insert of a 4.5 kilobase section of viral DNA 
into human chromosome 19, producing an immortal and highly proliferative cell 
line that is easily manipulated (Louis et al., 1997). The SV40 large T antigen is 
another viral gene that acts a proto-oncogene when transfected into mammalian 
cells, causing immortalisation (Jha et al., 1998).   Overexpression of human genes 
including human telomerase reverse transcriptase (hTERT) is another commonly 
used method of cell line immortalisation. hTERT overexpression inhibits telomere-
controlled senescence by preventing the shortening of telomeres with each mitotic 
cell division. Osteoblasts, endothelial cells, epithelial cells and fibroblasts are among 
a few of the cell types that have been immortalised by hTERT overexpression 
(reviewed by Lee et al. 2004). Combined overexpression of hTERT with cyclin D1 
and mutant cyclin dependant kinase 4 (CDK4) isoform have also been used in the 













5.1.3 Immortalisation of urothelial cell culture models 
Immortalisation of NHU cells has previously been achieved by multiple methods 
including overexpression of hTERT (Petzoldt et al., 1995; Georgopoulos et al., 2011) 
and transfection with the human papillomavirus 16 (HPV16) E6 gene (Diggle et al., 
2000). It was found that human urothelial (HU)-TERT cells had an increased 
lifespan in culture when compared to NHU cells but their ability to differentiate 
(ABS/Ca2+) and form a functional barrier was severely reduced. It was shown that 
hTERT immortalisation did not cause gross genomic or karyotypic alterations but 
P16INK4a and proliferator-activated receptor γ (PPARγ) expression were inhibited. 
PPARγ is known to be an important regulator of NHU cell differentiation (Varley et 
al., 2004) and its inhibition in HU-TERT cells would explain cells inability to 
differentiate in vitro. As the production of a barrier between urine and the 
underlying stromal cells is a key function of the urothelium it is an important aspect 
to replicate in urothelial cell culture models. 
 
A separate human urothelial cell line was immortalised through transfection with a 
construct containing the SV40 large T antigen and named the UROtsa cell line (Rossi 
et al., 2001). UROtsa cells have an undifferentiated cell morphology and have been 
used, amongst other things, to research heavy metal toxicity in urothelial cells 
(Somji et al., 2008). A major concern with the use of UROtsa cells in toxicity testing, 
apart from their dedifferentiated phenotype, is that the cell line appears to have 
become contaminated with the T24 bladder cancer cell line.  A study of multiple 
UROtsa sources found that all cell lines tested lacked the large T-antigen and short 
tandem repeat analysis identified as characteristic of the T24 bladder cancer cell line 
(Johnen et al., 2013). Depending on when the contamination occurred, this has 
serious implications for all publications using UROtsa cells and reduces the 
credibility of results published that relate to normal urothelial cell function. 
Immortalisation of NRU cells using any immortalisation technique has not been 
published.  
 





5.1.4 Overexpression of BMI1  
BMI1 is a 37 kDa protein originally identified in lymphoid tumours in mice (Haupt 
et al., 1991b). It was the first functional polycomb group (PcG) protein to be 
discovered and shares a high level of homology between humans and rodents 
(Alkema et al., 1993). In particular the N terminal ring finger domain and central 
helix-turn-helix-turn (H-T-H-T) motif, the regions essential for inducing telomerase 
activity, are conserved between species (Li et al., 2006; Cohen et al., 1996). BMI1 is 
expressed in most tissues but expression is particularly high in the brain, blood, 
bone marrow and lungs (Huber et al., 2011). As a member of polycomb repression 
complex 1 (PRC1), it is involved in maintaining specific gene repression through 
epigenetic silencing (Pirrotta, 1998; Ringrose and Paro, 2004). BMI1 knockout in 
mouse models is not embryonically lethal, unlike loss of polycomb repression 
complex 2 (PRC2) members, but the lack of BMI1 does lead to posterior 
transformation (Alkema et al., 1995), neurological abnormalities and severe 
hematopoietic defects (van der Lugt et al., 1994). 
 
BMI1 was initially identified as an oncogene which, in combination with c-Myc, 
caused lymphomagenesis in mice (van Lohuizen et al., 1991; Haupt et al., 1991a). It 
has now been shown that BMI1 is up-regulated in a number of cancers, including 
epithelial carcinomas (Raaphorst, 2005; Huber et al., 2011; Kim et al., 2004; Song et 
al., 2006; Leung et al., 2004; Kang et al., 2006), where it is believed to be involved in 
cancer stem cell (CSC) maintenance (Valk-Lingbeek et al., 2004; Liu et al., 2006b). 
BMI1 is highly expressed in CSCs (Lessard and Sauvageau, 2003; Liu et al., 2006c; 
Song et al., 2006; Liu et al., 2006a) but its up-regulation in cancer is not restricted to 
CSCs, preventing it from being used as a CSC marker (Oishi N and XW, 2011). BMI1 
expression has an inverse relationship with microRNA-218 (miRNA-218), a 
microRNA on chromosome 4 that is lost in cancers including colon, cervical, lung 
and bladder (Martinez et al., 2007; Davidson et al., 2010; Tatarano et al., 2011). By 
inducing expression of miRNA-218 in cancer cells, BMI1 is down-regulated which 
acts to induce apoptosis and inhibit cell proliferation (He et al., 2012). 





Through epigenetic inhibition of gene transcription, BMI1 regulates cell 
proliferation and prevents cells from becoming senescent (Jacobs et al., 1999). This 
function has been most commonly reported in stem cells where cell maintenance 
and self-renewal are dependent on BMI1 expression. This has been documented in 
normal and progenitor liver stem cells (Lessard and Sauvageau, 2003), 
hematopoietic stem cells (Hosen et al., 2007) and neural stem cells (Molofsky et al., 
2005). In keratinocytes BMI1 is only expressed by basal and suprabasal cells 
(Balasubramanian et al., 2008). 
 
 
Figure 5.1 – BMI1 increases cell self-renewal, proliferation and stemness while decreasing 
apoptosis and senescence. Cartoon illustrating some of the molecular actions of BMI1 
associated with stemness and immortalisation. BMI1 activates transcription factors KLF4, 
SOX2 and GATA3 as well as the telomerase reverse transcriptase (TERT) to promote self-
renewal and stemness. BMI1 activation of the NF-κB and P16INK4a pathways result in 
increased cell proliferation while inhibition of P21 inhibits apoptosis. Downstream inhibition 
of E-cadherin enables epithelial mesenchymal transition (EMT) and cell invasion (adapted 





































In vitro, down-regulation of BMI1 gene expression occurs when cells become 
senescent, although expression is unaltered in quiescent cells when compared to 
proliferating (Itahana et al., 2003).  In human stem and cancer cell lines, loss of BMI1 
causes cell senescence through signalling events including p16INK4a expression and 
down regulation of SOX-2 and KLF4 (Dong et al., 2011; Molofsky et al., 2005). Due 
to its ability to inhibit senescence, over-expressing BMI1 has been used as a 
technique to increase the lifespan of cells in culture (Saito et al., 2005; Fulcher et al., 
2009; Dimri et al., 2002).  
 
BMI1 has been overexpressed in epithelial cells, stromal cells and fibroblasts to 
increase cellular lifespan in culture and is able to do so without altering cell 
morphology or phenotype (Dimri et al., 2002; Itahana et al., 2003; Takeda et al., 2004; 
Tátrai et al., 2012). Furthermore overexpression of BMI1 in normal human bronchial 
epithelial cells increased cell lifespan while preserving the ability of cells to 
differentiate in culture and generate a functional barrier with a TEER equivalent to 
that of untransfected cells (Fulcher et al., 2009).  
 
The effects of BMI1 overexpression in NRU or NHU cells have not previously been 
reported. The generation of immortalised NRU and NHU cell lines that retain the 
ability to differentiate and generate functional barriers in vitro would be beneficial in 
further comparing NRU and NHU cells, as a means of validating the systems for use 
in toxicity studies. It would also increase their utility in toxicity studies due to the 
increased potential for lifespan expansion of immortalised cell lines compared to 










To investigate the effect of BMI1 overexpression on the lifespan and differentiation 
potential of NRU and NHU cells in vitro and compare results against cells 
overexpressing human telomerase reverse transcriptase (hTERT). 
 
5.2.1 Objectives 
1. Generate a BMI1 overexpression retrovirus and transduce NRU and 
NHU cells 
 
2. Determine the lifespan of NRU cells overexpressing BMI1 or hTERT 
 
3. Investigating the effect BMI1 and hTERT overexpression on NHU cell 
lifespan 
 
4. Investigate the ability of BMI1 and hTERT overexpressing NHU cells 














5.3 Experimental approach 
 
5.3.1 Development of a BMI1 overexpressing retroviral cell line 
Next generation sequencing data was used to demonstrate whether NHU cells 
express BMI1 transcript. NHU cell cDNA was used to amplify the BMI1 protein-
coding sequence, which was cloned into a pLXSN retroviral plasmid. The plasmid 
was sequenced to ensure the entire cDNA had been amplified and ligated before 
being transformed and amplified in bacteria. The PT67 mammalian retroviral 
packaging cell line was transfected with the pLXSN BMI1 plasmid, ready for 
transduction of urothelial cells. Additional packaging cell lines containing a 
previously developed pLXSN hTERT plasmid (Georgopoulos et al., 2011) or pLXSN 
plasmid without an insert (pLXSN Empty) were also generated to act as controls. 
Successful transfection of packaging cells was confirmed using antibiotic (G418) 
selection. Untransfected packaging cells acted as antibiotic-selection controls. 
 
 
5.3.2 Effect of BMI1 or hTERT overexpression on NRU cell growth 
and lifespan in culture 
 
3 NRU cell lines isolated and cultured using the optimised NRU cell isolation 
(dispase/trypsin) and culture (PI3K inhibition / 0.06 mM Ca2+) protocols (see 
Chapters 3 and 4) were transduced with pLXSN empty, pLXSN BMI1 or pLXSN 
hTERT and cultured under antibiotic selection (0.025 mM G418). The effects of 
transduction on cell growth in culture monitored by phase contrast microscopy and 











5.3.3 Effect of BMI1 and hTERT overexpression on NHU cell 
growth, lifespan and ability to form a functional barrier in culture 
Population doubling graphs were generated using cell counts for NHU cells 
transduced with pLXSN, pLXSN BMI1 or pLXSN hTERT and cultured under 
antibiotic selection (0.025 mM G418) to monitor the effect on cell growth. NHU cells 
were differentiated (ABS/Ca2+) and their ability to generate functional barriers in 
vitro examined.  
5.3.4 Cell lines 
Table 5.1 NRU Cells 
Code No. of 
animals 
Sex Source Strain Age/ 
Weight 
R041 12 M University of York Wistar 250-300g 
R042 10 M/F Covance Inc. Wistar 300-350g 
R046 10 M University of York Wistar 300-350g 
 
Table 5.2 NHU Cells 
Code Tissue of origin Sex Age 
Y1533 Ureter M 45 
Y1570 Ureter F 51 
 
  





5.4.1 Development of a BMI1 overexpressing pLXSN retrovirus 
Next generation sequencing data generated using RNA from freshly isolated (P0), 
proliferating and differentiated NHU cells was used to confirm that NHU cells 
expressed BMI1 transcripts. As can be seen in Figure 5.2, all 7 known BMI1 
transcript variants, including the full protein-coding BMI1-001 transcript, were 
expressed in primary, proliferating and differentiated NHU cells.  
 
 
Figure 5.2 – BMI1 transcripts are expressed by P0, proliferating and differentiated NHU 
cells. Next generation sequencing (Section 2.6.3.9) data showing mean reads per kilobase per 
million mapped reads (RPKM) for BMI1 transcript expression in freshly isolated (P0), 
























RNA was isolated from proliferating NHU cells and primers were designed to 
amplify the full Bmi-001 protein coding sequence, with restriction enzyme sites for 
BamH1 incorporated into the forward primer and Hpa1 on the reverse primer and a 
Kozac sequence before the start codon (appendix 1.6). BMI1 cDNA was amplified 
using High Fidelity Taq polymerase, which produced a product with TA overhangs 
for ligation into pGEM T easy vector that was subsequently transformed into 
bacteria. Ampicillin-selection was initially used to identify successfully transformed 
bacteria (Figure 5.3). Plasmids from 10 single selected colonies were sequenced to 
find a colony containing the complete BMI1 cDNA sequence. A single colony was 
found in which the BMI1 sequence had two single base changes from the reference 
sequence (Appendix 2.3) (Figure 5.4), neither of which affected the amino acid 
sequence encoded. This single colony was selected and cultured under continued 
ampicillin-selection.  
 
BMI1 cDNA was cut from the pGEM T vector using the restriction enzymes BamH1 
and Hpa1 (Figure 5.5), purified and ligated into pLXSN retroviral plasmid. Bacteria 
were transfected with the pLXSN BMI1 vector and a colony RT-PCR conducted to 
ensure colony had been successfully transfected (Figure 5.6). A colony containing 
pLXSN BMI1 was chosen, sequenced to ensure the BMI1 sequence was correct and 
used to generate pLXSN BMI1 for transfection of PT67 packaging cells.  After 5 days 
of G418 selection untransfected PT67 cells had died whereas ones transduced with 


















Figure 5.3 – Successful ligation of BMI1 into pGEM T and subsequent transfection of 
E.Coli, as confirmed by antibiotic selection. Ampicillin-selection of XL1-Blue competent E. 
coli were transformed with pGEM T easy BMI1, pGEM T easy insert DNA (+ control) and 

















Figure 5.4 – BMI1 was accurately amplified from NHU cell RNA with only two, non-
amino acid altering mutations. BMI1 was sequenced (Section 2.6.5.5) after amplification 
from NHU RNA. Restriction sites are coloured in yellow, the Kozak sequence in green and 
alternate exons colours in black and grey. Two bases that were changed from the Reference 
sequence are highlighted in red. 
 





Figure 5.5 - BMI1 was successfully cut from the pGEMT BMI1 vector. Gel electrophoresis 
(section 2.6.5.3) of pGEM T BMI1 isolated from transformed XL1-Blue competent E. coli (1), 
after single BamH1 restriction enzyme digestion (2) and after a double restriction enzyme 











Figure 5.6 - BMI1 was successfully ligated into pLXSN vector and used to transfect 
bacteria. Colony RT-PCR (Section 2.6.3.8) amplifying BMI1 (221bp) from 8 bacterial colonies 
after transfection with pLXSN BMI1.  Base pair ladder indicates the size of the product in 

















Figure 5.7 – Packaging cells were successfully transfected with pLXSN BMI1, pLXSN hTERT and pLXSN Empty vectors. Phase contrast images of PT67 
packaging cells transfected with pLXSN empty, pLXSN hTERT & pLXSN BMI1 on days 3 and 5 of G418 selection showing complete death of untransfected 
cells. Scale bar = 50 µm. 
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5.4.2 Overexpression of BMI1 and hTERT in NRU cells 
NRU cells transduced with retrovirus during primary culture to overexpress BMI1 
or hTERT showed no difference in morphology to cells transduced with empty 
pLXSN at passage one, following one subculture (Figure 5.8). Population growth 
was consistent between all transduced cell lines, with 80-90% confluence achieved 
after 7 days of culture under antibiotic (G418) selection. Non-transduced control 
NRU cells did not grow in the presence of G418 and approximately 95% of cells 
died within 7 days of G418 selection and were discontinued.  
 
When passaged a second time (P2), NRU cultures transduced with pLXSN, pLXSN 
BMI1 or pLXSN hTERT all failed to proliferate and approximately 95% of cells were 
dead within 7 days (Figure 5.10). NRU cells transduced with BMI1 or hTERT 
appeared to die at the same rate as cells containing pLXSN empty vector.  
 
The growth of passage 1 and passage 2 NRU cells transduced with pLXSN BMI1 or 
pLXSN hTERT was quantified (Figure 5.11 & Figure 5.12) and in support of results 
seen by phase contrast microscopy showed that NRU cells at P1 all shared typical 
growth kinetics irrespective of BMI1 or hTERT overexpression. No differences were 
found between NRU cells transduced with pLXSN empty vector and cells 
transduced with either pLXSN BMI1 or pLXSN hTERT. After an additional passage 
(P2), all NRU cells showed minimal growth between days 1 and 3 of culture and 
significant reductions in biomass between days 3 and 5. Overexpression of BMI1 or 
hTERT did not have a significant effect on NRU (P2) cell growth compared to the 

















Figure 5.8 – NRU cells were successfully transfected with pLXSN Empty vector, pLXSN hTERT, pLXSN BMI1 vectors. Phase contrast images of 
transduced and untransduced NRU cells cultured in KSFMc medium (0.06mM Ca2+) during the first 7 days after subculture (P1) under G418 selection. Scale 
bar = 50 µm.  
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Figure 5.9 – BMI1 and hTERT were both expressed by NRU cells overexpressing BMI1. 
RT-PCR (section 2.6.3.8) showing BMI1 expression in NRU cells (P1) transduced with 
pLXSN BMI1 (B), pLXSN empty vector (E) and pLXSN hTERT (H). GAPDH was included as 
a loading control. 
 
 
Figure 5.10 – hTERT and BMI1 overexpressing cells did not survive after passage 2. Phase 
contrast images of transduced NRU cells cultured in KSFMc medium (0.06 mM Ca2+) on 
days 3, 5 and 7 after second subculture (P2).  Cells remained under G418 selection pressure. 




B           E            H 




   
   




   
   
   
   
   
   
   
   
   
   
   




   
   
   
   
   
   
   
   
   
   
   











Figure 5.11 – BMI1 and hTERT overexpressing NRU cells grew at passage 1 equivalent to 
control cells. AlamarBlue assay (Section 2.5.3.1) generated growth curves for control, 
pLXSN BMI1 and pLXSN hTERT transfected NRU cells (P1) cultured in KSFMc medium 









Figure 5.12 – BMI1 and hTERT overexpressing NRU cells failed to grow at passage 2. 
AlamarBlue assay (Section 2.5.3.1) generated growth curves for control, pLXSN BMI1 and 
pLXSN hTERT transfected NRU cells (P2) cultured in KSFMc medium (0.06 mM Ca2+) 







































































5.4.3 The effect of overexpressing BMI1 and hTERT on NHU cell 
growth 
Sublines of NHU cells from two donors (Y1533 & Y1570) transduced with pLXSN 
BMI1, pLXSN hTERT or pLXSN empty vector at passage 1 were maintained over 
several months. Cultures were passaged when 80-90% confluent and population 
doubling curves generated (Figure 5.13 & Figure 5.14). Data from the individual 
donors is displayed separately to illustrate the donor variations observed.  
 
BMI1 overexpressing NHU cells from both donors showed no difference in growth 
rate compared to NHU cells overexpressing hTERT or transfected with pLXSN 
empty vector up to passage 10 (Y1533) and passage 8 (Y1570), at which point NHU 
cells transduced with empty vector became senescent. BMI1 and hTERT 
overexpressing cells continued to proliferate beyond the point at which empty 
vector cells became senescent, with BMI1-transduced cells achieving a greater 
number of population doublings than hTERT-overexpressing NHU cells at each 
time point.  
 
One NHU cell line (Y1570) showed a greater population doubling rate than cells 
from donor Y1533. This variation between donors was mirrored by BMI1 and 
hTERT-overexpressing cells, indicating that overexpression of either protein did not 
have any effect on the NHU cell growth rate.   
 
Cells throughout culture were monitored by phase contrast microscopy (Figure 
5.14) to allow changes in cell morphology to be monitored. NHU cell lines 
overexpressing BMI1 or hTERT showed no alterations in cell morphology between 
passages 6-9. NHU cell cultures transfected with pLXSN empty vector began to 
contain flattened cells at passage 7 (P7) and had a larger, more rounded cell 
morphology by passage 9 (P9). Based on the growth curves generated, this 
coincided with a decrease in cell proliferation and eventual senescence.    
 








Figure 5.13 – BMI1 and hTERT overexpression increased NHU cell lifespan in culture 
compared to control cells. NHU cell population doubling curves (Section 2.5.4) were 
generated for two cell lines transduced with pLXSN BMI1, pLXSN hTERT and pLXSN 
empty vector. Numbers indicate the passage number of the cell line at each time point (n=2, 















































































Figure 5.14 – BMI1 and hTERT overexpressing NHU cells maintained a normal 
morphology in culture up to passage 9 whereas control (Empty vector) NHU cells became 
more rounded and were less densely packed in culture. Representative phase contrast 
images of NHU cells transduced with pLXSN BMI1, pLXSN hTERT and pLXSN empty 


























To confirm the overexpression of BMI1 and hTERT in transduced NHU cells, RT-
PCR was conducted on RNA from pLXSN BMI1, pLXSN hTERT and pLXSN empty 
vector transfected NHU cells at passages 2-12. In pLXSN BMI1 transfected NHU 
cells, BMI1 was detected at passages 2-12 (Figure 5.15). hTERT was not found to be 
expressed by BMI1 overexpressing NHU cells. 
 
pLXSN hTERT transfected NHU cells showed both expression of hTERT at passages 
2-12 and also expression of BMI1 (Figure 5.16). hTERT expression appeared to 
increase over the time course. BMI1 expression was visually reduced compared to 
expression in pLXSN BMI1 transfected NHU cells (Figure 5.16), but was 
consistently expressed by hTERT overexpressing cells at passages 2-12.  
 
As NHU cells transfected with pLXSN empty vector became senescent, RT-PCR was 
only conducted on RNA from cells up to passage 8 (Figure 5.17). At no passage did 
empty vector-transduced NHU cells express BMI1 or hTERT transcript. The lack of 
BMI1 and hTERT expression in the empty vector cells indicated that the expression 
seen in the pLXSN BMI1 and pLXSN hTERT transfected cells was a result of the 
retroviral transduction. As BMI1 was expressed by both pLXSN hTERT transfected 
NHU cell lines (Y1533 and Y1570), it suggests that the expression of BMI1 in hTERT 














Figure 5.15 – BMI1 expression was maintained in NHU cells over multiple passages. RT-
PCR (section 2.6.3.8) results showing BMI1 and hTERT expression in BMI1 overexpressing 
NHU cells at passages 2-12 (Y1533). Water was used as a negative (no-template) control, 
RNA from BMI1 or hTERT-overexpressing PT67 was used as positive controls; GAPDH was 
used as a loading control.  
 
 
Figure 5.16 - BMI1 and hTERT were both expressed by hTERT overexpressing NHU cells 
over several passages. RT-PCR (Section 2.6.3.8) results showing BMI1 and hTERT 
expression in hTERT overexpressing NHU cells at passages 2-12 (Y1533). Water was used as 
a negative control, BMI1 or hTERT overexpressing PT67 cDNA as positive controls and 















Figure 5.17 – BMI1 and hTERT were not expressed by Empty vector (control) NHU cells. 
RT-PCR (section 2.6.3.8) results showing BMI1 and hTERT expression in pLXSN Empty 
vector transduced NHU cells at passages 2-8 (Y1533). Water was used as a negative control, 
BMI1 or hTERT overexpressing PT67 cDNA as positive controls and GAPDH as a loading 
control. (n=2, Y1533, Y1570) 
 
5.4.4 Generation of a functional barrier in vitro  
At passage three, NHU cells transduced with pLXSN BMI1, pLXSN hTERT and 
pLXSN empty vector were subjected to the ABS/[Ca2+] differentiation protocol and 
all were found able to generate a barrier in vitro, as measured by TEER. This was 
conducted in two NHU cell lines and although there were variations between the 
two donor cell lines, no significant differences in the ability of cells to generate a 
barrier occurred as a result of overexpressing BMI1 or hTERT compared to empty 























Figure 5.18 – Functional TEER barriers (>1000 kOhm.cm2) were generated by control, 
BMI1 and hTERT overexpressing NHU cells at passage 3.  TEER measurements (Section 
2.5.5.2) for two NHU cell lines (P3) transfected with pLXSN BMI1, pLXSN hTERT or pLXSN 













































At passage 6 (Figure 5.19) NHU cells from both NHU cell lines (Y1533 & Y1570) 
produced a lower TEER than at passage 3 (Figure 5.18). Cells overexpressing BMI1 
(green) from both donor cell lines were able to generate a barrier at passage 6 with 
one donor cell line (Y1533) forming a barrier within three days. NHU cells 
overexpressing hTERT (red) from one donor cell line (Y1570) showed no significant 
difference in TEER throughout the time course compared to cells overexpressing 
BMI1. NHU cells overexpressing hTERT in the other donor cell line (Y1533) took 
longer to generate a TEER over 1500 kOhms.cm2 compared to cells overexpressing 
BMI1 and were not able to maintain the TEER between days 7 and 13. NHU cells 
transfected with pLXSN empty vector (blue) had reduced TEER values compared to 
BMI1 and hTERT overexpressing cells. Y1533 empty vector cells at passage 6 failed 
to produce a barrier whereas Y1570 empty vector cells were able to generate a TEER 
of over 1500 kOhm.cm2 however this took longer than in BMI1 and hTERT 
overexpressing cells and the TEER did not become as high as in the overexpressing 
cells.  
 
Compared against cells at passage 3 (Figure 5.18) and passage 6 (Figure 5.19), BMI1 
and hTERT overexpressing NHU cells at passage 10 (Figure 5.20) did not generate 
as high TEERs however, unlike NHU cells transfected with empty vector, which had 
become senescent, BMI1 and hTERT cells were able to produce a barrier. BMI1 
overexpressing NHU cells generated barriers of approximately 1500 kOhm.cm2. 
hTERT overexpressing NHU cells produced lower TEERs and took longer to reach a 
maximum resistance. There was a significant difference between the TEERs 
generated between BMI1 and hTERT overexpressing NHU cells from the Y1533 
donor line (solid bars) at passage 10 whereas NHU cells from the second, Y1570 



















Figure 5.19 - Functional TEER barriers (>1000 kOhm.cm2) were generated by control, BMI1 
and hTERT overexpressing NHU cells at passage 6.  TEER measurements (Section 2.5.5.2) 
for two NHU cell lines (P6) transfected with pLXSN BMI1, pLXSN hTERT or pLXSN empty 


















































Figure 5.20 – BMI1 overexpressing NHU cells generated a functional TEER barrier (>1000 
kOhm.cm2) at passage 10 unlike hTERT overexpressing NHU cells.  TEER measurements 
(Section 2.5.5.2) for two NHU cell lines (P6) transfected with pLXSN BMI1, pLXSN hTERT or 













































5.5 Conclusions and Discussion 
A BMI1 overexpressing retroviral plasmid was created and used to generate BMI1-
overexpressing NRU and NHU cell lines. hTERT-overexpressing NRU and NHU 
cell lines were also generated using an existing pLXSN hTERT vector.  
 
In NRU cells, overexpression of either BMI1 or hTERT did not increase cell lifespan 
in culture or allow cells to be subcultured further than untransduced cells. This is in 
contrast to BMI1 and hTERT-overexpressing NHU cells which continued to grow in 
culture for multiple passages after pLXSN empty vector control cells had become 
senescent.. BMI1 expressing NHU cells did not express hTERT, however, hTERT 
overexpressing NHU cells did express BMI1. A correlation between BMI1 and 
hTERT expression in cancerous cells has been established (Zhang et al., 2008) and in 
combination, BMI1 and hTERT overexpression has been used to immortalise a 
number of primary cell lines (Saito et al., 2005; Zhang et al., 2006; Haga et al., 2007). 
In hTERT immortalised oral epithelial cells, BMI1 activation was shown to occur 
and be crucial for cells retaining their immortalised phenotype and for epithelial-
mesenchymal transition (Qiao et al., 2013). The lack immortalisation in NRU cells 
could be as a result of overexpressing human BMI1 in rats however this would seem 
unlikely due to the high sequence homology between human and rat BMI1 
transcripts (appendix 2.3). The inability of hTERT overexpression to increase NRU 
cell lifespan could also be due to the difference between human and rat TERT that 
share approximately 75% identity.  
 
Functionally, BMI1 and hTERT cells were capable of generating functional barriers 
in vitro at passage 6 and 10, when empty vector control cells were not capable of 
generating a high barrier. Variations between NHU cell lines could be as a result of 
differences between donors, highlighting the requirement for these results to be 
replicated in additional NHU cell lines from multiple donors. At passage 10, BMI1-
overexpressing NHU cells were capable of generating higher TEERs than hTERT-
overexpressing NHU cells but TEERs were reduced compared against those 





5.6 Key Findings 
 Retrovirus for overexpression of human BMI1 was successfully generated 
 
 BMI1 and hTERT-overexpression failed to immortalise NRU cell lifespan in 
culture, despite evidence of successful overexpression.  
 
 BMI1-overexpressing NHU cell proliferation was comparable to that of 
NHU cells overexpressing hTERT 
 
 BMI1 and hTERT-overexpressing NHU cells were capable of generating 
functional barriers at P6 and P10.  
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6.1 Chapter Introduction 
 
6.1.1 Cellular Metabolism 
Cellular metabolism involves a series of enzyme-catalysed reactions within cells, 
resulting in the transformation of a compound to its metabolites. Metabolic 
reactions can be divided into either catabolism or anabolism, both of which are 
essential for all living cells. Catabolism involves the breakdown of large molecules 
into their smaller components, with digestion of food being a key example. 
Anabolism, alternatively, is the addition of reactive groups or molecules to a 
compound in order to synthesise complex molecules.  One important example of 
anabolism is the metabolism of xenobiotics (discussed by Iyanagi, 2007) 
 
Xenobiotics are compounds foreign to an organism that, if allowed to accumulate, 
could cause toxicity or other damage. These can include compounds that organisms 
are inadvertently or advertently exposed to in their environment or by ingestion. 
Pharmaceutical agents, pesticides and natural poisons are all examples of 
xenobiotics that humans are routinely exposed to and which have to be cleared from 
body in order to prevent toxicity (discussed by Omiecinski et al., 2011).  
 
6.1.2 Xenobiotic metabolism in humans and rats 
Differences in isoform composition, expression, localisation and catalytic activities 
exist between the metabolic enzymes of humans and rats. Such differences can have 
significant impacts on the rate and mechanism of xenobiotic metabolism, affecting 
the activity of a compound and its metabolites (Martignoni et al., 2006). 
Cellular metabolism of xenobiotics occurs predominantly in the liver and consists of 
two distinct phases (illustrated in Figure 6.1). Phase I involves the addition of polar 
or reactive groups to the target compound and is largely conducted by the 
cytochrome P450 (CYP) superfamily of enzymes. Phase I metabolism by CYPs 
accounts for approximately 75% of the total metabolism of pharmaceutical agents. 
Phase II metabolic enzymes such as UDP-glucuronosyltransfereases, 




methyltransferases, sulfontransfereases and glutathione S-transferases are then able 
to add complex, water-soluble molecules to the phase I (intermediate) metabolite in 
conjugation reactions. The conjugated xenobiotic metabolite is then excreted from 
cells, where it can either be immediately eliminated from the body, for example by 
glomerular filtration in the kidneys, or undergo further (phase III) metabolism prior 
to elimination (reviewed by Jancova et al., 2010). 
 
Figure 6.1 – Illustration of Phase I and Phase II xenobiotic metabolic reactions. Phase I 
metabolism, predominantly conducted by CYPs, involving oxidation of electrophilic 
xenobiotics or reduction of nucleophilic xenobiotics. Phase II conjugation reactions then take 
place to add glutathione groups (SG) sulfate groups (SO3H), acetyl groups (Ac) and 
glucuronide groups (GI) to the phase I metabolite, rendering the compound inactive. Phase 
II metabolites are then further metabolised or immediately removed from the body.  
 
Through the addition of polar or reactive groups, phase I metabolism can generate 
active metabolites or metabolites with increased activity compared to the original 
compound. This has been exploited in the cases of pharmaceutical prodrugs, 
including cyclophosphamide (used in the treatment of cancer and autoimmune 
diseases) and codeine (used as an analgesic), which need to be metabolised into 
active metabolites in order to have their intended effects. The illicit drug heroin also 
requires metabolism to its active compounds in order to cause euphoria. Metabolic 
activation of xenobiotics can result in toxicity if the metabolite is produced in high 
enough quantities, as is the case when the rate of phase I metabolism exceeds that of 
Phase III or elimination 
Hydrophilic 
metabolite 
        Phase I                                    Phase II 




phase II (reviewed by Ekins and Wrighton, 1999; reviewed by Turpeinen et al., 
2006).  
 
6.1.3 Cytochrome P450 enzymes 
The cytochrome P450 (CYP) superfamily of enzymes are primarily responsible for 
phase I metabolism. CYPs can be constitutively or inducibly expressed in multiple 
tissues and play an important role in the metabolism of both  xenobiotics and 
endogenous molecules (reviewed by Anzenbacher and Anzenbacherová, 2001).  
Mammalian CYPs are membrane-associated proteins located in mitochondria or the 
endoplasmic reticulum. CYPs are terminal oxidase enzymes in electron transfer 
chains (Meunier et al., 2004). To function, CYP enzymes require additional proteins 
such as cytochrome P450 reductase (CPR) and NADPH electron donor.  
 
 CYPs are most highly expressed in the liver, where their expression profiles and 
characteristics have been extensively studied, but they are also expressed in other 
organs including the intestine, kidneys, heart, lungs and bladder (Zhang et al., 1999; 
Knights et al., 2013; reviewed by Chaudhary et al., 2009; Hukkanen et al., 2002; 
Brauers et al., 2000; Bieche et al., 2007). 
 
In humans, there are 57 CYP genes and more than 60 CYP pseudogenes, divided 
into 18 different families that are indicated by a number (e.g. CYP1). Within each 
family there are multiple subfamilies, indicated by a letter (e.g. CYP1A), and within 
each subfamily individual enzymes are identified by a number (e.g. CYP1A1).  
Members of the CYP1, CYP2, and CYP3 families are almost exclusively responsible 
for pharmaceutical compound metabolism in humans. The other CYP families are 
involved in the metabolism of endogenous molecules such as vitamin D and retinoic 
acid (detailed by Sim and Ingelman-Sundberg, 2010). The specific CYPs that conduct 
the majority of pharmaceutical compound metabolism are illustrated in Figure 6.2, 
which denotes the percentage of pharmaceutical compounds they metabolise.  
 













Figure 6.2 – percentage of total CYP metabolism of pharmaceutical agents by the 
individual CYP enzymes. The 8 CYP enzymes responsible for pharmaceutical agent 
metabolism and the percentage of pharmaceutical agents they metabolise are depicted 
(adapted from Wrighton and Stevens, 1992). 
 
The expression of CYPs by different tissues can have important ramifications for 
drug discovery and for predicting xenobiotic toxicity, as expression in the target 
tissue may modulate the effect or activity of a particular drug.  
 
6.1.4 CYPs and the bladder 
Many known bladder toxicants are known to be metabolised to active states by 
cytochromes including acrylamides, cyclophosphamide and 4-aminobiphenyl 
(Turpeinen et al., 2006; Ingelman-Sundberg, 2004; Ekhart et al., 2008). If this 
metabolism were to occur within the bladder, it would localise the toxicity and 
subject the urothelium to potentially harmful concentrations of active carcinogens.  
 
Multiple CYPs including CYP1A1, CYP1A2, CYP1B1, CYP2D6 and CYP2E1 have all 
been shown to be expressed in the bladder, with several other CYPs expressed by 
urothelial carcinomas (Brauers et al., 2000). The CYP2B family of enzymes 












tamoxifen and ifofamide have not been investigated in the urothelium (Ekins and 
Wrighton, 1999; Gervot et al., 1999). CYP2Bs are not constituently expressed, but 
instead require induction by xenobiotics such as phenobarbital in order to be 
present in a tissue and as such are not identified under control conditions (reviewed 
by Wang and Tompkins, 2008). Regulation of CYP2B induction by phenobarbital is 
known to involve constitutive androstane receptor (CAR), which translocate to 
hepatocyte nuclei in response to phenobarbital treatment (Gervot et al., 1999). The 
phenobarbital-responsive enhancer module (PBREM), which is highly conserved in 
humans and rats, is a 51 base pair DNA sequence containing two DR4 nuclear 
receptor response elements, NR1 and NR2. CAR heterodimerises with the retinoid X 
receptor (RXR) in response to phenobarbital-induced nuclear translocation. The 
CAR-RXR heterodimer has high affinity for the NR1 site of the PBREM and binding 
results in the induction of CYP2B genes (Kawamoto et al., 1999; Kodama and 
Negishi, 2006). A second member of the orphan nuclear receptor family, Pregnane X 
Receptor (PXR), is also known to bind to the PBREM and the similar xenobiotic 
response enhancer module (XREM) to activate CYP2B expression (Goodwin et al., 
2001).   
 
Figure 6.3 - Phenobarbital induces nuclear translation of CAR where it heterodimerises 
with RXR to bind to the PBREM, facilitating CYP2B gene expression. Phenobarbital also 
induces PXR to bind to either PBREM or XREM, also facilitating CYP2B gene expression.  




CAR-mediated regulation of CYP2B expression is known to be sexually dimorphic 
in certain rat strains, such as Wistar and the Wistar Kyoto (WKO) rats, in which 
phenobarbital-induced CAR translocation and PBREM activation only occurred in 
male rats. Such discrepancies between sexes were not observed in Fisher 344 rats 
(Yoshinari et al., 2001). Human CYP2B expression varies greatly between males and 
females and between different ethnic populations. Females have increased CYP2B1 
mRNA, protein and enzyme activity compared to males. Hispanic populations were 
found to have greater CYP2B1 expression and activity than Caucasian or African 
populations. In females a clear genotype-phenotype association has been 
demonstrated in which gene expression is a clear indicator of activity, whereas in 
males such an association could not be established (Lamba et al., 2003).  
 
Humans express two CYP2B homologues, namely CYP2B6 and CYP2B7, with 
CYP2B6 being the most abundant and important in terms of xenobiotic metabolism 
(reviewed by Wang and Tompkins, 2008). In rats, six CYP2B homologues are 
expressed (CYP2B1, CYP2B2, CYP2B3, CYP2B12, CYP2B15 and CYP2B21), with 
CYP2B1 and CYP2B2 often considered as equivalent to CYP2B6 in humans 
(Desrochers et al., 1996; Du et al., 2004; Keeney et al., 1998). Along with CYP2B3, 
CYP2B1 and CYP2B2 are most abundantly expressed by hepatocytes, but have also 
been found in lung and gastrointestinal tract epithelial cells  (Mitschke et al., 2008; 
Czekaj et al., 2000) 
 
6.1.5 Modelling CYPs in vitro 
Primary hepatocytes are capable of retaining a differentiated phenotype in vitro for a 
limited period, however, they suffer a reduction in CYP expression over time and 
have a limited lifespan in culture (Abdel-Razzak et al., 1993). Immortalised 
hepatocyte cell lines have limited or no metabolic functions and hence are not useful 
tools to study xenobiotic metabolism in vitro (Westerink and Schoonen, 2007). As 
such, in vivo models or isolated microsomes from primary cells are used to 
investigate CYP metabolism.  





In vitro systems are a desirable platform for studying CYP metabolism. The 
generation of a metabolically-functional in vitro system has thus far proved illusive 
but, if achieved, would be of significant benefit to investigators of xenobiotic 
metabolism and toxicity.  
  






To investigate the potential of urothelial cells to express CYP2B enzymes after 




1. Determine whether CYP2B induction occurs in rat urothelial cells after in 
vivo exposure to phenobarbital 
2. Investigate which CYP2B enzyme is expressed by rat urothelial cells after in 
vivo exposure to phenobarbital 
3. Explore the potential of an experimental CYP2B-inducing compound to 
induce rat urothelial cell CYP2B expression in vivo.  
4. Assess the ability of urothelium in rat and human cell and organ culture 








6.2 Experimental approach 
6.2.1 CYP2B induction in vivo 
Surplus bladder and liver tissue was collected from Syngenta studies where rats had 
been dosed with phenobarbital or a compound under development that was shown 
to induce CYP2B activation in the liver. Bladders were collected from untreated 
control and treated rats upon sacrifice. Tissue was either formalin-fixed and 
processed into paraffin wax for histology, or the urothelium was harvested for RNA 
isolation using the dispase protocol (see chapter 3). CYP2B1/2 labelling in 
urothelium from control and treated rats was quantified using image analysis 
software (Tissue Gnostics).  >1000 urothelial cells were analysed per bladder to 
provide an arbitrary DAB intensity labelling score. Control and phenobarbital-
treated rat liver sections were used as controls.  
 
6.2.2 CYP2B induction in vitro 
NRU and NHU cells were isolated and cultured as previously described (see 
chapters 2 and 3).  Cells were dosed with phenobarbital (500 µM) at concentrations 
reported to induce CYP2B expression in the literature (Sidhu and Omiecinski, 1995; 
Joannard et al., 2006). CYP2B induction was investigated at different time points up 
to 72 hours by RNA analysis and western blotting. Negative (medium only) controls 
were included as comparisons.  
 
6.2.3 CYP2B induction in ex vivo organ culture models 
Rat bladders were dissected into quarters and cultured urothelium-side up on PET 
cell culture inserts (pore size 3 µm) at a liquid interface. Phenobarbital was added to 
the medium both above and below the membrane. Tissue was treated for 72 hours 
before either formalin-fixation and paraffin wax embedding for 
immunohistochemistry or the urothelium separated using the dispase protocol (see 
chapter 3) and RNA isolated for analysis.  





6.2.4 Cell lines 
Table 6.1 NRU Cells 
Code No. of 
animals 
Sex Source Strain Age/Weight 
R051 20 M/F University of Manchester  Wistar 200-300 g 
R053 6 F University of York  Wistar 200-250 g 
R054 5 F University of York  Wistar 200-250 g 
 
 
Table 6.2 NHU Cells 
Code Tissue of Origin Sex Age Age of cells during 
experiments 
Y1533 Ureter M 45 P1-4 
Y1570 Ureter F 51 P1-4 
  





6.3.1 CYP2B expression in rat urothelium 
Immunolabelling using antibodies against CYP2B1/2 was conducted on bladder 
sections from control and phenobarbital-treated (dietary 1200 ppm) rats (male and 
female) after 3, 7 and 14 days of treatment. After three days (Figure 6.4), urothelial 
cells from phenobarbital-treated rat bladders showed a high intensity of labelling 
compared to control animals. The pattern of immunolabelling appeared perinuclear 
and was present throughout the urothelium in phenobarbital-treated animals. 
Individual variations were noted within the phenobarbital-treated group, with one 
bladder having a visibly lower intensity of labelling compared to the others, but still 
higher than the controls.  Urothelium from control rats was very low to completely 
absent of CYP2B1/2 labelling. At the 7 (Figure 6.5) and 14-day (Figure 6.6) time 
points, phenobarbital-treated animals also had an obvious increased intensity of 
CYP2B1/2 labelling than controls. As with the 3-day time point, individual 
variations in CYP2B1/2 expression existed between phenobarbital-treated animals, 
but in all cases, labelling was more intense than the controls.  
 
Liver sections from control and phenobarbital-treated rats were included as 
negative and positive controls, respectively (Figure 6.7). At the different 
magnifications shown, CYP2B1/2 labelling was apparent surrounding blood vessels 
in the phenobarbital-treated liver sections but was almost completely absent in the 
livers of control animals. Negative controls from which primary antibody was 
omitted were included and showed no labelling (Appendix 2.4).  



















Figure 6.4 – CYP2B1/2 expression was induced in rat bladders after 3 days of 
phenobarbital treatment in vivo. CYP2B1/2 was immunolabelled (Section 2.7.2) in control 
and phenobarbital-treated rat urothelium after 3 days of treatment. Scale bars = 50 µm (n=3 
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Figure 6.5 - CYP2B1/2 expression was induced in rat bladders after 7 days of 
phenobarbital treatment in vivo. CYP2B1/2 was immunolabelled (Section 2.7.2) in control 
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Figure 6.6 – CYP2B1/2 expression was induced in rat bladders after 14 days of 
phenobarbital treatment in vivo. CYP2B1/2 was immunolabelled (Section 2.7.2) in control 
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Figure 6.7  – CYP2B1/2 was expressed by hepatocytes in close proximity to blood vessels 
in phenobarbital-treated by not control rat livers after 7 days of treatment in vivo. 
CYP2B1/2 was immunolabelled (Section 2.7.2) in control and phenobarbital-treated rat liver 
sections after 7 days of dietary administration. Sections are shown at multiple magnifications 
to illustrate the specific labelling pattern around blood vessels (indicated by arrows) in 
phenobarbital-treated animals. Scale bars = 200 µm (n = 3 individual rats).   
Quantification of urothelial CYP2B labelling (Figure 6.8) revealed significant 
increases in labelling intensity between control and phenobarbital-treated urothelial 
cells at each time point and also an increase between phenobarbital-treated 
urothelial cells from days 3 and 14. A significant difference was also shown between 
control and phenobarbital-treated hepatocytes.  
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 Figure 6.8 - CYP2B1/2 expression was significantly increased in phenobarbital-treated rat 
urothelium compared to controls. Computational quantification (Section 2.7.3) of urothelial 
CYP2B1/2 immunolabelling in control and phenobarbital-treated rats after 3 (D3), 7 (D7) and 
14 (D14) days dietary administration was conducted. Mean DAB intensity in >1000 urothelial 
cells from three rat bladders per treatment/time group were generated using TissueGnostics 
software after CYP2B immunolabelling. Error bars  ± SD (n=3). (* = p <0.05, ** = p <0.01, *** = 
p<0.001, using a 2-way ANOVA with a Tukeys post hoc test of comparison).  
To support the immunolabelling results, RT-PCR was conducted on urothelial 
cDNA from 5 control and 5 phenobarbital-treated animals after 7 days of treatment 
(Figure 6.9) Generic CYP2B primers, designed to amplify all rodent CYP2B 
homologues, showed clear expression of CYP2B enzymes in the urothelium of 2 
control and 5 phenobarbital-treated rats. While showing the ability of rat urothelial 
cells to express CYP2B in response to phenobarbital, this result also demonstrated a 
high level of individual variation between animals:  a result observed when visually 
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Figure 6.9 – CYP2B enzymes were expressed in rat urothelial cells after 7 days of dietary 
phenobarbital treatment. RT-PCR of CYP2B expression in rat urothelial cDNA after 7 days 
of treatment with a vehicle control or phenobarbital. Krt7 was included as a control 
urothelial cell marker, smooth muscle actin (SMA) as a marker of stromal cell contamination 
and GAPDH as a loading control. Positive (+) and negative (-) primer controls were rat liver 
cDNA (CYP2B & GAPDH), normal rat urothelial cell cDNA (Krt7) and rat genomic DNA 
(SMA). Negative (no template) control substituted water for cDNA. Reverse transcriptase 
negative (RT-) samples were also included alongside reverse transcriptase positive (RT+) 





























6.3.2 CYP2B homologue expression in rat urothelial cells 
Primers were designed to specifically amplify each of the 6 CYP2B homologues 
present in the rat genome and RT-PCR was conducted on urothelial cDNA from five 
control and five phenobarbital (day 7) treated rats (Figure 6.10).  Primers designed 
to individually amplify both CYP2B1 (lower band) and CYP2B2 (higher band) 
produced weak bands in one control and two phenobarbital-treated rat urothelial 
samples.  CYP2B3 amplifying primers also produced weak results in three 
phenobarbital-treated samples. CYP2B12 and CYP2B15 primers did not generate 
bands from either control or phenobarbital-treated samples. CYP2B21 primers 
produced weak bands in two phenobarbital-treated samples.   
 
Together, the RT-PCR results presented a confusing picture of CYP2B expression by 
the urothelium, with multiple homologues being expressed in some but not all of 
the individual rats after 7 days of phenobarbital treatment. To further clarify which 
homologues were expressed, the PCR product amplified from cDNA using generic 
CYP2B primers (Figure 6.9) from one control and five phenobarbital-treated 
urothelial samples was TA-cloned into a vector, transformed into bacteria and single 
clones isolated, cloned and sequenced. Based on specific base pair differences 
between CYP2B homologues, individual enzymes were identified as expressed 
(Figure 6.10). Although this approach was not quantitative, it was unequivocal in 
demonstrating the expression of five out of six CYP2B homologues by 
phenobarbital-induced rat urothelial cells. CYP2B1, as in the RT-PCR results (Figure 



















Figure 6.10 – The specific CYP2B enzyme expressed in rat urothelial cells was not able to 
be confirmed by RT-PCR. RT-PCR (30 cycles) was conducted on control or 7-day 
phenobarbital-treated rat urothelial cDNA. Specific primers were designed to amplify each 
of the 6 CYP2B enzymes found in rat. GAPDH was included as a loading control. Positive (+) 
control cDNA and negative (-) no template (water) controls were included for each primer 
set. Rat liver cDNA was used as a control for CYP2B1/2, CYP2B3, CYP2B12, CYP2B15 and for 























CYP2B2 CYP2B3 CYP2B12 CYP2B15 CYP2B21 
                                                                                         
 
Figure 6.11 – 5 of the 6 CYP2B genes expressed in rats were expressed by rat urothelial 
cells in response to phenobarbital. Aligned sequencing of cloned CYP2B RT-PCR product 
from 1 control and 5 phenobarbital-treated urothelial samples using generic CYP2B primers. 
Individual CYP2B enzymes were identified from small base pair variations within the 
amplified region. These differences are shaded to indicate specificity of CYP2B product, as 
indicated by colour in the table. Primer regions are shaded in yellow at either end of the 





CONTROL 1 AGGAGATTGATCAGGTGATTGGCTCACACCGGCTACCAACCCCTGATGATCGTACCA 
CONTROL 1 AGGAGATTGATCAGGTGATCGGCTCACAGCGGGTCCCAACCCTTGATGACCGCTCCA 
PHENOB. 1 AGGAGATTGATCAGGTGATTGGCTCTCACAGGCCACCATCCCTTGATGATCGTACCA 
PHENOB. 1 AGGAGATTGATCAGGTGATTGGCTCTCACAGGCCACCATCCCTTGATGATCGTACCA 
PHENOB. 2 AGGAGATTGATCAGGTGATTGGCTCACACCGGCTACCAACCCCTGATGATCGTACCA 
PHENOB. 2 AGGAGATTGATCAGGTGATCAGCTCACACCGGCTACCAACCCTTGATGATCGTATCA 
PHENOB. 3 AGGAGATTGATCAGGTGATTGGCTCACACCGGCTACCAACCCCTGATGATCGTACCA 
PHENOB. 3 AGGAGATTGATCAGGTGATCGGCTCACAGCGGGTCCCAACCCTTGATGACCGCTCCA 
PHENOB. 4 AGGAGATTGATCAGGTGATCGGCTCACAGCGGGTCCCAACCCTTGATGACCGCTCCA 
PHENOB. 4 AGGAGATTGATCAGGTGATTGGCTCTCACAGGCCACCATCCCTTGATGATCGTACCA 
PHENOB. 5 AGGAGATTGATCAGGTGATTGGCTCACACCGGGTCCCAACCCTTGATGACCGCATCA 
 
 
CONTROL 1 AAATGCCATATACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTGACCCC 
CONTROL 1 AAATGCCATACACTGAGGCAGTCATCCATGAGATTCAGAGATTTTCTGATGTTTCTCC 
PHENOB. 1 AAATGCCATACACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 1 AAATGCCATACACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 2 AAATGCCATATACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 2 AAATGCCATACACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 3 AAATGCCATATACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 3 AAATGCCATACACTGAGGCAGTCATCCATGAGATTCAGAGATTTTCTGATGTTTCTCC 
PHENOB. 4 AAATGCCATACACTGAGGCAGTCATCCATGAGATTCAGAGATTTTCTGATGTTTCTCC 
PHENOB. 4 AAATGCCATACACTGATGCAGTCATCCACGAGATTCAGAGATTTGCAGATCTTGCCCC 
PHENOB. 5 AAATGCCATACACTGATGCGGTCATCCATGAGATTCAGAGATTTTCAGATCTTGTCCC 
 
 
    CONTROL 1 AATTGGTCTACCACACAGAGTCACCAAAGACACCGTGTTCCGAGGGTACCTGCTA 
    CONTROL 1 AATGGGTTTGCCATGCAGAATCACCAAAGACACATTGTTCCGAGGGTACCTGCTA 
    PHENOB. 1 AATTGGTTTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCTA 
    PHENOB. 1 AATTGGTTTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCTA 
    PHENOB. 2 AATTGGTCTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCTA 
    PHENOB. 2 AATTGGTTTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCAA 
    PHENOB. 3 AATTGGTCTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCTA 
    PHENOB. 3 AATGGGTTTGCCATGCAGAATCACCAAAGCCACATTGTTCCGAGGGTACCTGCTA 
    PHENOB. 4 AATGGGTTTGCCATGCAGAATCACCAAAGACACATTGTTCCGAGGGTACCTGCTA 
    PHENOB. 4 AATTGGTTTACCACACAGAGTCACCAAAGACACCATGTTCCGAGGGTACCTGCTA 
    PHENOB. 5 GATTGGTCTGCCACACAGAGTCACCAAAGACACAATGTTCCGAGGGTACCTGCTA 
 




6.3.4 Rat In vivo case study – chemical induction of CYP2B 
A compound under development by Syngenta was found to cause urothelial 
hyperplasia in rats during 28 day toxicity studies. Liver biochemistry assays were 
conducted by Leatherhead Food Research (LFR) on behalf of Syngenta and the raw 
data was generously volunteered to assist this study. These data (Figure 6.11 to 
Figure 6.12) are reproduced here with the full knowledge and permission of 
Syngenta.  
 
Analysis of liver biochemistry data (Figure 6.12) revealed that the compound 
significantly increased total hepatic cytochrome P450 content after 28 days at dietary 
doses exceeding 3000 ppm. A specific marker of CYP2B (7-pentoxyresorufin O-
depentylase) enzyme activity revealed that at dietary doses exceeding 500 ppm, 
CYP enzyme activity was significantly increased relative to controls. This was 
further confirmed by immunolabelling of liver sections from control and dosed 
(3000 ppm for 28 days) rats (Figure 6.13). No labelling was observed in control liver 
sections, but clearly defined regions of labelling were seen in the livers of treated 
animals. This pattern of labelling was similar to the CYP2B1/2 labelling seen in liver 
sections of rats treated with phenobarbital (Figure 6.14).  
 





Figure 6.12 – Hepatic CYP content was increased in a dose dependant manner in response 
to the Syngenta compound. Mean total hepatic Cytochrome P450 content in control and 










Figure 6.13 – Hepatic CYP2B enzyme expression was increased in response to the 
Syngenta compound in a dose dependant manner. Hepatic 7-pentoxyresorufin O-
depentylase (CYP2B marker) activity in control and dosed male (blue) and female (red) rats 
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Figure 6.14 – CYP2B expression was induced in rat hepatocytes after 28 days of treatment 
with the Syngenta compound. Immunohistochemistry labelling of CYP2B1/2 was conducted 
in liver sections from control rats and rats treated with a developmental compound after 28 
days of treatment. Scale bars = 200 µm. Arrows indicate the location of blood vessels. 
Results were replicated in three individual animals per group (n=3).  
 
Having established the potential of the compound to induce CYP2B expression in 
the liver, CYP2B1/2 immunolabelling was conducted on bladder tissue from control 
and dosed (dietary 3000 ppm) rats after 28 days (Figure 6.15). In sections from both 
control and dosed rats, a small amount of background labelling was present and 
there were variations between animals within treatment groups. The urothelium of 
dosed animals appeared thicker than in control animals, supporting the reports of 
hyperplasia in the treatment group. Superficial cells in particular showed defined, 
intense CYP2B1/2 labelling (examples indicated). The CYP2B1/2 expression by 
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Figure 6.15 – CYP2B1/2 expression was induced by the Syngenta compound in vivo after 
dietary administration for 28 days. Immunohistochemistry labelling of CYP2B1/2 was 
conducted on control (left) and Syngenta compound-treated (right) rat urothelium after 28 
days of treatment. Arrows indicate examples of strong superficial cell labelling. Scale bars = 
50 µm. (n=4). 
 




6.3.4 Investigation of urothelial CYP2B expression in vitro 
CYP2B induction in NRU cell monolayers 
NRU cells were harvested and cultured as previously described (Chapter 3). 80-90% 
confluent primary and subcultured (P1) NRU cell cultures were treated for 72 hours 
with a physiologically relevant concentration of phenobarbital (500 µM) and 
monitored by phase contrast microscopy (Figure 6.16). Subcultured NRU cells 
treated with phenobarbital appeared to have a reduced cell density compared to 




Figure 6.16 – Phenobarbital had no visible effect on NRU cells in culture after 72 hours of 
treatment. Phase contrast images showing primary (P0) and subcultured (P1) NRU cells 
after 72 hours in control medium (KSFMc) with 500 µM phenobarbital. Scale bar = 50 µm 
(n=2; R051, R053). 
 
 








     




At 72 hours, RNA was harvested from NRU cell cultures and CYP2B expression 
assessed by RT-PCR (Figure 6.17). Due to limited cell numbers, protein analysis by 
western blot was not possible. RT-PCR results showed faint bands in primary (P0) 











Figure 6.17 – CYP2B enzyme induction did not occur in NRU cells in response to 
phenobarbital. RT-PCR results showing CYP2B expression in primary and subcultured (P1) 
NRU cells after 72 hours treatment with 500 µM phenobarbital (Pheno).  Rat liver cDNA was 
used as positive control, water as a negative control and GAPDH as a loading control (n=2 
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CYP2B induction in an ex vivo organ culture system 
 
Isolated NRU cells grown in monolayer culture were not able to replicate the 
urothelial induction of CYP2B enzymes seen in vivo, and so induction in an ex vivo 
organ culture model was investigated as an intermediary between in vitro and in 
vivo. Rat bladders were dissected into four approximately 1 cm2 sections and 
cultured on a porous membrane, leaving the urothelium attached to the underlying 
stromal tissue.  
 
Bladder tissue was cultured submerged in medium with and without phenobarbital 
(500 µM) for 72 hours. To ensure that the organ cultures maintained their in vivo 
urothelial phenotype, cytokeratin 5 (CK5) was immunolabelled as a basal cell 
marker, cytokeratin 7 (CK7) as a urothelial cell marker, Ki67 as a marker of 
proliferation and uroplakin 3a (UPK3a) as superficial cell marker in organ cultures 
and in bladder tissue fixed immediately after being harvested (without culture) 
(Figure 6.18).  Ki67 labelling appeared reduced in organ cultures compared to native 
tissue, possibly due to a thinning of the urothelium in phenobarbital-treated organ 
cultures, but organ cultures maintained cytokeratin 5 and 7 expression in similar 
localisations to native tissue and the presence of UPK3a positive cells demonstrated 
the retention of the differentiated superficial cell layer.   
 
Immunolabelling of CYP2B1/2 was conducted on control and phenobarbital-treated 
(72 hours) Wistar rat organ cultures. Organ cultures treated with phenobarbital 
showed intense CYP2B1/2 labelling (Figure 6.19). At the transcript level (Figure 
6.19), urothelial cells from one control and one phenobarbital-treated organ culture 
showed expression of CYP2B1/2, but expression appeared greatest in urothelial cells 
from control than phenobarbital-treated organ cultures. No difference in CYP2B 
expression was obvious between the two concentrations of phenobarbital tested (250 
& 500 µM).  
 















Figure 6.18 - Confirmation of urothelial cell layer maintenance in control and phenobarbital-treated rat organ cultures.  Immunolabelling of the basal cell 
marker cytokeratin 5 (CK5), the whole urothelial cell marker cytokeratin 7 (CK7), the proliferation marker Ki67 and the superficial cell maker uroplakin 3a 
(UPK3A) in native rat bladder and in control and phenobarbital-treated (500 µM) rat organ cultures (OC) after 72 hours of culture. Scale bar = 50 µm. 
































Figure 6.19 – CYP2B enzyme induction occurred in rat organ cultures after 72 hours of 
treatment with phenobarbital. Immunolabelling of CYP2B1/2 was conducted in control and 
phenobarbital-treated (500 µM) rat organ cultures generated from two independent Wistar 







Figure 6.20 – CYP2B enzyme expression was not induced in rat organ cultures in response 
to 72 hours of phenobarbital treatment. RT-PCR results showing CYP2B expression in 
isolated urothelial cells from organ cultures after 72 hours treatment with phenobarbital at 
concentrations of 250 and 500 µM.  Rat liver cDNA was used as positive control, water as a 
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CYP2B6 induction in NHU cells 
80-90% confluent NHU cell cultures were induced to adopt a differentiated 
phenotype using the established ABS/calcium protocol (see chapter 2) over 7 days in 
culture before being treated with phenobarbital (500 µM) for 72 hours (Figure 6.21). 
No visible difference in cell phenotype or density was observable between control 











Figure 6.21 – Differentiated NHU cells were not visible affected by treatment with 
phenobarbital over 72 hours. Phase contrast images showing differentiated (ABS/Ca2+) 














     




After 72 hours, RNA and protein lysates were harvested from control and 
phenobarbital-treated NHU cells. CYP2B6 transcript was detected in control NHU 
cells, but not in cells treated with phenobarbital (Figure 6.22). Both control and 
treated cells showed weak expression of CYP2B and CYP3A4, but there was no 
increase in expression between control and phenobarbital-treated NHU cells. 
CYP3A4 is known to metabolise similar xenobiotics to CYP2B enzymes, but is not 
present in rats.  
 
At the protein level (Figure 6.23), CYP2B6 was weakly expressed in both control and 
phenobarbital-treated NHU cells. There was no increase in expression in the 
phenobarbital-treated samples, indicating that CYP2B enzyme expression was not 
induced in NHU cells. Human liver, which was included as a control, also had 
minimal CYP2B6 protein expression. By contrast, CYP3A4 was highly expressed in 
human liver, although no expression was seen in NHU cells. Rat liver samples were 
included to demonstrate the specificity of the antibodies and as expected showed no 
expression of CYP2B6 or CYP3A4 protein.  Cytochrome P450 reductase (CPR), 
which is required by all CYPs for catalysis, was included as a loading control and 
was present in all samples, but reduced in the NHU cell samples compared to the 


















Figure 6.22 – CYP2B6 and associated CYP3A4 enzyme transcript induction did not occur in 
NHU cells in response to 72 hours of phenobarbital treatment.  RT-PCR results for CYP2B6 
and CYP3A4 expression in human urothelial cells after 72 hours of treatment. Human 
genomic DNA was included as a positive template control (+). GAPDH was included as a 








Figure 6.23 – CYP2B6 and associated CYP3A4 enzyme protein induction did not occur in 
NHU cells in response to 72 hours of phenobarbital treatment. Western blot analysis of 
CYP2B6 and CYP3A4 expression in control and phenobarbital-treated, differentiated 
(ABS/Ca2+) NHU cell microsomes. Differentiated NHU cells were cultured for 72 hours in 
differentiation medium (KSFMc containing 5%ABS and 2mM Ca2+) ± 500µM phenobarbital. 
Human liver microsomes were included as positive controls, with rat liver microsomes as 
negative controls for CYP2B6. Cytochrome P450 reductase (CPR) was included as a loading 
control. 
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6.4 Conclusions and Discussion 
CYP2B enzyme expression can be induced in rat urothelial cells in vivo by  
phenobarbital and also by a CYP2B-inducing compound  after oral administration 
for at least 3 days. Attempts to identify the specific CYP2B homologue expressed 
revealed that transcripts for multiple CYPs are expressed by rat urothelial cells at 
the 72 hour time point studied after induction. Results also showed that variations 
in CYP2B induction occur between individuals within a treatment group. In vitro 
urothelial cell models were not able to replicate the CYP2B induction seen in vivo. 
Both human and rat urothelial cell models showed expression, but as it was not 
inducible at the transcript level or, in NHU cells, at the protein level it is most likely 
a result of the culture system as opposed to induction by phenobarbital. The success 
in modelling CYP2B expression in an ex vivo organ culture model, however, does 
suggest that the time points that CYP2B transcript was assessed after phenobarbital 
treatment (72 hours in vitro) was too late. It appears in the ex vivo model that 
transcript is down regulated after induction, suggesting that the peak transcript 
expression is sooner than 72 hours after induction. This could also have implications 
of the transcript data seen in vivo and suggests that harvesting RNA for analysis at 
an earlier time point could demonstrate CYP2B induction more clearly. Further 
work is required to replicate the in vitro/ex vivo data, including assessing the 
expression of CYP2B enzyme transcript at earlier time points. 
 
6.5 Key findings 
 CYP2B enzyme expression can be induced by xenobiotics in rat urothelial 
cells, possibly leading to CYP2B metabolism of xenobiotics excreted in urine.  
 
 In vitro urothelial cell models are not capable of replicating the CYP2B 
induction seen in vivo, but an ex vivo organ culture model could be capable of 
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The aim of this project was to develop a NRU cell culture system and conduct 
comparisons between it and an established NHU cell culture system as a means of 
validating normal urothelial cell culture models for use in toxicity testing. This aim 
has been partly achieved, as a cell culture system has been developed and 
optimised to enable the reproducible establishment and maintenance of NRU cell 
cultures up to passage 2. Investigations into the pathways regulating proliferation 
in normal urothelial cells in vitro uncovered species differences between rats and 
humans, supporting observations described in the literature (Chopra et al., 2008b). 
In an attempt to improve the ability of normal urothelial cell culture models to be 
incorporated into toxicity testing, an immortalised NHU cell line that could be 
differentiated up to at least passage 10 was successfully generated through the 
overexpression of BMI1. Finally, a novel mechanism of metabolism within rat 
bladders was discovered through xenobiotic induction of CYP2B enzymes. CYP2B 
expression was demonstrated in vivo and, although induction did not occur in NRU 
cell cultures, the in vivo results were replicated in an ex vivo organ culture model.  
 
Key experimental findings: 
 
1. Optimisation of the isolation and culture of normal rat urothelial cells in vitro 
 
2. Pathways regulating urothelial cell proliferation in vitro differ between NRU and 
NHU cells, with the PI3K/Akt pathway being active in NRU cells whereas the 
EGFR/MAPK pathway is known to drive proliferation in (undifferentiated) NHU 
cells (Varley et al., 2005).  
 
3. Human BMI1 overexpression did not immortalise NRU cells but did enable NHU 
cells to be passaged and successfully differentiated beyond passage 10. 
 
 
4. Xenobiotic induction of CYP2B enzymes occurs in rat urothelium and this result 









7.1 Development of a NRU cell culture system 
 
A NRU cell culture system was developed, based on an existing NHU cell culture 
system, and optimised using protocols described in the literature. The NRU cell 
culture system developed had to be as similar as possible to the established NHU 
cell culture system, enabling accurate comparisons to be made between the two 
systems. The lack of consistency between NRU cell culture systems described in the 
literature (discussed in Chapter 3), in particular the rats used (strains & ages) and 
the isolation protocols employed, necessitated the creation of an optimised protocol 
for the clean isolation and subsequent culture of NRU cells.  
 
Aspects of cell isolation protocols described in the literature were compared against 
the NHU cell isolation protocol, and subsequently adapted and optimised to 
maximise the yield of NRU cells isolated. NRU cells were cultured in KSFMc 
medium and grew in “cobblestone-like” colonies, as previously described in the 
literature (Zhang et al., 2001). The presence of serum (fetal bovine serum) was 
assessed and an interesting strain variation discovered between the rat strains used. 
NRU cells isolated from Wistar rats, a commonly used outbred strain, grew in 
serum-free KSFMc medium but their growth was inhibited by the presence of 
serum. NRU cells isolated from a rare inbred rat strain (Homozygous Scottish) grew 
in the presence of serum but their growth was diminished in the absence of serum. 
NRU cells from a third, outbred, strain of rat (Sprague Dawley) appeared to grow 
equally in the presence and absence of serum although this result was only 
performed on one occasion.  
 
Strain differences are not uncommon in rodents in vivo and can have a number of 
implications in relation to pharmacokinetics, metabolism and susceptibility to 
xenobiotic toxicity (reviewed by Kacew and Festing, 1996). Saccharin-induced 
toxicity in the urinary bladder, for instance, occurs in Wistar rats, but not in 
Sprague-Dawley rats (Fukushima et al., 1983). In vitro, strain differences have been 




beta-cells (Reimers et al., 1996) and oocytes (Sterthaus et al., 2009) isolated from 
different rat strains. Differences included cellular ability to repair DNA after 
exposure to ultraviolet (UV) radiation, metabolic competency and gene stability. In 
relation to cellular proliferation, mesenchymal stem cells (MSCs) from different 
mouse strains have been shown to differ in cell surface epitopes, rates of 
proliferation and differentiation capabilities (Peister et al., 2004).  
 
Physiological differences between rat strains, such as the variation in serum 
requirements demonstrated between NRU-W, NRU-HS and NRU-SD cells, are a 
major disadvantage in toxicity testing as they can complicate the extrapolation of 
results between rats and humans. The fact that results from two different rat strains 
can be contradictory makes choosing the most relevant strain difficult and affects 
the confidence with which results can be used to predict effects in man. Being able 
to rely on rat in vivo results being relevant to humans would be hugely 
advantageous during compound development, allowing unsuitable candidate 
compounds to be excluded at an earlier stage, thus reducing the number of in vivo 
studies conducted and the costs associated with them.   
 
No single rat strain would appear to be more reliable at predicting the toxicity of all 
xenobiotics in humans, as demonstrated by the number of rat strains used in 
toxicity testing (e.g. Wistar, Sprague Dawley, F344). Based on evidence reviewed by 
Kacew and Festing (1996), it would appear that choosing the correct rat strain for 
predicting effects in humans is dependent on the organ/tissue of interest and type of 
compound being tested. Within the urinary bladder alone there are advantages and 
disadvantages described for using Wistar, Sprague-Dawley and F344 rats in toxicity 
testing (Pamukcu et al., 1980, Fukushima et al., 1983, Garland et al., 1989).  
 
The use of outbred rat strains further complicates the extrapolation of results to 
humans as genetic variations exist within as well as between strains, leading to 
altered characteristics (Ito et al., 2007). There can be significant genetic variations 




strains sometimes being indistinguishable from each other contrasted by high 
variation between rats of the same strain (Lovell and Festing, 1982). Additionally, 
quality control issues have been reported in outbred rat strains, in which outbred 
rats with reduced lifespan and increased body fat were produced and marketed 
under the same strain name as animals without these defects (Nohynek et al., 1993).  
 
Such differences within strains are believed to be responsible for the lack of 
reproducibility of certain results, such as bisphenol A toxicity (reviewed by 
Sekizawa, 2008). This lack of reproducibility can significantly reduce the 
effectiveness of toxicity testing and increases the risk of compounds that are not 
toxic in humans being discarded and compounds that are toxic to humans being 
developed. These disadvantages in the use of outbred strains have led to calls for 
inbred strains, such as F344, to be universally used in toxicity testing, replacing the 
outbred strains (discussed by Festing, 2010).  
 
Based on the single interstrain variation discovered (requirement of serum for cell 
growth in vitro), NRU cells isolated from Wistar rats (NRU-W) would appear to be 
the most similar to NHU cells. Identifying whether this is the case would require 
multiple variations to be assessed in a number of rat strains. Although interesting, 
this observation was not pursued, as it would have detracted from the main aim of 
the project, to compare rat and human urothelial cells. The obscurity of the inbred 
(Homozygous Scottish) rat strain and lack of access to tissue from multiple rat 
strains further discouraged additional investigation into interstrain variations. This 
variation does act, however, to further demonstrate the difficulties associated with 
using rats in toxicity testing and highlights the requirement of a more human-
relevant system to be developed and incorporated into toxicity studies.  
 
Additional aspects of the culture system, including cell seeding density and tissue 
culture plastic substrate, were optimised to generate a NRU cell culture system in 
which cells could be cleanly isolated and grown in culture up to passage 1. Primary 




cultured and passaged once but, despite optimisation of several aspects of the cell 
culture system including seeding density and tissue culture plastic substrate, cell 
population growth ceased and cultures died at passage 1. This is in contrast to NHU 
cell cultures, which were able to undergo 6 passages before the onset of senescence 
as measured by expression of p16INK4a (Puthenveettil et al., 1999). There has been a 
suggestion that regulation of rat urothelial cell proliferation may differ from that of 
human urothelial cells as a result of differences in cell cycle regulation (observed as 
differences in Ki67 expression by human and rat urothelium in situ (discussed by 
Festing, 2010) and that these differences may be responsible for pathologies of the 
bladder seen in rat (Chopra et al., 2008). As such, the exogenously-regulated signal 
transduction pathways driving proliferation were investigated, both to identify any 
interspecies variations in proliferation regulation and as an approach to increase 
NRU cell lifespan in culture through the use of exogenous factors to promote cell 
proliferation.  
 
7.2 Regulation of urothelial growth pathways 
 
To explore potential species variation in the regulation of urothelial cell 
proliferation, the pathways regulating proliferation were investigated in NRU cells 
and compared against those active in NHU cells. In monolayer culture, NHU cell 
proliferation is known to be regulated by EGFR/MAPK pathway which is activated 
by both autocrine and exogenous EGF present in KSFMc medium (Varley et al., 
2005). It has been shown that EGFR/MAPK pathway activation in low-density NHU 
cells inhibits GSK3β-mediated destruction of β-catenin, allowing β-catenin to 
translocate from the cytoplasm to the cell nuclei where it regulates proliferation-
associated gene expression (Georgopoulos et al., 2014). In proliferating NRU cells, 
which were found to have limited proliferative capabilities in culture compared to 
NHU cells, the PI3K/Akt pathway appeared to be active based on p-Akt 
immunoreactivity. Subsequent pharmacological stimulation of this pathway did not 
affect the overall rate of NRU cell proliferation. The lack of difference between 




was already being stimulated in NRU cells, although the mechanism of activation is 
unknown. One possible mechanism by which the PI3K/Akt pathway induction in 
NRU cells was being regulated is through the transforming growth factor β (TGFβ) 
pathway. In mouse urothelium in vivo, TGFβ expression was associated with re-
epithelialization and differentiation after injury (de Boer et al., 1994). In vitro, 
exogenous TGFβ has been shown to have a negative effect on undifferentiated 
NHU cell proliferation and no effect upon differentiation, but to enhance wound 
healing in differentiated NHU cells through a TGFβ/TGFBR/Smad3 autocrine 
signalling loop (Fleming et al., 2012). Crosstalk between the TGFβ and PI3K/Akt 
pathway has been established in normal (Suwanabol et al., 2012) and cancer 
(Assinder et al., 2009, Zhang et al., 2013) cells from other tissues and offers a 
potential mechanism by which proliferation of NRU cells was regulated. NRU cells 
in culture maintained characteristics more closely associated with differentiated 
than proliferative NHU cells, such as growing in colonies and expressing ZO-1 and 
claudin 4, supporting the theory that TGFβ expression was inducing PI3K/Akt 
pathway-mediated NRU cell proliferation.  
 
Alternatively, E-cadherin has been shown to differentially regulate proliferation 
pathways in NHU cells with activation of the EGFR/MAPK, PI3K/Akt and β-
catenin/LEF pathways being dictated by E-cadherin (Georgopoulos et al., 2010). 
Loss of E-cadherin resulted in increased NHU cell proliferation through activation 
of the EGFR/MAPK pathway whereas expression of E-cadherin, achieved through 
culturing cells in physiological (2 mM) calcium, inhibited the β-catenin pathway 
through recruitment of β-catenin into adherens junctions. In Figure 7.1, this is 
represented by β-catenin translation and incorporation into E-cadherin containing 
adherens junctions in conditions of increased (2 mM) extracellular Ca2+. Activation 
of the PI3K/Akt pathway was shown to occur in NHU cells cultured in 
physiological calcium when cell-cell contacts were formed.  NHU cells cultured in 
physiological calcium that were not in contact with other cells showed little or no 





As NRU cells grew in densely packed colonies in which cells would be in close 
contact, E-cadherin regulated PI3K/Akt activation would also explain the results 
seen. Reducing extracellular Ca2+ concentrations reduced phospho-Akt 
immunoreactivity in NRU cells, potentially by reducing expression of E-cadherin 
although this was not confirmed. Reducing extracellular calcium ion concentrations 
alone, which might be expected to inhibit formation of adherens junctions, was not 
sufficient to enable NRU cells to be subcultured to P2 or completely inhibit the 
PI3K/Akt pathway.  
 
Rat and human serum Ca2+ concentrations have a similar range (approximately 9-10 
mg/dl) (Watchorn, 1933, Lester et al., 1982, Pitkin and Gebhardt, 1977) and the 
calcium binding domains on E-cadherin are highly conserved between all 
mammalian species (Posy et al., 2008). Therefore if E-cadherin does influence NRU 
cell proliferation in KSFMc (0.09 mM Ca2+), it would suggest a difference in 
urothelial cell expression of E-cadherin in adherens junctions between NRU and 
NHU cells. This theory is further supported by the fact that NRU cells grew in 
densely packed colonies in KSFMc medium, in which cell-cell contacts would be 
generated, rather than expanding to form monolayers like NHU cells. The role of E-
cadherin in NRU cells is a key area for further developing the cell culture system.  
 
As no increase in proliferation rate was seen between IGF1 stimulated and control 
NRU cells, it seems likely that control (KSFMc only) NRU cells had reached 
maximum proliferative rate in vitro. Whether this was achieved through an 
autocrine TGFβ signalling loop, an E-cadherin dependant mechanism or by an 
alternative, unknown, mechanism of PI3K/Akt activation is unclear, but additional 
stimulation of the PI3K/Akt pathway with IGF1 had no significant effect on cell 
growth or lifespan in culture.   
 
Proliferation of PI3K/Akt-inhibited NRU cell cultures was comparable with primary 
control (KSFMc only) NRU cells, but NRU cells were able to be subcultured to 




immunolabelling of phospho-Akt in NRU cells. It is interesting to speculate that the 
inhibition of the PI3K/Akt pathway may have enabled activation of the 
EGFR/MAPK pathway, either through an autocrine mechanism or by exogenous 
EGF present in KSFMc medium. In the literature, crosstalk between the MAPK and 
PI3K/Akt pathways have been demonstrated (reviewed by Mendoza et al., 2011) 
with negative feedback loops revealed between the MAPK and PI3K/Akt pathways 
as illustrated in Figure 7.1 (Zimmermann and Modelling, 1999, Yu et al., 2002, 
Hoeflich et al., 2009). In response to “strong” IGF1 stimulation, Akt was found to 
negatively regulate activation of the MAPK pathway (ERK) through the 
phosphorylation of inhibitory sites in the N-terminus of Raf (Guan et al., 2000, 
Modelling et al., 2002). Inhibition of the PI3K/Akt pathway prevented Akt inhibition 
of ERK, enabling activation of the MAPK pathway. As the EGFR/MAPK pathway 
regulates proliferation of “undifferentiated” NHU cells in vitro, it is tempting to 
speculate that activation of the MAPK pathway in NRU cells was achieved through 
inhibition of the PI3K/Akt pathway and that this lead to the increased growth 









Figure 7.1 – inhibitory crosstalk can occur between the EGFR/MAPK and the PI3K/Akt 
pathways but has yet to be investigated in urothelial cells. In conditions of physiological 
(2 mM) extracellular Ca2+ ions, β-catenin is sequestered to the cell membrane and does not 
participate in regulation of gene expression, stimulating proliferation. EGF-stimulated 
ERK activation results in a decrease in the tyrosine phosphorylation of Gab1 and a 
decreased association with the PI3K, resulting in reduced activation (Yu et al, 2002). This is 
possibly achieved through the regulation of SHP2 (not shown), although this has not been 
confirmed. Akt has been shown to antagonises Raf activity by direct phosphorylation of 
Ser 259. This modification creates a binding site for 14-3-3 protein (not shown), which is a 
known negative regulator of Raf (Zimmerman and Moelling, 1999). Under conditions of 
physiological extracellular calcium ion concentrations, β-cetenin is sequestered to cell 












7.3 Immortalisation of normal urothelial cells  
 
The limited growth capabilities of NRU cells in vitro made for comparison of NRU 
and NHU cells difficult and limited the usefulness of the culture system for toxicity 
testing. The finite nature of NHU cells and their individual donor variability also 
restricted the development of their use for standardised, reproducible toxicity 
testing. For use in toxicity testing, NHU cell culture systems would have to be 
capable of large-scale expansion and be able to be used in long-term (several 
months) experiments (Evans et al., 2001). In an attempt to address these issues, 
immortalisation of the two cell culture systems was attempted through the 
overexpression of BMI1. Comparisons were made to hTERT overexpressing cells 
and empty vector controls as hTERT overexpression in NHU cells is known to 
induce immortalisation, but inhibit capacity for differentiation and formation of a 
functional barrier in vitro (Georgopoulos et al. 2011; discussed by Hartung and 
Daston, 2009).  
 
Overexpression of BMI1 or hTERT in NRU cells did not increase lifespan in culture 
compared to control empty vector transfected cells. hTERT overexpression has 
already been shown to increase NHU cell lifespan (Georgopoulos et al., 2011) but it 
failed to have an effect in NRU cells. One explanation is that a species difference 
between human and rat telomerase expression exists that caused this result. In post-
embryonic mouse cells, telomerase expression is not repressed as it is in humans 
which prevents telomere degradation from causing in mouse cell senescence and, in 
turn, prevents telomerase overexpression from acting as a form of cellular 
immortalisation (Wright and Shay, 2000). If this also occurs in rat cells, it could 
explain why hTERT overexpression failed generate immortalised NRU cell lines. 
 
BMI1 transcript was shown to be overexpression in NRU cells but cells died at 
passage 2, leading to the conclusion that BMI1 does not immortalise or increase the 




between rat and human BMI1 genes (>75%), the difference in sequence had an 
affected on the activity of BMI1 in NRU cells.  
 
Alternatively, the molecular mechanism by which BMI1 immortalises human cells 
may not have the same effects in rat cells. BMI1 interacts with a large number of 
molecular control pathways within cells as discussed by Siddique and Saleem 
(2012), including tumour suppressor proteins p16INK4a, which regulates the 
retinoblastoma protein (RB) (Serrano et al., 1993) and ARF which positively 
regulates p53 (Quelle et al., 1995). A difference in spontaneous transformation 
(leading to immortalisation) as a result of p16INK4a and RB inhibition has been 
established between mice and humans (discussed by Hahn and Weinberg, 2002) 
and it is possible that BMI1’s effects on these proteins, and others, may differ 
between species.  
 
Human BMI1 transcript does immortalise rat cells in conjunction with hTERT 
overexpression as described by Zhang et al. (2009) but neither human nor rat BMI1 
transcript have not been overexpressed alone in rat cells as a method of 
immortalisation. Based on the results generated in this project, it would appear that 
overexpressing hTERT or BMI1 alone is insufficient to bring about the 
immortalisation of NRU cells, suggesting an additional level of complexity between 
the pathways regulating immortalisation in humans and rats.  As NRU cells did not 
survive, the activation of molecules downstream of BMI1, such as p16INK4a and ARF, 
were not able to be assessed in BMI1 overexpressing NRU cells. 
 
In NHU cells, BMI1 overexpressing cells were able to be subcultured further than 
control empty vector cells, with proliferation matching that of hTERT 
overexpressing NHU cells. BMI1 overexpressing cells were also capable of 
generating functional barriers in vitro at passages 3, 6 and 10. Further work would 
be required to investigate whether BMI1 overexpressing NHU cells are capable of 
maintaining their rate of growth in culture and whether they can generate 




overexpressing cells in the literature lost the ability to generate a high TEER value at 
passage 17 (Georgopoulos et al., 2011) so the ability of NHU cells to generate high 
TEERs beyond passage 17 would represent an achievement in developing a normal 
human urothelial cell culture system that can be used in toxicity testing.  
 
7.4 Xenobiotic induction of CYP2B enzymes in urothelial 
cells 
 
Xenobiotic metabolism within specific organs can have either protective or toxic 
effects, both of which are important to understand when investigating xenobiotic 
toxicity (discussed in Chapter 6). Attempts to model xenobiotic metabolism in vitro 
have had limited success and as such, an in vitro system capable of expressing 
metabolic enzymes would have multiple applications in toxicity testing.  
 
Induction of CYP2B enzymes in urothelial cells has not previously been 
demonstrated and would represent a method of urothelial defence and possible 
route of bladder-specific toxicity if active toxic metabolites were generated. In 
response to phenobarbital and a CYP2B-inducing compound under development 
by Syngenta, rat urothelial cells were shown, for the first time, to express CYP2B 
enzymes in vivo. CYP2B1/2 expression was demonstrated at the protein level 
whereas RT-PCR results found that all 6 CYP2B transcripts were present in rat 
urothelial cells after xenobiotic-induction.   
 
Assessment of CYP2B expression in NRU and NHU cells revealed that neither cell 
culture system expressed CYP2B in response to xenobiotic (phenobarbital) 
induction. The failure of the cell culture system to replicate the induction of CYP2B 
seen in vivo is disappointing, particularly given the level of differentiation attained 
by the NHU cell cultures, as they would have allowed comparisons to be made 
between rat and human CYP2B enzymes in relation to induction of expression and 




established primary hepatocyte cell culture systems (discussed by Castell et al., 
2006).  
 
To examine whether rat urothelial cells had the ability to express CYP2B enzymes in 
response to xenobiotic-induction when they retained a fully differentiated state and 
stromal communication, expression in a rat organ culture system was assessed. The 
urothelium maintained its structure in organ culture, as shown by superficial 
uroplakin 3a expression and basal cytokeratin 5 expression. 72 hours of 
phenobarbital treatment appeared to increase CYP2B1/2 protein expression, but 
CYP2B transcript appeared to be highest in control rather than phenobarbital-
treated cells. It is possible that this time point (72 hours) is after the peak in CYP2B 
transcript expression. An examination of CYP2B expression at earlier time points 
would determine whether CYP2B transcript is upregulated earlier than 72 hours 
and would explain the lack of CYP2B transcript seen in phenobarbital-treated cells 
after 72 hours.  
 
7.5 Practical difficulties experienced during the project 
 
One major difficulty during the project was sourcing a regular supply of rat bladder 
tissue from a consistent strain of rat. To minimise the number of rats used (3Rs) and 
limit financial costs, tissue was harvested from control animals from other projects 
that were being sacrificed. This method of procurement did enable a large amount 
of bladder tissue to be harvested during the course of the project, but there were 
inconsistencies regarding the strains available, the time between the death of the 
animal and the harvesting of the tissue, and the ability to harvest bladders 
aseptically for culture. 
 
Strains of rat used in this project include Wistar, Homozygous Scottish and Sprague 
Dawley. Ideally one strain would have been used throughout the project. As 
already described in section 7.1, there are arguments for and against choosing both 




commonly used in toxicity testing, this strain would most likely have been selected 
(Gad, 2007). 
 
Wherever possible, bladder tissue was harvested immediately after death of the rat. 
This is known to be important as in NHU cells, rapid post-mortem changes in the 
bladder affect the viability of NHU cells isolated (Garthwaite et al., 2014).  This, 
together with the issue of preventing bacterial contamination, was particularly 
problematic when the projects donating the tissue required the rats to be dissected 
before the bladders could be harvested.   
 
7.5 Limitations and future work 
 
This project was not able to fully validate the use of normal in vitro models for use 
in toxicity testing, but the species variations discovered have important implications 
when extrapolating results between rats and humans. Results have revealed species 
differences between rat and human urothelial cells in terms of growth potential, 
regulation of proliferation and ability of cells to be immortalised through BMI1 and 
hTERT overexpression. They also demonstrated the ability of rat urothelial cells to 
express CYP2B enzymes after xenobiotic-induction in vivo.  
 
The short lifespan of NRU cells in culture limited the amount of cell characterisation 
that could be achieved. In particular, the differentiation status of NRU cells in 
culture needs to be investigated in order to allow a complete comparison of NRU 
and NHU cell culture systems to be made. Results in this project, such as NRU cells 
growing in colonies and the expression of a few markers of differentiation, have 
hinted at the fact that NRU cells may have a different phenotype in culture to NHU 
cells and this needs to be assessed in order to completely understand the differences 
discovered. Distinguishing the type of cell death NRU cells were undergoing (e.g. 
senescence, apoptosis) would also be interesting to investigate as modulation of the 





In relation to overexpression of BMI1 in NHU cells, time was the limiting factor. 
Continuing to grow and differentiate BMI1 overexpressing NHU cell lines, in 
addition to investigating expression of cell senescence associated proteins such as 
p16INK4a, will reveal the full potential of these cells. Repeating the results in at least 
on more donor cell line is also required. To fully validate normal urothelial cell 
culture systems for use in toxicity testing additional work is required, in particular 
to explore the lifespan and differentiation capabilities of BMI1 overexpressing NHU 
cells. Further investigation of the growth pathways active in NRU cells and would 
be beneficial for clarifying the differences discovered between NRU and NHU cells.  
 
Induction of all 6 CYP2B transcripts was shown to occur in rat urothelial cells in vivo 
but, based on expression in other tissues (reviewed by Elia, 1996), one of more 
CYP2B enzymes are likely to be predominantly expressed. To further understand 
urothelial CYP2B expression and quantify the amount of CYP2B enzymes 
expressed, quantitative PCR could be conducted on control and phenobarbital-
treated rat urothelial RNA. Additionally, microarray analysis would quantify any 
differential induction of the six rat CYP2B gene transcripts by rat urothelium. 
Confirming the CYP2B induction seen in the rat ex vivo organ culture could also be 
important in validating the ex vivo model for use in metabolism/toxicity testing. 
Exploring CYP2B induction in a human organ culture could also be interesting and 
may provide a platform for rat and human CYP2B induction to be compared side 
by side and would also be interesting in understanding the role of the stroma in 
regulating urothelial CYP2B expression.   
 
Together, these results demonstrate the potential benefits of in vitro systems and 
highlight the necessity for human relevant models to be included in toxicity testing. 
The findings reveal species variations in urothelial cells from rats and humans that 
could have important implications for toxicity testing and demonstrate how these 
differences can be assessed in vitro. Additionally these data reveal a novel metabolic 




vivo model. Together this project supports the case for incorporating in vitro systems 
in toxicity testing and provides a platform for the complete validation of normal 




Chapter 8 Appendices 
Appendices 1 – Materials and Method 
 
Appendix 1.1 – Tissue harvesting and in vivo experimentation 
locations 
o Charles River 





o Food and environment research agency (FERA)  











o The University of Leeds 
Worsley Building 










o The University of York 
BSF 
Department of Biology 














Appendix 1.2 – List of Suppliers 
o Adgilent Technologies - www.agilent.com/home 
o Bayer Healthcare Pharmaceuticals - www.bayerpharma.com 
o BDH Chemicals - www.labdepotinc.com/Chemicals 
o Bioline - www.bioline.com 
o Bio-Rad – www.bio-rad.com 
o CA Hendley – Oakwood Hill Industrial Estate, Loughton, Essex, UK 
o Calbiochem - www.calbiochem.com 
o Cell Signalling Technologies - www.cellsignal.com  
o CellPath – www.cellpath.co.uk 
o Charles River Laboratories - www.criver.com  
o Clontech Laboratories – www.clontech.com 
o Corning Incorporated – www.corning.com 
o Dako – www.dako.com 
o Elga LabWater – www.elgalabwater.com 
o Envair – www.envair.co.uk 
o Eurofins UK – www.eurofins.co.uk  
o Fisher Scientific - www.fisher.co.uk 
o Harlan Sera-lab - www.harlanseralab.co.uk 
o Hettich Centrifuges UK - www.hettichcentrifuge.co.uk 
o Pierce - www.piercenet.com  
o Li-Cor Biosciences – www.licor.com 
o Life Technologies - www.lifetechnologies.com 
o Millipore – www.millipore.com 
o Molecular Probes – www.lifetechnologies.com 
o New England Bioscience Inc. – www.neb.com 




o Novocastra - www.novocastra.co.uk 
o Olympus – www.olympus.co.uk 
o Progen Scientific - www.progensci.co.uk 
o Promega – www.promega.com 
o Quiagen – www.quiagen.com 
o Sartorius lab products – www.satorius.co.uk 
o Sarstedt – www.sarstedt.com 
o Shimadzu Scientific instruments - www.ssi.shimadzu.com/ 
o Sigma Aldrich – www.sigmaaldrich.com 
o Scientific Lab Supplies (SLS) Ltd. - www.scientificlabs.co.uk  
o Starlab UK – www.Starlab.co.uk 
o Statebourne - www.statebourne.com 
o The Binding Site - www.thebindingsite.com 
o Thermo Electron Corporation – www.thermoscientific.com 
o Thermo Fisher – www.thermofisher.com 
o Thermo Scientific - www.thermoscientific.com 
o Vector Laboratories – www.vectorlabs.com 
o VWR chemcials – www. uk.vwr.com 
o Zeiss – www.zeiss.co.uk 
o Zymed – www.lifetechnologies.com 
 
Appendix 1.3 Online resources 
o Chromas (v2.4.3) - http://technelysium.com.au 
o GeneSnap 7.07 software - www.syngene.co.uk/genesnap 
o HistoQuest - www.tissuegnostics.com/EN/software/histoquest.php 
o Kalign multiple sequence alignment - www.ebi.ac.uk/Tools/msa/kalign 
o Primer-Blast - www.ncbi.nlm.nih.gov/tools/primer-blast 









Appendix 1.4 – Solutions 
Appendix 1.4.1 General solutions 
Phosphate Buffered Saline (PBS) 
5 x PBS tables (sigma) were dissolved in 1 L of dH2O and autoclaved at 121oC (1 bar) for 20 
minutes and cooled to room temperature before use. 
 
Tris Buffered Saline (TBS) 
1 L made in dH2O consisting of: 
0.5M Tris-HCL 
0.15M NaCl  
The pH adjusted to 7.6 
 
Appendix 1.4.2 Tissue Culture 
 
NHU cell “stripper” solution 
500ml HBSS (-Ca2+, Mg2+) (Gibco; Life Technologies) was supplemented with 5 mL 1M 
HEPES (Gibco; Life Technologies), 50 mLs of 1% (w/v) EDTA and 1mL Trasylol (Nordic 
Pharma) to achieve 100,000 KIU / 100 mLs.  
 
Cholera toxin 
Cholera toxin powder (Sigma Aldrich) was dissolved in 34.3 mL of KSFM medium 
(without supplements) and stored at 4oC. When diluted in 500 mL KSFMc medium the 
final concentration of cholera toxin is 30 ng/mL. 
 
Collagenase IV solution 
Collagenase IV powder (Sigma Aldrich) was dissolved in HBSS (+Ca2+, +Mg2+) +  
10mM HEPES (Life Technologies) to a final concentration of 10,000U per 100 
mL. The solution was filter sterilized through by a 0.2 µm low protein-binding 





0.5% Dispase II solution 
dPBS (-Mg2+, -Cl-) was headed to 37oC and dispase II added slowly to a concentration of 
0.5% (w/v). Samples were vortexed and filtered through Whatman 0 filter paper followed 
by a 0.2 µm low protein-binding syringe filter (Gelman; Sigma Aldrich). 0.5% Dispase 
II solution was aliquoted into 5 mL aliquots and stored at -20oC.  
  
0.1% EDTA solution 
1g EDTA (Fisher Scientific) was dissolved in 1000 mL of dPBS and autoclaved at 121oC (1 
bar) for 20 minutes and cooled to room temperature before use. 
 
Trypsin in Versene 
20 ml of 10x Trypsin (Sigma Aldrich) 
4 mL 1% (w/v) EDTA 
Made up to 200 mL using HBSS (-Ca2+, -Mg2+) 
 
Trypsin Inhibitor (Ti) 
100 mg of Trypsin inhibitor (Sigma) was dissolved in 5ml dPBS and filter sterilised with 




Appendix 1.4.3 Histology 
10% (v/v) Formalin 
100 mL 37% (v/v) Formaldehyde  
900 Ml of PBS containing 0.9 mM CaCl2 and 0.5 mM MgCl2 
Haematoxylin 
A solution containing 3g Haematoxylin in 20 mL 100% ethanol was added to a solution 
containing 0.3 g Sodium Iodate. 1 g Citric acid and 50 g Aluminium Potassium Sulphate 
in 850 mL of dH2O were mixed thoroughly together and 120 mL of glycerol added.  
 
Tris Buffered Saline (TBS) 
1 L made in dH2O consisting of: 
0.5M Tris-HCL (Sigma Aldrich) 
0.15M NaCl (SLS) 
The pH adjusted to 7.6 
 
 Tris Buffered Saline plus Tween®20 (TBST) 
1 L made in dH2O consisting of: 




0.15M NaCl  
0.1% Tween®20  (Sigma Aldrich) 
The pH adjusted to 7.6 
 
IF antibody diluent solution 
TBS (pH 7.6) containing 0.1% (w/v) NaN3 and 0.1% (v/v) BSA. IF antibody dilutent was 
kept at 4oC.  
 
 
IF anti-fade mounting solution 
0.1% (w/v) p-PhenylendiaminoDihydrochloride in 90% (w/v) glycerol in PBS. The 
solution was buffered to pH 8.0 using carbonate-bicarbonate buffer (pH 9.6).  
 
 
Appendix 1.4.4 Molecular Biology 
10 x TBE buffer 
0.9 M Tris, 0.9 M Boric acid, 25 mM EDTA in dH2O. TBE buffer was diluted 1:10 
prior to use.  
Luria Broth (LB) 
10 g Tryptone, 10 ng NaCl, 5 g Yeast extract was made up to 1 L in dH2O and 
autoclaved immediately. 
LB-Agar 
 2 % (w/v) agar was added to LB and the solution autoclaved immediately.  
 
Appendix 1.4.5 Western Blotting 
2 x SDS Lysis Buffer 
20% (v/v) glycerol, 2% (w/v) Sodium Dodecyl Sulphate, 125 mM Tris-HCL (pH 6.8), 0.42 g 
Sodium Fluoride (NaF), 18.4 mg Sodium orthovanadate (Na3PO4) 0.446 g tetra-Sodium 
pyrophosphate made up to 50 mL of dH2O. 2 x SDS lysis buffer was stored at -20oC.  
 
Protease inhibitor cocktail 
104 mM AEBSF, 80 µM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM Leupeptin and 1.5 






12 mM Tris, 96 mM Glycine, 20% (v/v) Methanol made up to 1 L in dH2O. 
 
Western Blot TBS 
10 mM Tris, 140 mM NaCl made up to 1 L in dH2O and the pH adjusted to pH 7.4. 
 
Western Blot TBST 
10 mM Tris, 140 mM NaCl and 0.1% (w/v) Tween®20 made up to 1 L in dH2O and the pH 




Appendix 1.6 Primers 
Target Forward/Reverse Species Sequence Product size 
BMI1 whole gene F Human AAAAAAGTTAACACCATGCATCGAACAACGAGAATC 999 
BMI1 whole gene R Human AAAAAAGGATCCTCAACCAGAAGAAGTTGCTGATG   
BMI1 F Human TCATCCTTCTGCTGATGCTG 221 
BMI1 R Human GCATCACAGTCATTGCTGCT   
CYP2B1/2 F Rat GGCCTGTGGTCATGCTATGT 720/740 
CYP2B1/2 R Rat GCAGGAAACCATAGCGGAGT   
CYP2B3 F Rat AGTGCGTCACAGGCAACATA 278 
CYP2B3 R Rat AAAGTCTCGGGGAGCATTGG   
CYP2B12 F Rat CCCAGTGCTCCACGAGATTT 701 
CYP2B12 R Rat CGGGACAGGAAGTTTATCTGGT   
CYP2B15 F Rat AGAAGAGGCCTTCTGCGTTC  650 
CYP2B15 R Rat AAGTCTCGTGGAGTGTTGGG    
CYP2B21 F Rat GTACTTTCCTGGCACCCACA 628 
CYP2B21 R Rat ACGCTTTCCTGTGGAGAAGG   
CYP2B generic F Rat CAAAAGGAGATTGATCAGGTGA 173 
CYP2B generic R Rat AGCAGGTACCCTCGGAAC   
CYP2B6 F Human TTGCTACTCCTGGTTCAGCG 84 
CYP2B6 R Human AAGGTTTCCCAAAAGGGGCA   
KRT7 F Rat GGCAGAGATTGACACCGTGA 257 
KRT7 R Rat CAGACAACCTGCTCTCCTCG   
GAPDH F Human/Rat CAAGGTCATCCATGACAACTTTG 90 
GAPDH R Human/Rat GGGCCATCCACAGTCTTCTG   








Appendix 1.7 – Aseptic removal of rat bladder tissue  
(protocol) 
 
1. Cull rats according to SK1 regulations 
 
2. Lay the animal on its back and spray the abdomen with 70% ethanol.  
 
3. Make incision in approximately the middle of the animal’s abdomen equidistant 
between the bottom of the sternum and the base of the tail. Only penetrate outer 












4. Use a pair of (round nose) scissors to detach the skin from the abdominal 
wall. To do this lift the skin of the animal using forceps and insert the end of 
a closed pair of scissors into the incision at approximately a 45o angle 
pointing down the animal (towards the tail). Open the scissors across the 
animal between the skin and abdominal wall, separating the two tissues. 
Use this technique (opening the scissors between the tissues) until the 


















5. Cut the skin diagonally from the central incision to the hips as indicated and 
pull back the skin to expose the lower abdominal wall (3).  
 
6. Spray the exposed area with 70% ethanol  
7. Using fresh instruments lift the abdominal wall at a point just below where the 
initial incision was made and make an incision in the pleural wall. Cut 
diagonally outwards to the hips (do not pierce internal organs) (3). This is often 





















8. Pull back the external tissue covering the lower organs of the abdomen. 
When pulled back completely the bladder will be lifted into an erect 
position, especially when full. Using a fresh set of instruments lift the 
bladder and cut it at the base. Unlike other tissue in this area, the base of the 
















Appendices 2 – Results 
 
Appendices 2.1 Antibody specificity 
All antibodies were used at optimised concentrations. Appropriate positive and 
secondary antibody only controls were included in each experiment.  
 
Appendix 2.1.1 Cytokeratin 7 
 





Cytokeratin 7 (CK7) labelling (red) of NRU-W (A) and NHU (B) cells cultured for 5 days 
in KSFMC medium. Cells were fixed (methanol: acetone) and cell nuclei were stained 
























Ki67 labelling (red) of NRU (A) and NHU (B) cells cultured for 5 days in KSFMC 
medium. Cells were fixed (methanol: acetone) and cell nuclei were stained with Hoechst 
33258.  Scale bars = 50μm. 
 
Appendix 2.1.3 – β-catenin 
 
β-catenin labelling (red) of NRU (A) and NHU (B) cells cultured for 5 days in KSFMC 
medium. Cells were fixed (methanol: acetone) and cell nuclei were stained with Hoechst 







Appendix 2.1.4 – phospho-ERK 
 
 Phospho-ERK labelling (red) of rat stromal cells (A) and NHU (B) cells cultured for 5 
days in KSFMC medium. Cells were fixed (methanol: acetone) and cell nuclei were 
stained with Hoechst 33258.  Scale bars = 50μm. 
 
Appendix 2.1.5 – phospho-Akt  
 
Phospho-Akt labelling (green & red) of control NRU (A) and NHU (2mM Ca+)  (B) cells 
cultured for 5 days in KSFMC medium. Cells were fixed (methanol: acetone) and cell 
nuclei were stained with Hoechst 33258.  Scale bars = 50μm. 
 
Appendix 2.1.6 – ZO-1 
 
–ZO-1 labelling (red) of control NRU (A) and differentiated (ABS/Ca2+) NHU (B) cells 
cultured for 5 days in KSFMC medium. Cells were fixed (methanol: acetone) and cell 





Appendix 2.1.7 – Claudin 4 (CL4) 
 
CL4 labelling (red) of control NRU (A) and differentiated (ABS/Ca2+) NHU (B) cells 
cultured for 5 days in KSFMC medium. Cells were fixed (methanol: acetone) and cell 
nuclei were stained with Hoechst 33258.  Scale bars = 50μm. 
 
Appendix 2.1.8 – Aquaporin 4 (AQP4) 
 
AQP4 labelling (red) of control NRU (A) and differentiated (ABS/Ca2+) NHU (B) cells 
cultured for 5 days in KSFMC medium. Cells were fixed (methanol: acetone) and cell 
nuclei were stained with Hoechst 33258.  Scale bars = 50μm. 
 
Appendix 2.1.9 – Secondary Antibody only negative control 
 
Secondary antibody only negative control labelling (red) of control NRU (A) and 
differentiated (ABS/Ca2+) NHU (B) cells cultured for 5 days in KSFMC medium. Cells 
were fixed (methanol: acetone) and cell nuclei were stained with Hoechst 33258.  Scale 
















CYP2B1/2 antibody titration on control and CYP2B-inducing xenobiotic treated (7 days) rat liver sections. CYP2B1/2 antibody was tested at dilutions of 








































Appendices 2.2 Primer Tm optimisation (examples) 
Gradient RT-PCR’s (30 cycles) were conducted to optimise the annealing 
temperature (Tm’s) for each primer set and to confirm the positive controls. Tm’s 
ranged from 65oC (left) to 55oC (right). A number of examples are included.  
Appendix 2.2.1 – BMI1 
 
 
Gradient RT-PCR specifically amplifying a 181 bp section of BMI1 from proliferating 
NHU cDNA.  
 
Gradient RT-PCR amplifying the entire BMI1 protein coding sequence from proliferating 





























Gradient RT-PCR using CYP2B1/CYP2B2 primers using control rat liver cDNA 
 





























































Negative (no primary antibody) control immunolabelling images of control and 
phenobarbital-treated rat bladders after 3 days of treatment.  Scale bars = 50 µm   






Negative (no primary antibody) control immunolabelling images of control and 











Negative (no primary antibody) control immunolabelling images of control and 
phenobarbital-treated rat bladders after 14 days of treatment. Scale bars = 50 µm 






ABS – Adult Bovine Serum 
Akt – protein kinase B 
AQP3 – Aquaporin 3 
AUM – Asymmetric Unit Plaques 
BLAST – Basic Logical Alignment and Search Tool 
bp – base pair 
BPE – Bovine Pituitary Extract 
BMI1 - B cell-specific Moloney murine leukemia virus Integration site 1 
Ca2+ - Calcium ion 
cDNA – complementary Deoxyribonucleic Acid 
CK - Cytokeratin 
CL4 – claudin 4 
CO2 – carbon dioxide 
CT – Cholera Toxin 
CYP – Cytochrome P450 
D - Day 
DEPC – Diethyl Pyrocarbonate 
DMEM – Bulbecco’s Modified Eagle’s Medium 
DMSO - Dimethyl sulfoxide 
DNA - Deoxyribonucleic Acid 
dNTP – Deoxynucleotide triphosphate 
E.coli – Escherichia coli 
EDTA - Ethylenediaminetetraacetic acid 
EGF – Epidermal Growth Factor 
EGFR – Epidermal Growth Factor Receptor 
ERK - Extracellular signal-regulated kinase 
FBS – Fetal Bovine Serum 
FERA – Food and Environment Research Agency 
GAPDH – Glyceraldehyde-3-phosphate dehydrogenase 
GSK3β - Glycogen synthase kinase 3 β 
hTERT – human telomerase reverse transcriptase 
IC50 – Half maximum inhibitory concentration  
IGF – Insulin Growth Factor 
JBU – Jack Birch Unit for Molecular Carcinogenesis 
Kb – Kilo-base 
kDa – Kilo Dalton 
KSFM – Keratinocyte Serum Free Medium  
KSFMc – Keratinocyte Serum Free Medium (complete) 
LB – Luria Broth 
M – Molar 
MAPK – Mitogen-Activated Protein Kinase 
MEK - Mitogen-Activated Protein Kinase Kinase 
mg – milligrams 
mL – millilitres 
mM – millimolar 
N2 – Nitrogen 




NHU – Normal Human Urothelial  
nM - nanomolar 
nm – nanometers 
NRU – Normal Rat Urothelial 
O2 – Oxygen 
oC – degrees centigrade 
P – Passage number 
PBS – Phosphate Buffered Saline 
PCR – Polymerase Chain Reaction 
PD - Population doubling 
Phospho – Phosphorylated  
PI3K - Phosphoinositide 3-kinase 
RNA – Ribonucleic Acid 
rmp – rotations per minute 
RT - Reverse Transcriptase  
SDS-PAGE – Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis 
TEER – Transepithelial Electrical Resistance 
TGF – Transforming Growth Factor 
UP3a – Uroplakin 3a 
v/v – volume/volume 
w/v – weight/volume 
ZO-1 – Zona occludin 1 
μg - micrograms 
μL – microliters 
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